WO2021027200A1 - Genetically engineered cells and uses thereof - Google Patents
Genetically engineered cells and uses thereof Download PDFInfo
- Publication number
- WO2021027200A1 WO2021027200A1 PCT/CN2019/124321 CN2019124321W WO2021027200A1 WO 2021027200 A1 WO2021027200 A1 WO 2021027200A1 CN 2019124321 W CN2019124321 W CN 2019124321W WO 2021027200 A1 WO2021027200 A1 WO 2021027200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- fusion protein
- hla
- peptide
- heavy chain
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 513
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 455
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 454
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 152
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 145
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 145
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 108
- 238000000034 method Methods 0.000 claims abstract description 68
- 201000011510 cancer Diseases 0.000 claims abstract description 65
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims description 365
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 319
- 210000004027 cell Anatomy 0.000 claims description 244
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 167
- 239000000427 antigen Substances 0.000 claims description 148
- 108091007433 antigens Proteins 0.000 claims description 148
- 102000036639 antigens Human genes 0.000 claims description 148
- 210000002865 immune cell Anatomy 0.000 claims description 147
- 239000012634 fragment Substances 0.000 claims description 140
- 230000027455 binding Effects 0.000 claims description 124
- 108090000623 proteins and genes Proteins 0.000 claims description 118
- 108010031480 Artificial Receptors Proteins 0.000 claims description 114
- 108091008874 T cell receptors Proteins 0.000 claims description 81
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 80
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 79
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 74
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 70
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 69
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 69
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 64
- 239000013598 vector Substances 0.000 claims description 56
- 108091008042 inhibitory receptors Proteins 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 50
- 102000005962 receptors Human genes 0.000 claims description 50
- 108020003175 receptors Proteins 0.000 claims description 50
- 210000000822 natural killer cell Anatomy 0.000 claims description 48
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 37
- 102000040430 polynucleotide Human genes 0.000 claims description 29
- 108091033319 polynucleotide Proteins 0.000 claims description 29
- 239000002157 polynucleotide Substances 0.000 claims description 29
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 27
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 27
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 25
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims description 25
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 25
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 25
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 25
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims description 25
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 22
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 22
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 20
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 20
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims description 19
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 18
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 16
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 16
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims description 16
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims description 16
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 16
- 101150037769 TRX2 gene Proteins 0.000 claims description 16
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims description 14
- 210000002540 macrophage Anatomy 0.000 claims description 14
- 239000013603 viral vector Substances 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 12
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 11
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 11
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 11
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 11
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 11
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 11
- 108090000015 Mesothelin Proteins 0.000 claims description 11
- 102000003735 Mesothelin Human genes 0.000 claims description 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 11
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 11
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 10
- 102100025221 CD70 antigen Human genes 0.000 claims description 10
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 10
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 10
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 10
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 10
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 10
- 102100035721 Syndecan-1 Human genes 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 101150029707 ERBB2 gene Proteins 0.000 claims description 9
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 9
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 9
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 9
- 102100034256 Mucin-1 Human genes 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 238000012737 microarray-based gene expression Methods 0.000 claims description 9
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 9
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims description 8
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims description 8
- 102100028801 Calsyntenin-1 Human genes 0.000 claims description 8
- 230000007018 DNA scission Effects 0.000 claims description 8
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 8
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims description 8
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 101150069255 KLRC1 gene Proteins 0.000 claims description 7
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 7
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000002463 transducing effect Effects 0.000 claims description 7
- 229910052720 vanadium Inorganic materials 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 108010042407 Endonucleases Proteins 0.000 claims description 6
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 claims description 6
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 5
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 5
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 5
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims description 5
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims description 5
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims description 5
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 claims description 5
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 claims description 5
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 claims description 5
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 claims description 5
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 claims description 5
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims description 5
- 101000866855 Homo sapiens Major histocompatibility complex class I-related gene protein Proteins 0.000 claims description 5
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 claims description 5
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 claims description 5
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000003714 granulocyte Anatomy 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 5
- 241000206602 Eukaryota Species 0.000 claims description 4
- 108010035233 HLA-A*34:01 antigen Proteins 0.000 claims description 4
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims description 4
- 108010021736 HLA-B15 Antigen Proteins 0.000 claims description 4
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims description 4
- 108010070768 HLA-C*03 antigen Proteins 0.000 claims description 4
- 108010007655 HLA-C*70 antigen Proteins 0.000 claims description 4
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 claims description 4
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims description 4
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims description 4
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims description 4
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 claims description 4
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims description 4
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 102100038313 Transcription factor E2-alpha Human genes 0.000 claims description 4
- 210000004180 plasmocyte Anatomy 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 108010042634 F2A4-K-NS peptide Proteins 0.000 claims description 3
- 101800001494 Protease 2A Proteins 0.000 claims description 3
- 101800001066 Protein 2A Proteins 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims description 2
- 238000010357 RNA editing Methods 0.000 claims description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 2
- 230000026279 RNA modification Effects 0.000 claims description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 4
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 4
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 102100032530 Glypican-3 Human genes 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 142
- 229920001184 polypeptide Polymers 0.000 abstract description 115
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 235000001014 amino acid Nutrition 0.000 description 353
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 100
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 98
- 102000004169 proteins and genes Human genes 0.000 description 69
- 235000018102 proteins Nutrition 0.000 description 60
- 230000003834 intracellular effect Effects 0.000 description 52
- 230000011664 signaling Effects 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 25
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 22
- 102000006390 HLA-B Antigens Human genes 0.000 description 21
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 18
- -1 MR1 Proteins 0.000 description 17
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 17
- 210000004970 cd4 cell Anatomy 0.000 description 17
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 16
- 230000004913 activation Effects 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 102100027207 CD27 antigen Human genes 0.000 description 13
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 13
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 13
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 12
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 12
- 101710187864 TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 12
- 101150013553 CD40 gene Proteins 0.000 description 11
- 102100039007 Multiple epidermal growth factor-like domains protein 10 Human genes 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 101710134037 Multiple epidermal growth factor-like domains protein 10 Proteins 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 9
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 9
- 102000001301 EGF receptor Human genes 0.000 description 9
- 108060006698 EGF receptor Proteins 0.000 description 9
- 102000010956 Glypican Human genes 0.000 description 9
- 108050001154 Glypican Proteins 0.000 description 9
- 108050007237 Glypican-3 Proteins 0.000 description 9
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 9
- 102000001708 Protein Isoforms Human genes 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 241001529453 unidentified herpesvirus Species 0.000 description 9
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 7
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 7
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000002698 KIR Receptors Human genes 0.000 description 6
- 108010043610 KIR Receptors Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102100040841 C-type lectin domain family 5 member A Human genes 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 241001416177 Vicugna pacos Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000004507 artificial chromosome Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002998 immunogenetic effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 108010068617 neonatal Fc receptor Proteins 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100039950 Eukaryotic initiation factor 4A-I Human genes 0.000 description 2
- 101150050927 Fcgrt gene Proteins 0.000 description 2
- 101710099785 Ferritin, heavy subunit Proteins 0.000 description 2
- 108010001086 HLA-F antigens Proteins 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 101000959666 Homo sapiens Eukaryotic initiation factor 4A-I Proteins 0.000 description 2
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000798076 Homo sapiens T cell receptor delta constant Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 101001022947 Lithobates catesbeianus Ferritin, lower subunit Proteins 0.000 description 2
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000701062 Saimiriine gammaherpesvirus 2 Species 0.000 description 2
- 102100032272 T cell receptor delta constant Human genes 0.000 description 2
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 102100022748 Wilms tumor protein Human genes 0.000 description 2
- 101710127857 Wilms tumor protein Proteins 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000044413 human MR1 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 101710186546 C-type lectin domain family 5 member A Proteins 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100064157 Drosophila melanogaster drpr gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000012695 Early-onset myopathy-areflexia-respiratory distress-dysphagia syndrome Diseases 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000010451 Folate receptor alpha Human genes 0.000 description 1
- 102100035139 Folate receptor alpha Human genes 0.000 description 1
- 108050001931 Folate receptor alpha Proteins 0.000 description 1
- 102000010449 Folate receptor beta Human genes 0.000 description 1
- 108050001930 Folate receptor beta Proteins 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101710089250 Heat shock 70 kDa protein 5 Proteins 0.000 description 1
- 101710157460 Hematopoietic cell signal transducer Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000749314 Homo sapiens C-type lectin domain family 5 member A Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 description 1
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 description 1
- 101000945492 Homo sapiens Killer cell immunoglobulin-like receptor 3DS1 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101000955275 Homo sapiens Multiple epidermal growth factor-like domains protein 10 Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 101710205775 Inducible T-cell costimulator Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 108010023842 KIR2DL1 Receptors Proteins 0.000 description 1
- 102000011417 KIR2DL1 Receptors Human genes 0.000 description 1
- 108010023852 KIR2DL2 Receptors Proteins 0.000 description 1
- 102000011419 KIR2DL2 Receptors Human genes 0.000 description 1
- 108010023867 KIR2DL3 Receptors Proteins 0.000 description 1
- 102000011414 KIR2DL3 Receptors Human genes 0.000 description 1
- 108010023844 KIR2DL4 Receptors Proteins 0.000 description 1
- 102000011416 KIR2DL4 Receptors Human genes 0.000 description 1
- 108010023851 KIR2DL5 Receptors Proteins 0.000 description 1
- 102000011418 KIR2DL5 Receptors Human genes 0.000 description 1
- 108010001248 KIR3DL1 Receptors Proteins 0.000 description 1
- 102000002066 KIR3DL1 Receptors Human genes 0.000 description 1
- 108010001228 KIR3DL2 Receptors Proteins 0.000 description 1
- 102000002073 KIR3DL2 Receptors Human genes 0.000 description 1
- 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 description 1
- 102100034833 Killer cell immunoglobulin-like receptor 3DS1 Human genes 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108050000731 Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102000007298 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 1
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 101710191252 T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 101150056647 TNFRSF4 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 101710165434 Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 108010056354 Ubiquitin C Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000048974 human HLA-B Human genes 0.000 description 1
- 102000047041 human KIR2DL1 Human genes 0.000 description 1
- 102000058207 human KIR2DL2 Human genes 0.000 description 1
- 102000058208 human KIR2DL3 Human genes 0.000 description 1
- 102000058198 human KIR2DL4 Human genes 0.000 description 1
- 102000058221 human KIR3DL1 Human genes 0.000 description 1
- 102000058220 human KIR3DL2 Human genes 0.000 description 1
- 102000058142 human KIR3DL3 Human genes 0.000 description 1
- 102000057310 human KLRC1 Human genes 0.000 description 1
- 102000044042 human KLRK1 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 201000009474 prostate rhabdomyosarcoma Diseases 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
Definitions
- the present invention relates to genetically engineered cells, and more particularly to engineered cells that are resistant to an allogeneic immune system, and further relates to methods for preparing the cells and uses thereof in allogeneic transplant.
- Allograft rejection is the main cause of failure of allogeneic organ transplantation or cell transplantation. While T cells play essential roles in allograft rejection, recent studies have demonstrated unexpected roles for non-T cells such as natural killer (NK) cells, B cells, macrophage and mast cells in regulating transplant outcomes. (Li, Transplantation, 2010; 90 (10) : 1043-1047) .
- NK natural killer
- B cells B cells
- macrophage and mast cells in regulating transplant outcomes.
- the unique self-non-self recognition system of the NK cells are highly relevant in allograft transplant. Briefly, individual NK cells have both stimulatory and inhibitory receptors on the cell surface, and signals from both types of receptors are required to establish NK tolerance to autologous cells. In humans, the inhibitory receptors include killer-cell immunoglobulin-like receptors (KIRs) .
- KIRs killer-cell immunoglobulin-like receptors
- NKG2A and CD94 usually form heterodimers on the cell surface and function as inhibitory receptors, in not only NK cells but also T cells. Binding of “self” Class I MHC to such inhibitory receptors inhibits NK cells, and prevents the NK cells from attacking “self” cells.
- NK cells in the recipients can readily recognize MHC incompatible allogeneic cells via “missing self” recognition, as allogeneic cells lack self Class I MHC to engage NK inhibitory receptors.
- the lack of inhibitory signals triggers NK activation, which includes cytolytic activities and production of potent pro-inflammatory cytokines.
- the same mechanism also applies in the activation of other immune cells, such as T cells, and results in allograft rejection.
- the chimeric antigen receptor T cell (CAR-T) therapy has shown promising curative effect in cancers such as recurrent and refractory lymphoma, leukemia, multiple myeloma.
- CAR-T chimeric antigen receptor T cell
- the existing autologous CAR-T technology requires individualized preparation of cells, and is therefore limited by the long production cycle, high cost, and in many cases, lack of adequate T cells from patients. Therefore, universal CAR-T (UCAR-T) therapies, in which the T cells are derived from healthy donors and prepared in advance for use by any patient, have attracted great interests.
- the bidirectional rejection between the T cell transplant and the recipient like in any other allograft transplantation, need to be addressed.
- the present disclosures address the needs to overcome allograft rejection in allogeneic organ transplantation and cell transplantation, and provide related advantages.
- fusion proteins comprising a presenting peptide covalently linked to a beta-2-microglobulin ( ⁇ 2M) peptide via a linker, wherein the fusion protein binds a major histocompatibility (MHC) heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- MHC major histocompatibility
- the fusion proteins provided herein bind a major histocompatibility (MHC) heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- MHC major histocompatibility
- the inhibitory receptor of the immune cell is NKG2A.
- the inhibitory receptor of the immune cell is selected from the group consisting of KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, and LIR1.
- the MHC heavy chain is a classical Class I MHC heavy chain, a non-classical Class I MHC heavy chain, or an MHC-like heavy chain.
- the MHC heavy chain is a classical Class I MHC heavy chain selected from the group consisting of an HLA-A heavy chain, an HLA-B heavy chain, and an HLA-C heavy chain.
- the MHC heavy chain is a nonclassical Class I MHC heavy chain selected from the group consisting of an HLA-E heavy chain, an HLA-F heavy chain, and an HLA-G heavy chain.
- the MHC heavy chain is an MHC-like molecule heavy chain selected from the group consisting of a CD1 heavy chain, an MR1 heavy chain, an FcRn heavy chain, and UL18. In some embodiments, the MHC heavy chain is an HLA-E heavy chain.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the presenting peptide is an HLA-E-restricted presenting peptide, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- the presenting peptide is derived from a virus, a prokaryote, a eukaryote or a mammal. In some embodiments the presenting peptide is derived from a human.
- the presenting peptide is a signal peptide of a Class I MHC molecule or a fragment thereof.
- fusion proteins provided herein comprise a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- the presenting peptide has 5-30 amino acids. In some embodiments, the presenting peptide has 7-20 amino acids. In some embodiments, the presenting peptide has 8-10 amino acids.
- the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof, wherein the Class I MHC molecule is selected from the group consisting of the heavy chains of HLA-A1, HLA-A2, HLA-A*3401, HLA-A*80, HLA-B7, HLA-B*13, HLA-B15, HLA-Cw3, HLA-Cw*2, HLA-Cw*0809, HLA-Cw7, HLA-Cw*1701, HLA-G, and HLA-F.
- the amino acid sequence of the presenting peptide comprises X1X2X3X4X5X6X7X8L; wherein X1 is V or I; X2 is T, A, M or L; X3 is A, P, K or N; X4 is P, L, or T; X5 is R, Q or K; X6 is T or A; X7 is L, I, V or P; X8 is V, L, I, F or T (SEQ ID NO: 115) .
- the amino acid sequence of the presenting peptide is selected from the group consisting of SEQ ID NOs: 21-73.
- the amino acid sequence of presenting peptide is VMAPRTVLL (SEQ ID NO: 38) .
- the fusion proteins provided herein comprise less than 500, less than 400, less than 300, or less than 200 amino acids. In some embodiments, the fusion protein comprises about 120-180 amino acids.
- the fusion proteins provided herein comprise the presenting peptide, the linker, and the ⁇ 2M peptide from N-terminus to C-terminus.
- the amino acid sequence of the linker is SEQ ID NO: 1 or 2.
- the amino acid sequence of the ⁇ 2M peptide is at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 81. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is SEQ ID NO: 81.
- the fusion proteins provided herein consist of the presenting peptide, the linker, and the ⁇ 2M peptide.
- the amino acid sequence of the fusion proteins provided herein is at least 85%, at least 90%, or at least 95%identical an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18. In some embodiments, the amino acid sequence of the fusion protein is selected from the group consisting of SEQ ID NOs: 5 and 13-18.
- nucleic acids that encode the fusion proteins provided herein.
- nucleic acids comprising (i) a first fragment encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain; and (ii) a second fragment encoding a synthetic receptor.
- the synthetic receptor is selected from the group consisting of a chimeric antigen receptor (CAR) , a T cell receptor (TCR) , a TCR receptor fusion construct (TRuC) , a T cell antigen coupler (TAC) , an antibody TCR receptor (AbTCR) and a chimeric CD3 receptor.
- CAR chimeric antigen receptor
- TCR T cell receptor
- TRuC TCR receptor fusion construct
- TAC T cell antigen coupler
- AbTCR antibody TCR receptor
- the synthetic receptor is a CAR.
- the synthetic receptor comprises an antigen-binding domain that specifically binds a tumor antigen.
- the tumor antigen is selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- the tumor antigen is CD19 or BCMA.
- the synthetic receptor comprises an antigen-binding domain that specifically binds a viral antigen.
- the viral antigen is EBV or HPV.
- the first and second fragments are connected via a polynucleotide encoding a 2A peptide.
- the 2A peptide is a P2A peptide, a T2A peptide, a F2A peptide, or an E2A peptide.
- the nucleic acids provided herein encode the synthetic receptor, the 2A peptide, the fusion protein, from N-terminus to C-terminus.
- the first and second fragments are connected via an IRES sequence.
- vectors that comprise the nucleic acids disclosed herein.
- the vector is a viral vector.
- the viral vector is a lentiviral vector, an adenoviral vector, or an adeno-associated viral vector.
- nucleic acids disclosed herein are also genetically engineered cells comprising the nucleic acids disclosed herein, or the vectors disclosed herein.
- the cells provided herein further express a synthetic receptor.
- the cells provided herein further comprise a second nucleic acid that encodes a synthetic receptor.
- the synthetic receptor is selected from the group consisting of a CAR, a TCR, a TRuC, a TAC, an AbTCR, and a chimeric CD3 receptor.
- the synthetic receptor is a CAR.
- the synthetic receptor comprises an antigen-binding domain that specifically binds a tumor antigen.
- the tumor antigen is selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- the tumor antigen is CD19 or BCMA.
- the synthetic receptor comprises an antigen-binding domain that specifically binds a viral antigen.
- the viral antigen is EBV or HPV.
- the fusion proteins provided herein form a complex with an endogenous MHC heavy chain on the cell surface.
- the cells provided herein lack endogenous expression of at least one gene encoding a Class I MHC molecule or an MHC-like molecule on the cell surface. In some embodiments, the cells provided herein lack endogenous expression of a Class I MHC molecule selected from the group consisting of heavy chains of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G on the cell surface. In some embodiments, the cells provided herein lack endogenous expression of ⁇ 2M on the cell surface. In some embodiments, the cells provided herein lack endogenous expression of an MHC-like molecule selected from the group consisting of a CD1 heavy chain, an MR1 heavy chain, an FcRn heavy chain, and UL18 on the cell surface.
- the cells provided herein are immune cells.
- the cells provided herein are leukocytes.
- the leukocyte is selected from the group consisting of a T cell, a NK cell, a NKT cell, a B cell, a plasma cell, a dendritic cell, a neutrophil, a monocyte, a macrophage, and a granulocyte.
- the leukocyte is a NK cell.
- the leukocyte is a T cell.
- At least one gene encoding a component of TCR complex is inactivated in the T cell.
- compositions having the cells of provided herein and a pharmaceutically acceptable excipient.
- the cells comprise a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- the cells express a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- Provided herein are also methods of treating cancer in a subject comprising administering a therapeutically effective amount of the cells provided herein to the subject.
- a subject in need of an allogeneic transplant comprising administering an effective amount of an cell to the subject, wherein the cell comprises a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- fusion protein comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- kits for genetically engineering a cell for an allogeneic transplant comprising transducing the cell with the nucleic acids provided herein.
- kits for genetically engineering a cell for an allogeneic transplant comprising transducing the cell with the vectors provided herein.
- methods provided herein further include inactivating at least one gene encoding a Class I MHC molecule or an MHC-like molecule in the cell.
- the inactivated gene encodes a Class I MHC molecule selected from the group consisting of heavy chains of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G.
- the inactivated gene encodes ⁇ 2M.
- the inactivated gene encodes an MHC-like molecule selected from the group consisting of a CD1 heavy chain, an MR1 heavy chain, an FcRn heavy chain and UL18.
- the gene is inactivated by DNA cleavage, DNA cleavage and repair, base editing, prime editing, RNA interference, or RNA editing.
- the gene is inactivated by DNA cleavage using a rare endonuclease selected from the group consisting of a RNA-directed endonuclease, a TAL nuclease, a homing endonuclease, a zinc-finger nuclease, and a Mega-TAL nuclease.
- the gene is inactivated by DNA cleavage and repair.
- the gene is inactivated by using a CRISPR-Cas system.
- the CRISPR-Cas system is a CRISPR-Cas9 system.
- the cell is an immune cell.
- the immune is selected from the group consisting of a T cell, a NK cell, a NKT cell, a B cell, a plasma cell, a monocyte, a macrophage, a dendritic cell and a granulocyte.
- FIG. 1 is a schematic diagram of a fusion protein and a schematic diagram of an expression vector.
- FIG. 1, panel A is a schematic diagram of an exemplary fusion protein (or “chimeric molecule” ; or “CM” ) provided herein.
- FIG. 1, panel B is a schematic diagram of a vector having nucleic acid fragments encoding both the fusion protein (CM) and CAR.
- FIG. 2 shows the co-expression of the fusion protein (CM) and the CAR in genetically engineered Jurkat T cells.
- Panel A shows results for untransduced cells in a control group.
- Panel B shows results for cells transduced with a CAR19-P2A-CM virus, wherein the CM comprised an HLA-E-restricted presenting peptide. As indicated by the arrow, the expression of HLA-E at the cell surface was detected with an HLA-E antibody.
- Panel C shows cells transduced with CAR19-P2A-CM-c, wherein the CM comprised an HLA-C-restricted presenting peptide. The expression of HLA-E at the cell surface was not detected by the HLA-E antibody.
- FIG. 3 shows the expression of the fusion protein (CM) in primary T cells.
- Panel A shows total UCAR-T-CM cells.
- Panel B shows that about 80%of UCAR-T-CM cells having both the TCR gene and ⁇ 2M gene knockout were double negative when stained with a CD3 antibody and an HLA-ABC antibody.
- Panel C shows the expression of the fusion protein (CM) in CD3 and HLA-ABC double negative UCAR-T-CM cells, as indicated by the positive staining for HLA-E.
- FIG. 4 shows that UCAR-T cells expressing the fusion protein (CM) were resistant against killing by NK cells.
- FIG. 5 shows that the UCAR-T cell expressing the fusion protein (CM) were resistant to growth inhibition by allogeneic PBMC cells and expanded rapidly upon stimulation by tumor cells.
- CM fusion protein
- FIG. 6 shows that the UCAR-T cell expressing the fusion protein (CM) efficiently arrested growth of tumor cells and also killed tumor cells in allogeneic PBMC environment.
- CM fusion protein
- FIG. 7 shows results from flow cytometry analysis, which demonstrated that the fusion protein (CM) and the HLA-E heavy chain molecule formed a complex on the cell membrane in ⁇ 2M-knockout cells.
- FIGs. 8A-8B show results from flow cytometry analysis, which demonstrated that different presenting peptides were associated with different levels of expression of the HLA-E complex on cell membrane.
- FIG. 8A shows the data from the flow cytometry analysis and
- FIG. 8B quantifies the data shown in FIG. 8A.
- compositions and methods for improving success rate in allogeneic organ transplantation or allogeneic cell transplantation e.g. universal CAR-T therapy
- One advantage provided by the compositions and methods of the present disclosures is to overcome allograft rejection by the recipient’s immune system.
- a fusion protein comprising a ⁇ 2M polypeptide and a presenting peptide can be expressed in a cell for transplantation, which can form an MHC complex with an endogenously expressed MHC heavy chain on the cell surface, such that the MHC complex can bind an inhibitory receptor of the immune cells (e.g. NK cells and T cells) of the recipient, and prevent the recipient’s immune cells from eliciting an immune response against the allogeneic cell.
- an inhibitory receptor of the immune cells e.g. NK cells and T cells
- an allograft cell lacks the expression of HLA-E on the cell surface, which is a nonclassical Class I MHC complex that binds the inhibitory receptor NKG2A on immune cells (e.g. NK cells or T cells) , the allograft cell would be recognized and killed by the immune cells of the recipient (Saunders et al., Immunological Reviews (2015) 267: 148-166) .
- immune cells e.g. NK cells or T cells
- the fusion protein can form an HLA-E complex with an endogenously expressed HLA-E heavy chain on the cell surface, which binds to the inhibitory receptor NKG2A on a NK cell or T cell to inhibit the activation of the NK cell or T cell.
- a full MHC complex e.g. ⁇ 2M plus HLA-E heavy chain, at least 500 amino acids
- the compositions and methods disclosed herein are advantageous at least because fusions proteins provided herein can be significantly smaller (e.g. less than 300 amino acids) , which enables genetic engineering with greater accuracy and efficiency.
- polypeptide, ” “peptide, ” “protein, ” and their grammatical equivalents as used interchangeably herein refer to polymers of amino acids of any length, which can be linear or branched. It can include unnatural or modified amino acids, or be interrupted by non-amino acids.
- a polypeptide, peptide, or protein can also be modified with, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification.
- fusion protein and its grammatical equivalents as used herein refer to a protein, peptide or polypeptide that has an amino acid sequence derived from two or more separate proteins, peptides or polypeptides.
- the fusion protein also include linking regions of amino acids between amino acid portions derived from separate proteins, peptides or polypeptides. Such linking regions of amino acids are referred herein as “linkers. ”
- MHC complex and “MHC, ” are used interchangeably herein consistently with their usage commonly accepted in the art. Briefly, the terms refer to a group of closely linked genes that code for cell surface proteins essential for the acquired immune system to recognize foreign molecules in vertebrates, which in turn determines histocompatibility. The main function of MHC is antigen presentation, and extremely rich polymorphism has been observed.
- the human MHC is also referred to as a human leukocyte antigen ( “HLA” ) .
- HLA human leukocyte antigen
- MHC complexes are heterodimers and composed of two “MHC proteins. ” It is understood that an “MHC gene” refers to a polynucleotide encoding an MHC protein.
- MHC complexes include Class I MHC (or MHC-I Class) , Class II MHC (or MHC-II Class) and MHC-like complexes (or “MHC analogs, ” or “MHC homologs” ) .
- Class I MHC complexes are heterodimeric glycoproteins consisting of two peptide chains associated by non- covalent bonds, a polymorphic heavy chain (i.e. “Class I MHC heavy chain, ” also referred to as “Class I MHC alpha chain” ) , and a light chain, which is beta-2-microglobulin ( ⁇ 2M) .
- Class I MHC complexes display peptide fragments of proteins from within the cell to immune cells, which triggers an immediate response from the immune system against a particular non-self antigen displayed by Class I MHC complexes.
- classic Class I MHC also known as MHC-Ia
- nonclassical Class I MHC also known as MHC-Ib
- HLA-E HLA-E
- HLA-F HLA-G
- HLA-G HLA-G
- MHC-like complexes also called MHC analogs, or MHC homologs, are structurally similar to the Class I MHC complexes. Some MHC-like complexes are also consisted of a heavy chain (i.e. “MHC-like heavy chain” ) non-covalently associated with the ⁇ 2M protein. Exemplary MHC-like complexes include, but are not limited to, CD1, MR1, Neonatal Fc-receptor (FcRn) , and human cytomegalovirus (HCMV) -derived UL18. CD1 is structurally similar to other Class I MHC complexes and consists of a heavy chain and ⁇ 2M.
- CD1 presents lipid antigens and further includes CD1a, CD1b, CD1c, CD1d and CD1e.
- MR1 MHC-related 1
- MHC-related 1 is structurally similar to the Class I MHC complexes and consists of a heavy chain and ⁇ 2M.
- MR1 mainly presents small aromatic molecules, which activate mucosal associated invariant T cells (MAIT) . These small aromatic molecules are in general smaller than the polypeptide presented by Class I MHC or the lipid presented by CD1.
- Neonatal Fc-receptor (FcRn) transports immunoglobulin G (IgG) across cell layers, extending IgG half-life in circulation and providing newborns with humoral immunity.
- FcRN consists of a heavy chain and ⁇ 2M.
- UL18 shares homology with MHC heavy chains, and binds to ⁇ 2M to form a complex expressed on the cell surface, which allows the cell to evade NK cell-mediated cytolysis.
- beta-2-microglobulin ( ⁇ 2M) peptide refers to the full length protein of beta-2-microglobulin, or a functional fragment or variant thereof.
- ⁇ 2M is a light chain of the Class I MHC complexes. Inactivation of the ⁇ 2M gene effectively eliminates the expression of Class I MHC from the cell surface. Cells with no expression of Class I MHC on the surface are recognized and killed by NK cells.
- Human ⁇ 2M has a molecular weight of 11, 800 Daltons and consists of 119 amino acids (SEQ ID NO: 7) . The first 20 amino acids at the N-terminus form the signal peptide of human ⁇ 2M, which can be cleaved. The mature form of human ⁇ 2M does not include the signal peptide and consists of 99 amino acids (SEQ ID NO: 81) .
- Exemplary functional fragments of ⁇ 2M include, for example, the truncated form ⁇ N6 ⁇ 2M (93 amino acids) , which lack the 6 N-terminal amino acids of the mature ⁇ 2M, and and ⁇ N10 ⁇ 2M (89 amino acids) , which lack the 10 N-terminal amino acids of the mature ⁇ 2M (Sulatskaya et al., Int. J. Mol. Sci. (2016) 19: 2762) .
- Exemplary variants includes, for example, the following isoforms provided on UniProt: entries F5H6I0 (101 amino acids) , H0YLF3 (71 amino acids) , B4E0X1 (122 amino acids) , A6XMH4 (124 amino acid) , A6XMH5 (92 amino acids) , A6XND9 (101 amino acids) , Q9UM88 (29 amino acids) , Q16446 (51 amino acids) , and J3KNU0 (57 amino acids) .
- variant refers to a different protein or polypeptide comprising one or more (such as, for example, about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) amino acid substitutions, deletions, and/or additions as compared to the reference protein or reference polypeptide.
- the changes to an amino acid sequence can be amino acid substitutions.
- the changes to an amino acid sequence can be conservative amino acid substitutions.
- a functional fragment or a functional variant of a protein or polypeptide maintains the basic structural and functional properties of the reference protein or polypeptide.
- a variant of human ⁇ 2M can have one or more (such as, for example, about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) changes to the amino acid sequence of wild type human ⁇ 2M.
- the variant of human ⁇ 2M has the basic structural and functional properties of human ⁇ 2M.
- a human ⁇ 2M variant can also bind to an MHC heavy chain to form an MHC complex that can be recognized by immune cells.
- presenting peptide refers to short peptides that can stably bind to the antigen binding groove of an MHC to form a stable MHC complex that can be recognized by receptors on immune cells.
- the presenting peptides generally have 7-30 amino acids. In some embodiments, the presenting peptides have 7-20 amino acids, 7-17 amino acids, 7-15 amino acids, 7-12 amino acids, or 8-10 amino acids.
- Each MHC has its own matched presenting peptides.
- a presenting peptide that is “restricted” to a particular MHC molecule means that the presenting peptide can form a stable complex with this particular MHC molecule.
- an HLA-C restricted presenting peptide can form a stable complex with HLA-C on the cell surface
- an HLA-E restricted presenting peptide can form a stable complex with HLA-E on the cell surface.
- Presenting peptides that are restricted to a particular HLA can be identified by selecting the presenting peptides that stably bind to the HLA.
- a presenting peptide that is restricted to a particular Class I MHC or MHC-like complex can be covalently linked to ⁇ 2M to form a fusion protein, which can form a stable complex with the particular MHC heavy chain.
- a fusion protein having an HLA-C restricted presenting peptide covalently linked to ⁇ 2M can form a stable complex with an HLA-C heavy chain on the cell surface
- a fusion protein having an HLA-E restricted presenting peptide covalently linked to ⁇ 2M can form a stable complex with an HLA-E heavy chain on the cell surface.
- inhibitory receptor refers to the receptor molecule expressed on the surface of the immune cell that can inhibit the activity of the immune cells upon binding to its ligand.
- the immune system employs a variety of inhibitory mechanisms to control immune responses as well as to ensure immune tolerance and homeostasis, including inhibitory pathways mediated via the inhibitory receptors.
- NK cells are regulated by the autologous Class I MHC-binding receptors, which confer dominant suppression of NK cells upon binding to self MHC class I molecules.
- Class I MHC-binding inhibitory receptors are expressed by not only NK cells, but also subsets of T cells, especially CD8+ T cells. There are at least two families of these inhibitory receptors, including the killer immunoglobulin-like receptor (KIR) family and the C type lectin-like family (e.g. NKG2A/B, CD94) .
- KIR killer immunoglobulin-like receptor
- C type lectin-like family e.g. NKG2A/B, CD94
- binding moiety e.g. antibody
- SPR e.g., Biacore
- a specific reaction will be at least twice background signal or noise and can be more than 10 times background.
- a binding moiety that specifically binds a target molecule can bind the target molecule at a higher affinity than its affinity for a different molecule.
- “specifically binds” means, for instance, that a binding moiety binds a molecule target with a K D of about 0.1 mM or less.
- “specifically binds” means that a polypeptide or molecule binds a target with a K D of at about 30 ⁇ M or less.
- “specifically binds” means that a polypeptide or molecule binds a target with a K D of at about 10 ⁇ M or less or about 1 ⁇ M or less.
- “specifically binds” means that a polypeptide or molecule binds a target with a K D of at about 0.1 ⁇ M or less, about 0.01 ⁇ M or less, or about 1 nM or less.
- nucleotide e.g., DNA, RNA, DNA, and RNA.
- nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase.
- nucleic acids or polypeptides refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity.
- the percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software that can be used to obtain alignments of amino acid or nucleotide sequences are well-known in the art.
- two nucleic acids or polypeptides provided herein are substantially identical, meaning they have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and in some embodiments at least 95%, 96%, 97%, 98%, 99%nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection.
- identity exists over a region of the amino acid sequences that is at least about 10 residues, at least about 20 residues, at least about 40-60 residues, at least about 60-80 residues in length or any integral value there between. In some embodiments, identity exists over a longer region than 60-80 residues, such as at least about 80-100 residues, and in some embodiments the sequences are substantially identical over the full length of the sequences being compared, such as the coding region of a target protein or an antibody. In some embodiments, identity exists over a region of the nucleotide sequences that is at least about 10 bases, at least about 20 bases, at least about 40-60 bases, at least about 60-80 bases in length or any integral value there between.
- identity exists over a longer region than 60-80 bases, such as at least about 80-1000 bases or more, and in some embodiments the sequences are substantially identical over the full length of the sequences being compared, such as a nucleotide sequence encoding a protein of interest.
- antibody and its grammatical equivalents as used herein refer to an immunoglobulin molecule that recognizes and specifically binds a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of any of the foregoing, through at least one antigen-binding site wherein the antigen-binding site is usually within the variable region of the immunoglobulin molecule.
- a target such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of any of the foregoing.
- the term encompasses intact polyclonal antibodies, intact monoclonal antibodies, single-domain antibodies (sdAbs; e.g., camelid antibodies, alpaca antibodies) , single-chain Fv (scFv) antibodies, heavy chain antibodies (HCAbs) , light chain antibodies (LCAbs) , multispecific antibodies, bispecific antibodies, monospecific antibodies, monovalent antibodies, and any other modified immunoglobulin molecule comprising an antigen-binding site (e.g., dual variable domain immunoglobulin molecules) as long as the antibodies exhibit the desired biological activity.
- Antibodies also include, but are not limited to, mouse antibodies, camel antibodies, chimeric antibodies, humanized antibodies, and human antibodies.
- An antibody can be any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) , based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively.
- the term “antibody” as used herein include “antigen-binding domain” of intact antibodies.
- the term “antigen-binding domain” as used herein refers to a portion or fragment of an intact antibody that is the antigenic determining variable region of an intact antibody.
- antigen-binding domains include, but are not limited to, Fab, Fab', F (ab’) 2 , Fv, linear antibodies, single chain antibody molecules (e.g., scFv) , heavy chain antibodies (HCAbs) , light chain antibodies (LCAbs) , disulfide-linked scFv (dsscFv) , diabodies, tribodies, tetrabodies, minibodies, dual variable domain antibodies (DVD) , single variable domain antibodies (sdAbs; e.g., camelid antibodies, alpaca antibodies) , and single variable domain of heavy chain antibodies (VHH) .
- scFv single chain antibody molecules
- HCAbs heavy chain antibodies
- LCAbs light chain antibodies
- dsscFv disulfide-linked scFv
- VHH single variable domain of heavy chain antibodies
- vector refers to a vehicle that is used to carry genetic material (e.g. a nucleic acid sequences) , which can be introduced into a host cell, where it can be replicated and/or expressed.
- vectors applicable for use include, for example, expression vectors, plasmids, phage vectors, viral vectors, episomes and artificial chromosomes, which can include selection sequences or markers operable for stable integration into a host cell’s chromosome. Additionally, the vectors can include one or more selectable marker genes and appropriate expression control sequences.
- Selection control sequences can include constitutive and inducible promoters, transcription enhancers, transcription terminators, and the like which are well known in the art.
- both nucleic acids can be inserted, for example, into a single expression vector or in separate expression vectors.
- the encoding nucleic acids can be operationally linked to one common expression control sequence or linked to different expression control sequences, such as one inducible promoter and one constitutive promoter. The introduction of nucleic acids into a host cell can be confirmed using methods well known in the art.
- nucleic acids are expressed in a sufficient amount to produce a desired product (e.g. a fusion protein as described herein) , and it is further understood that expression levels can be optimized to obtain sufficient expression using methods well known in the art.
- operably linked refers to functional linkage between a regulatory sequence (such as a promoter, and/or enhancer) and a second nucleic acid sequence, wherein the regulatory sequence directs transcription of the second nucleic acid sequence; or the linkage between two nucleic acid sequences to be co-expressed that are in the same reading frame.
- a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
- a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
- operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.
- exogenous and its grammatical equivalents as used herein are intended to mean that the referenced molecule is introduced into the host cell.
- the molecule can be introduced, for example, by introduction of an encoding nucleic acid into the host genetic material such as by integration into a host chromosome or as non-chromosomal genetic material such as a plasmid.
- introduction of an encoding nucleic acid into the host genetic material such as by integration into a host chromosome or as non-chromosomal genetic material such as a plasmid.
- the term refers to introduction of the encoding nucleic acid in an expressible form into the cell.
- endogenous and its grammatical equivalents as used herein refer to a referenced molecule that is naturally present in the host cell.
- the term when used in reference to expression of an encoding nucleic acid refers to expression of an encoding nucleic acid naturally contained within the cell.
- genetic engineering or its grammatical equivalents when used in reference to a cell is intended to mean alteration of the genetic materials of the cell that is not normally found in a naturally occurring cell. Genetic alterations include, for example, modifications introducing expressible nucleic acids, other nucleic acid additions, nucleic acid mutations/alterations, nucleic acid deletions and/or other functional disruption of the cell’s genes. Such modifications can be done in, for example, coding regions and functional fragments thereof of a gene. Additional modifications can be done in, for example, non-coding regulatory regions in which the modifications alter expression of a gene.
- transduce, ” “transfect” and their grammatical equivalents as used herein refer to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
- a “transduced” or “transfected” cell is one which has been transduced with an exogenous nucleic acid.
- the cell can be the primary subject cell, or its progeny.
- the terms “inactivate, ” “disrupt, ” and their grammatical equivalents when used in connection with a gene are intended to mean a genetic alteration that renders the encoded gene product inactive or attenuated.
- the genetic alteration can be, for example, deletion of the entire gene, deletion of a regulatory sequence required for transcription or translation, deletion of a portion of the gene which results in a truncated gene product, or by any of various mutation strategies that inactivate or attenuate the encoded gene product.
- a gene disruption also includes a null mutation, which refers to a mutation within a gene or a region containing a gene that results in the gene not being transcribed into RNA and/or translated into a functional gene product. Such a null mutation can arise from many types of mutations including, for example, inactivating point mutations, deletion of a portion of a gene, entire gene deletions, or deletion of chromosomal segments.
- the term “encode” and its grammatical equivalents refer to the inherent property of specific sequences of nucleotides in a polynucleotide or a nucleic acid, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
- a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein.
- nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA can include introns.
- a polypeptide, peptide, protein, antibody, polynucleotide, vector, cell, or composition which is “isolated” is a polypeptide, peptide, protein, antibody, polynucleotide, vector, cell, or composition which is in a form not found in nature.
- Isolated polypeptides, peptides, proteins, antibodies, polynucleotides, vectors, cells, or compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature.
- a polypeptide, peptide, protein, antibody, polynucleotide, vector, cell, or composition which is isolated is substantially pure.
- treat and its grammatical equivalents as used herein in connection with a disease or a condition, or a subject having a disease or a condition refer to an action that suppresses, eliminates, reduces, and/or ameliorates a symptom, the severity of the symptom, and/or the frequency of the symptom associated with the disease or disorder being treated.
- the term “treat” and its grammatical equivalents refer to an action that reduces the severity of the cancer or tumor, or retards or slows the progression of the cancer or tumor, including (a) inhibiting the growth, or arresting development of the cancer or tumor, (b) causing regression of the cancer or tumor, or (c) delaying, ameliorating or minimizing one or more symptoms associated with the presence of the cancer or tumor.
- administer and its grammatical equivalents as used herein refer to the act of delivering, or causing to be delivered, a therapeutic or a pharmaceutical composition to the body of a subject by a method described herein or otherwise known in the art.
- the therapeutic can be a compound, a polypeptide, a cell, or a population of cells.
- Administering a therapeutic or a pharmaceutical composition includes prescribing a therapeutic or a pharmaceutical composition to be delivered into the body of a subject.
- Exemplary forms of administration include oral dosage forms, such as tablets, capsules, syrups, suspensions; injectable dosage forms, such as intravenous (IV) , intramuscular (IM) , or intraperitoneal (IP) ; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and rectal suppositories.
- oral dosage forms such as tablets, capsules, syrups, suspensions
- injectable dosage forms such as intravenous (IV) , intramuscular (IM) , or intraperitoneal (IP)
- transdermal dosage forms including creams, jellies, powders, or patches
- buccal dosage forms inhalation powders, sprays, suspensions, and rectal suppositories.
- an effective amount, ” “therapeutically effective amount, ” and their grammatical equivalents as used herein refer to the administration of an agent to a subject, either alone or as a part of a pharmaceutical composition and either in a single dose or as part of a series of doses, in an amount that is capable of having any detectable, positive effect on any symptom, aspect, or characteristics of a disease, disorder or condition when administered to the subject.
- the therapeutically effective amount can be ascertained by measuring relevant physiological effects. The exact amount required vary from subject to subject, depending on the age, weight, and general condition of the subject, the severity of the condition being treated, the judgment of the clinician, and the like. An appropriate “effective amount” in any individual case can be determined by one of ordinary skill in the art using routine experimentation.
- pharmaceutically acceptable excipient refers to a material that is suitable for drug administration to an individual along with an active agent without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition.
- subject refers to any animal (e.g., a mammal) , including, but not limited to, humans, non-human primates, canines, felines, rodents, and the like, which is to be the recipient of a particular treatment.
- a subject can be a human.
- a subject can be a patient with a particular disease.
- a subject can also be a recipient of a transplant.
- ranges throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1 , 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
- GenBank numbers GI numbers and/or SEQ ID NOS. It is understood that one skilled in the art can readily identify homologous sequences by reference to sequence sources, including but not limited to GenBank (ncbi. nlm. nih. gov/genbank/) and EMBL (embl. org/) .
- fusion proteins when expressed in a host cell, fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, can form a complex with an endogenous MHC heavy chain on the cell surface, wherein said complex can bind an inhibitory receptor of an immune cell to inhibit the immune cell.
- a fusion protein having human ⁇ 2M covalently linked to an HLA-E restricted presenting peptide can be expressed in a T cell, which can form an HLA-E complex with an endogenous HLA-E heavy chain on the T cell surface.
- the HLA-E complex on the T cell surface can then be recognized by the immune cells (e.g NK cells) of the recipient, inhibiting the immune cells and protecting the T cell from a potential allogeneic immune response from these immune cells (e.g. NK cell-mediated cell lysis) .
- the immune cells e.g NK cells
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein has less than 500 amino acids. In some embodiments, the fusion protein has less than 400 amino acids. In some embodiments, the fusion protein has less than 300 amino acids. In some embodiments, the fusion protein has less than 200 amino acids. In some embodiments, the fusion protein has about 100 to about 300 amino acids. In some embodiments, the fusion protein has about 100 to about 200 amino acids.
- the fusion protein has about 120 to about 180 amino acids. In some embodiments, the fusion protein has about 120 to about 160 amino acids. In some embodiments, the fusion protein has about 140 to about 160 amino acids. In some embodiments, the fusion protein lacks an MHC heavy chain. In some embodiments, the fusion protein lacks a Class I MHC heavy chain. In some embodiments, the fusion protein lacks an MHC-like heavy chain. In some embodiments, the fusion protein lacks an HLA-A heavy chain. In some embodiments, the fusion protein lacks an HLA-B heavy chain. In some embodiments, the fusion protein lacks an HLA-C heavy chain. In some embodiments, the fusion protein lacks an HLA-E heavy chain.
- the fusion protein lacks an HLA-F heavy chain. In some embodiments, the fusion protein lacks an HLA-G heavy chain. In some embodiments, the fusion protein lacks a CD1 heavy chain. In some embodiments, the fusion protein lacks an MR1 heavy chain. In some embodiments, the fusion protein lacks an FcRn heavy chain. In some embodiments, the fusion protein lacks UL18.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell; and provided herein are fusion proteins that bind an MHC heavy chain to form an MHC complex, which binds an inhibitory receptor of a T cell to inhibit the T cell.
- the immune cell is an NK cell; and provided herein are fusion proteins that bind an MHC heavy chain to form an MHC complex, which binds an inhibitory receptor of an NK cell to inhibit the NK cell.
- the inhibitory receptor of the immune cell is NKG2A.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the NKG2A receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human NKG2A can have an amino acid sequence corresponding to the sequence having GenBank No. AAL65234.1 (Accession: AAL65234.1 GI: 18182682; see below) .
- the inhibitory receptor of the immune cell is a KIR receptor.
- the inhibitory KIR receptor can be selected from the group consisting of KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, and KIR3DL3.
- the inhibitory receptor of the immune cell is KIR2DL1.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR2DL1 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR2DL1 can have an amino acid sequence corresponding to the sequence having GenBank No. SPC71652.1 (Accession: SPC71652.1 GI: 1373834531; see below) .
- the inhibitory receptor of the immune cell is KIR2DL2.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR2DL2 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR2DL2 can have an amino acid sequence corresponding to the sequence having GenBank No. ACI49717.1 (Accession: ACI49717.1 GI: 209512829; see below) .
- the inhibitory receptor of the immune cell is KIR2DL3.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR2DL3 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR2DL3 can have an amino acid sequence corresponding to the sequence having GenBank No. ADN34702.1 (Accession: ADN34702.1 GI: 307141824; see below) .
- the inhibitory receptor of the immune cell is KIR2DL4.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR2DL4 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR2DL4 can have an amino acid sequence corresponding to the sequence having GenBank No. ABW73959.1 (Accession: ABW73959.1 GI: 158551989; see below) .
- the inhibitory receptor of the immune cell is KIR2DL5.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR2DL5 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR2DL5 can have an amino acid sequence corresponding to the sequence having GenBank No. SHO29775.1 (Accession: SHO29775.1 GI: 1313716695; see below) .
- the inhibitory receptor of the immune cell is KIR3DL1.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR3DL1 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR3DL1 can have an amino acid sequence corresponding to the sequence having GenBank No. ADM64608.1 (Accession: ADM64608.1 GI: 305690575; see below) .
- the inhibitory receptor of the immune cell is KIR3DL2.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR3DL2 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR3DL2 can have an amino acid sequence corresponding to the sequence having GenBank No. CUX91181.1 (Accession: CUX91181.1 GI: 998428963; see below) .
- the inhibitory receptor of the immune cell is KIR3DL3.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the KIR3DL3 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human KIR3DL3 can have an amino acid sequence corresponding to the sequence having GenBank No. SHO29793.1 (Accession: SHO29793.1 GI: 1313716772; see below) .
- the inhibitory receptor of the immune cell is leukocyte immunoglobulin-like receptor 1 “LIR1. ”
- LIR1 leukocyte immunoglobulin-like receptor 1
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds the LIR1 receptor of an immune cell to inhibit the immune cell.
- the immune cell is a T cell.
- the immune cell is an NK cell.
- a human LIR1 can have an amino acid sequence corresponding to the sequence having GenBank No. AAG08984.1 (Accession: AAG08984.1 GI: 9954210; see below) .
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the MHC heavy chain is a classical Class I MHC heavy chain, a non-classical Class I MHC heavy chain, or an MHC-like heavy chain.
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind a classical Class I MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the classical Class I MHC heavy chain can be selected from the group consisting of an HLA-A heavy chain, an HLA-B heavy chain, and an HLA-C heavy chain.
- the classical Class I MHC heavy chain is an HLA-A heavy chain.
- fusion proteins comprising an HLA-A-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion protein binds an HLA-A heavy chain to form an HLA-A complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an HLA-A heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- Human HLA-A heavy chain is highly polymorphic.
- the amino acid sequence of one allelic form of human HLA-A heavy chain corresponds to the sequence having GenBank No. BAB63400.1 (Accession: BAB63400.1 GI: 15277272) .
- the classical Class I MHC heavy chain is an HLA-B heavy chain.
- fusion proteins comprising an HLA-B-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an HLA-B heavy chain to form an HLA-B complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an HLA-B heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- Human HLA-B heavy chain is highly polymorphic.
- the amino acid sequence of one allelic form of human HLA- B heavy chain corresponds to the sequence having GenBank No. AAA59682.1 (Accession: AAA59682.1 GI: 403145) .
- the classical Class I MHC heavy chain is an HLA-C heavy chain.
- fusion proteins comprising an HLA-C-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an HLA-C heavy chain to form an HLA-C complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an HLA-C heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- Human HLA-C heavy chain is highly polymorphic.
- the amino acid sequence of one allelic form of human HLA-C heavy chain corresponds to the sequence having GenBank No. BAB63310.1 (Accession: BAB63310.1 GI: 15277217) .
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind a nonclassical Class I MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the nonclassical Class I MHC heavy chain can be selected from the group consisting of an HLA-E heavy chain, an HLA-F heavy chain, and an HLA-G heavy chain.
- the nonclassical Class I MHC heavy chain is an HLA-E heavy chain.
- fusion proteins comprising an HLA-E-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an HLA-E heavy chain to form an HLA-E complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an HLA-E heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- Human HLA-E heavy chain is polymorphic.
- the amino acid sequence of one allelic form of human HLA-E heavy chain corresponds to the sequence having GenBank No. ARB08449.1 (Accession: ARB08449.1 GI: 1168024009) .
- the nonclassical Class I MHC heavy chain is an HLA-F heavy chain.
- fusion proteins comprising an HLA-F-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an HLA-F heavy chain to form an HLA-F complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an HLA-F heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- Human HLA-F heavy chain is polymorphic.
- the amino acid sequence of one allelic form of human HLA-F heavy chain corresponds to the sequence having GenBank No. BAB63337.1 (Accession: BAB63337.1 GI: 15277244)
- the nonclassical Class I MHC heavy chain is an HLA-G heavy chain.
- fusion proteins comprising an HLA-G-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an HLA-G heavy chain to form an HLA-G complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an HLA-G heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- Human HLA-G heavy chain is highly polymorphic.
- the amino acid sequence of one allelic form of human HLA-G heavy chain corresponds to the sequence having GenBank No. BAB63336.1 (Accession: BAB63336.1 GI: 15277243)
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MHC-like heavy chain to form an MHC-like complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the MHC-like complex can be selected from the group consisting of CD1, MR1, FcRN and UL18.
- the MHC-like heavy chain is a CD1 heavy chain.
- fusion proteins comprising a CD1-restricted presenting molecule covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion protein binds a CD1 heavy chain to form a CD1 complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have a CD1 heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- the MHC-like heavy chains include a CD1a heavy chain, a CD1b heavy chain, a CD1c heavy chain, a CD1d heavy chain and a CD1e heavy chain.
- a human CD1a heavy chain can have an amino acid sequence corresponding to the NCBI Reference Sequence NP_001754.2 (Accession: NP_001754.2 GI: 110618224) .
- a human CD1b heavy chain can have an amino acid sequence corresponding to the NCBI Reference Sequence: XP_011508421.1 (Accession: XP_011508421.1 GI: 767910806) .
- a human CD1c heavy chain can have an amino acid sequence corresponding to the NCBI Reference Sequence: XP_005245636.1 (Accession: XP_005245636.1 GI: 530365569) .
- a human CD1d heavy chain can have an amino acid sequence corresponding to the NCBI Reference Sequence: NP_001358692.1 (Accession: NP_001358692.1 GI: 1707918971; precursor)
- a human CD1e heavy chain can have an amino acid sequence corresponding to the sequence having GenBank No. AAI31694.1 (Accession: AAI31694.1 GI: 124297103) .
- the MHC-like heavy chain is an MR1 heavy chain.
- a human MR1 heavy chain can have an amino acid sequence corresponding to the sequence having GenBank No. AAH12485.1 (Accession: AAH12485.1) .
- fusion proteins comprising a MR1-restricted presenting molecule covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an MR1 heavy chain to form a MR1 complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an MR1 heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids. In some embodiments, the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- a human MR1 heavy chain can have an amino acid sequence corresponding to the sequence having GenBank No. CAB77667.1 (Accession: CAB77667.1 GI: 7271191) .
- the MHC-like heavy chain is an FcRn heavy chain.
- fusion proteins comprising an FcRn-restricted presenting molecule covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind an FcRn heavy chain to form a FcRn complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have an FcRn heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- a human FcRn heavy chain can have an amino acid sequence corresponding to the sequence having UniProtKB/Swiss-Prot: P55899.1 (Accession: P55899.1; GI: 2497331) .
- the MHC-like heavy chain is UL18.
- fusion proteins comprising a UL18-restricted presenting molecule covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion proteins bind a UL18 to form a UL18 complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- the fusion protein does not have a UL18 polypeptide.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- a human UL18 can have an amino acid sequence corresponding to the sequence having GenBank No. AJY57863.1 (Accession: AJY57863.1 GI: 777959438)
- fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- the presenting peptide can be derived from a virus, a prokaryote, a eukaryote, or a mammal.
- the presenting peptide is derived from a virus.
- the presenting peptide is derived from a prokaryote.
- the presenting peptide is derived from a eukaryote.
- the presenting peptide is derived from a mammal.
- the presenting peptide is derived from a human.
- the presenting peptide can have 5-30, 5-25, 5-20, 7-20, 7-18, 7-15, 8-12, or 8-10 amino acids. In some embodiments, the presenting peptide has 5-30 amino acids. In some embodiments, the presenting peptide has 5-25 amino acids. In some embodiments, the presenting peptide has 5-20 amino acids. In some embodiments, the presenting peptide has 7-20 amino acids. In some embodiments, the presenting peptide has 7-18 amino acids. In some embodiments, the presenting peptide has 7-15 amino acids. In some embodiments, the presenting peptide has 8-12 amino acids. In some embodiments, the presenting peptide has 8-10 amino acids.
- the presenting peptide can be a signal peptide of a Class I MHC molecule or a fragment thereof. In some embodiments, the presenting peptide is a fragment of a signal peptide of a Class I MHC molecule. In some embodiments, provided herein are fusion proteins comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof. In some embodiments, the fusion protein does not have an MHC heavy chain. In some embodiments, the fusion protein does not have an HLA-E heavy chain.
- the fusion protein does not have an HLA-A heavy chain, an HLA-B heavy chain, an HLA-C heavy chain, an HLA-E heavy chain, an HLA-F heavy chain, or an HLA-G heavy chain. In some embodiments, the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids. In some embodiments, the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- the signal peptide of Class I MHC molecule is the peptide present at the N-terminus of a Class I MHC heavy chain, which guides and positions a newly synthesized Class I MHC heavy chain protein to the endoplasmic reticulum, allowing the mature heavy chain molecule, ⁇ 2M and the presenting peptide to form a complex on the cell surface.
- the polypeptide is cleaved off in the mature protein.
- a signal peptide of the Class I MHC molecule generally has between 13-80 amino acids. Some signal peptides of the Class I MHC molecule have between 20-50 amino acids.
- the presenting peptide is a signal peptide of a Class I MHC molecule or a fragment thereof.
- the Class I MHC molecule can be selected from the group consisting of HLA-A1, HLA-A2, HLA-A*3401, HLA-A*80, HLA-B7, HLA-B*13, HLA-B15, HLA-Cw3, HLA-Cw*2, HLA-Cw*0809, HLA-Cw7, HLA-Cw*1701, HLA-G, and HLA-F.
- the presenting peptide is a signal peptide or a fragment thereof of HLA-A1.
- the presenting peptide is a signal peptide or a fragment thereof of HLA-A2. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-A*3401. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-A*80. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-B7. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-B*13. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-B15.
- the presenting peptide is a signal peptide or a fragment thereof of HLA-Cw3. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-Cw*2. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-Cw*0809. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-Cw7. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-Cw*1701. In some embodiments, the presenting peptide is a signal peptide or a fragment thereof of HLA-G.
- the presenting peptide is a signal peptide or a fragment thereof of HLA-F.
- these exemplified signal peptides of a Class I MHC molecule or fragments thereof are HLA-E restricted presenting peptides.
- the presenting peptide that is a signal peptide of a Class I MHC molecule or a fragment thereof can have 5-30 amino acids.
- the presenting peptide that is a signal peptide of a Class I MHC molecule or a fragment thereof can have 5-25 amino acids, 5-20 amino acids, 7-18 amino acids, 7-15 amino acids, 8-12 amino acids, or 8-10 amino acids.
- the presenting peptide that is a fragment of a signal peptide of a Class I MHC molecule or a fragment thereof can have 8-10 amino acids.
- the presenting polypeptide is a signal peptide of a Class I MHC molecule or a fragment thereof, and has the following amino acid sequence: X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 L; wherein X 1 is V or I; X 2 is T, A, M or L; X 3 is A, P, K or N; X 4 is P, L, or T; X 5 is R, Q or K; X 6 is T or A; X 7 is L, I, V or P; X 8 is V, L, I, F or T (SEQ ID NO: 115) .
- the presenting peptide is a signal peptide of Class I MHC molecule or a fragment thereof, and the amino acid sequence of the presenting peptide is selected from the group consisting of (1) YLLPRRGPRL (SEQ ID NO: 21) ; (2) ALALVRMLI (SEQ ID NO: 22) ; (3) AISPRTLNA (SEQ ID NO: 23) ; (4) QMRPVSRVL (SEQ ID NO: 24) ; (5) SQQPYLQLQ (SEQ ID NO: 25) ; (6) VTAPRTLLL (SEQ ID NO: 26) ; (7) VTAPRTVLL (SEQ ID NO: 27) ; (8) VTAPRTLVL (SEQ ID NO: 28) ; (9) VMAPQALLL (SEQ ID NO: 29) ; (10) VMAPRALLL (SEQ ID NO: 30) ; (11) VMAPRTLTL (SEQ ID NO: 31) ; (12) VMAPRTLFL (SEQ ID NO:
- the amino acid sequence of the presenting peptide is (1) YLLPRRGPRL (SEQ ID NO: 21) . In some embodiments, the amino acid sequence of the presenting peptide is (2) ALALVRMLI (SEQ ID NO: 22) . In some embodiments, the amino acid sequence of the presenting peptide is (3) AISPRTLNA (SEQ ID NO: 23) . In some embodiments, the amino acid sequence of the presenting peptide is (4) QMRPVSRVL (SEQ ID NO: 24) . In some embodiments, the amino acid sequence of the presenting peptide is (5) SQQPYLQLQ (SEQ ID NO: 25) .
- the amino acid sequence of the presenting peptide is (6) VTAPRTLLL (SEQ ID NO: 26) . In some embodiments, the amino acid sequence of the presenting peptide is (7) VTAPRTVLL (SEQ ID NO: 27) . In some embodiments, the amino acid sequence of the presenting peptide is (8) VTAPRTLVL (SEQ ID NO: 28) . In some embodiments, the amino acid sequence of the presenting peptide is (9) VMAPQALLL (SEQ ID NO: 29) . In some embodiments, the amino acid sequence of the presenting peptide is (10) VMAPRALLL (SEQ ID NO: 30) .
- the amino acid sequence of the presenting peptide is (11) VMAPRTLTL (SEQ ID NO: 31) . In some embodiments, the amino acid sequence of the presenting peptide is (12) VMAPRTLFL (SEQ ID NO: 32) . In some embodiments, the amino acid sequence of the presenting peptide is (13) VMAPRTLVL (SEQ ID NO: 33) . In some embodiments, the amino acid sequence of the presenting peptide is (14) VMAPRTLIL (SEQ ID NO: 34) . In some embodiments, the amino acid sequence of the presenting peptide is (15) IMAPRTLVL (SEQ ID NO: 35) .
- the amino acid sequence of the presenting peptide is (16) VMAPRTLLL (SEQ ID NO: 36) . In some embodiments, the amino acid sequence of the presenting peptide is (17) VMPPRTLLL (SEQ ID NO: 37) . In some embodiments, the amino acid sequence of the presenting peptide is (18) VMAPRTVLL (SEQ ID NO: 38) . In some embodiments, the amino acid sequence of the presenting peptide is (19) VMAPRSLLL (SEQ ID NO: 39) . In some embodiments, the amino acid sequence of the presenting peptide is (20) VMAPRSLIL (SEQ ID NO: 40) .
- the amino acid sequence of the presenting peptide is (21) VMTPRTLVL (SEQ ID NO: 41) . In some embodiments, the amino acid sequence of the presenting peptide is (22) VMAPRILIL (SEQ ID NO: 42) . In some embodiments, the amino acid sequence of the presenting peptide is (23) AMAPRTLIL (SEQ ID NO: 43) . In some embodiments, the amino acid sequence of the presenting peptide is (24) VIAPRTLVL (SEQ ID NO: 44) . In some embodiments, the amino acid sequence of the presenting peptide is (25) VMAPQSLLL (SEQ ID NO: 45) .
- the amino acid sequence of the presenting peptide is (26) VMAPRTFVL (SEQ ID NO: 46) . In some embodiments, the amino acid sequence of the presenting peptide is (27) VMTPRTLIL (SEQ ID NO: 47) . In some embodiments, the amino acid sequence of the presenting peptide is (28) VTAPRTLIL (SEQ ID NO: 48) . In some embodiments, the amino acid sequence of the presenting peptide is (29) VMAPWTLLL (SEQ ID NO: 49) . In some embodiments, the amino acid sequence of the presenting peptide is (30) VMVPRSLIL (SEQ ID NO: 50) .
- the amino acid sequence of the presenting peptide is (31) AMAPRTLVL (SEQ ID NO: 51) . In some embodiments, the amino acid sequence of the presenting peptide is (32) VIAPRTLIL (SEQ ID NO: 52) . In some embodiments, the amino acid sequence of the presenting peptide is (33) VIAPRTLLL (SEQ ID NO: 53) . In some embodiments, the amino acid sequence of the presenting peptide is (34) VLAPRTLIL (SEQ ID NO: 54) . In some embodiments, the amino acid sequence of the presenting peptide is (35) VMALRTLIL (SEQ ID NO: 55) .
- the amino acid sequence of the presenting peptide is (36) VMAPRGLIL (SEQ ID NO: 56) . In some embodiments, the amino acid sequence of the presenting peptide is (37) VMAPRNLIL (SEQ ID NO: 57) . In some embodiments, the amino acid sequence of the presenting peptide is (38) VMAPRTLFV (SEQ ID NO: 58) . In some embodiments, the amino acid sequence of the presenting peptide is (39) VMAPRTLLM (SEQ ID NO: 59) . In some embodiments, the amino acid sequence of the presenting peptide is (40) VMAPRTLVM (SEQ ID NO: 60) .
- the amino acid sequence of the presenting peptide is (41) VMAPRTSLL (SEQ ID NO: 61) . In some embodiments, the amino acid sequence of the presenting peptide is (42) VMAPRTSVL (SEQ ID NO: 62) . In some embodiments, the amino acid sequence of the presenting peptide is (43) VMAPWTLIL (SEQ ID NO: 63) . In some embodiments, the amino acid sequence of the presenting peptide is (44) VMAPWTLVL (SEQ ID NO: 64) . In some embodiments, the amino acid sequence of the presenting peptide is (45) VMDPRTLLL (SEQ ID NO: 65) .
- the amino acid sequence of the presenting peptide is (46) VMGPRTLIL (SEQ ID NO: 66) . In some embodiments, the amino acid sequence of the presenting peptide is (47) VMGPRTLLL (SEQ ID NO: 67) . In some embodiments, the amino acid sequence of the presenting peptide is (48) VMVPQTLIL (SEQ ID NO: 68) . In some embodiments, the amino acid sequence of the presenting peptide is (49) VMVPRTLLL (SEQ ID NO: 69) . In some embodiments, the amino acid sequence of the presenting peptide is (50) VVAPRTLIL (SEQ ID NO: 70) .
- the amino acid sequence of the presenting peptide is (51) VVAPRTLLL (SEQ ID NO: 71) . In some embodiments, the amino acid sequence of the presenting peptide is (52) VMVPRTLIL (SEQ ID NO: 72) . In some embodiments, the amino acid sequence of the presenting peptide is (53) VMATRTLLL (SEQ ID NO: 73) .
- HLA-E restricted presenting peptides are also described in the art. See e.g. United States Patent Application 20190314445; Celik et al., Immunogenetics 2016.68: 29-41; Hannoun et al. Immunology Letters 2018.202: 65-72; et al. Cell Rep 2018. 14 (8) : 1967-1976; et al. Front Immunol 2018. 9: 2410. All of these references are hereby incorporated by reference in their entireties. Similarly, presenting peptides that are restricted to HLA-A, HLA-B, HLA-C, HLA-F, or HLA-G are also well known in the art. See e.g. Gfeller et al. Front Immunol 2018.
- the presenting polypeptide can also be derived from a virus protein, such as of CMV, EBV, HIV, etc.
- the presenting peptide is a fragment of CMV.
- the presenting peptide is a fragment of EBV.
- the presenting peptide is a fragment of HIV.
- the fusion proteins provided herein have a presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- the fusion proteins provided herein have the presenting peptide, the linker, and the ⁇ 2M peptide from N-terminus to C-terminus.
- the fusion proteins provided herein have the ⁇ 2M peptide, the linker, and the presenting peptide, from N-terminus to C-terminus.
- the fusion proteins disclosed herein further include a membrane localization signal peptide at its N-terminus, which guides the fusion protein to locate to the cell membrane and is subsequently cleaved off the fusion protein.
- Membrane localization signal peptides can be between about 20-80 amino acids in length.
- Exemplary membrane localization signal peptide can have the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
- the fusion proteins provided herein consist of the presenting peptide, the linker, and the ⁇ 2M peptide from N-terminus to C-terminus.
- the fusion proteins provided herein consist of the ⁇ 2M peptide, the linker, and the presenting peptide from N-terminus to C-terminus.
- the fusion proteins provided herein have a presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- the linker links the presenting peptide and ⁇ 2M peptide of the fusion protein, and provides sufficient flexibility such that the fusion protein can form a stable complex with an MHC heavy chain.
- the linker provide herein can have about 5 to 50 amino acids, and contains at least one of the following five amino acids (Gly, Ala, Pro, Val, and Leu) , and at least one of the eight amino acids (Ser, Thr, Glu, Lys, Asn, Gln, Asp, and Arg) . In some embodiments, the linker provided herein has between 5 and 30 amino acids.
- the amino acid sequence of the linker can be (G4S) (G2S) (GS) (G3S) , namely, GGGGSGGSGSGGGS (SEQ ID NO: 114) .
- the amino acid sequence of the linker is (GGGGS) 3, or (G4S) 3, namely, GGGGSGGGGSGGGGS (SEQ ID NO: 1) .
- the amino acid sequence of the linker is (G4S) 4 sequence, namely, GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 2) .
- the fusion proteins provided herein have a presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- the ⁇ 2M peptide is a wild type ⁇ 2M protein.
- the ⁇ 2M peptide is wild type human ⁇ 2M (SEQ ID NO: 7) .
- the ⁇ 2M peptide is a functional fragment of a wild type ⁇ 2M protein.
- the ⁇ 2M peptide is a functional variant of a wild type ⁇ 2M protein.
- the ⁇ 2M peptide is a functional fragment of wild type human ⁇ 2M.
- the ⁇ 2M peptide is a functional variant of wild type human ⁇ 2M. In some embodiments, the ⁇ 2M peptide is a functional variant of a wild type ⁇ 2M protein having an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identical to SEQ ID NO: 7. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 85%identical to SEQ ID NO: 7. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 90%identical to SEQ ID NO: 7. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 95%identical to SEQ ID NO: 7.
- the amino acid sequence of the ⁇ 2M peptide is at least 98%identical to SEQ ID NO: 7. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 99%identical to SEQ ID NO: 7. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is SEQ ID NO: 7.
- the ⁇ 2M peptide is the mature form of human ⁇ 2M (SEQ ID NO: 81) , and the fusion proteins provided herein have a presenting peptide covalently linked to the mature human ⁇ 2M peptide via a linker.
- the ⁇ 2M peptide is a functional fragment of the mature form of human ⁇ 2M protein.
- the ⁇ 2M peptide is a functional variant of the mature form of human ⁇ 2M protein.
- the ⁇ 2M peptide is a functional variant of the mature form of human ⁇ 2M protein having an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identical to SEQ ID NO: 81. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 85%identical to SEQ ID NO: 81. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 90%identical to SEQ ID NO: 81. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 95%identical to SEQ ID NO: 81.
- the amino acid sequence of the ⁇ 2M peptide is at least 98%identical to SEQ ID NO: 81. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is at least 99%identical to SEQ ID NO: 81. In some embodiments, the amino acid sequence of the ⁇ 2M peptide is SEQ ID NO: 81.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18. In some embodiments, the fusion protein does not have an MHC heavy chain. In some embodiments, the fusion protein does not have an HLA-E heavy chain.
- the fusion protein does not have an HLA-A heavy chain, an HLA-B heavy chain, an HLA-C heavy chain, an HLA-E heavy chain, an HLA-F heavy chain, or an HLA-G heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids. In some embodiments, the fusion protein has about 120 to about 180 amino acids.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 90%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 95%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 98%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 99%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises amino acids 21-143 of SEQ ID NO: 5.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 90%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 95%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 98%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 99%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises amino acids 21-143 of SEQ ID NO: 13.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 90%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 95%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 98%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 99%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises amino acids 21-143 of SEQ ID NO: 14.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 90%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 95%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 98%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 99%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises amino acids 21-143 of SEQ ID NO: 15.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 90%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 95%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 98%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 99%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises amino acids 21-143 of SEQ ID NO: 16.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 90%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 95%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 17.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 98%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 99%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises SEQ ID NO: 17. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises amino acids 21-143 of SEQ ID NO: 17.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 85%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 90%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 95%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 98%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence that is at least 99%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein comprises amino acids 21-144 of SEQ ID NO: 18.
- the amino acid sequence of the fusion protein provided herein consists of an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18.
- the amino acid sequence of the fusion protein provided herein is at least 85%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 90%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 95%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 98%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5.
- the amino acid sequence of the fusion protein provided herein is at least 99%identical to SEQ ID NO: 5 or amino acids 21-143 of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of SEQ ID NO: 5. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of amino acids 21-143 of SEQ ID NO: 5.
- the amino acid sequence of the fusion protein provided herein is at least 85%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 90%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 95%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 98%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13.
- the amino acid sequence of the fusion protein provided herein is at least 99%identical to SEQ ID NO: 13 or amino acids 21-143 of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of SEQ ID NO: 13. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of amino acids 21-143 of SEQ ID NO: 13.
- the amino acid sequence of the fusion protein provided herein is at least 85%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 90%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 95%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 98%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14.
- the amino acid sequence of the fusion protein provided herein is at least 99%identical to SEQ ID NO: 14 or amino acids 21-143 of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of SEQ ID NO: 14. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of amino acids 21-143 of SEQ ID NO: 14.
- the amino acid sequence of the fusion protein provided herein is at least 85%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 90%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 95%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 98%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15.
- the amino acid sequence of the fusion protein provided herein is at least 99%identical to SEQ ID NO: 15 or amino acids 21-143 of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of SEQ ID NO: 15. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of amino acids 21-143 of SEQ ID NO: 15.
- the amino acid sequence of the fusion protein provided herein is at least 85%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 90%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 95%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 98%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16.
- the amino acid sequence of the fusion protein provided herein is at least 99%identical to SEQ ID NO: 16 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of amino acids 21-143 of SEQ ID NO: 16.
- the amino acid sequence of the fusion protein provided herein is at least 85%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 90%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 95%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 98%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 16.
- the amino acid sequence of the fusion protein provided herein is at least 99%identical to SEQ ID NO: 17 or amino acids 21-143 of SEQ ID NO: 16. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of SEQ ID NO: 17. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of amino acids 21-143 of SEQ ID NO: 17.
- the amino acid sequence of the fusion protein provided herein is at least 85%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 90%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 95%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein is at least 98%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18.
- the amino acid sequence of the fusion protein provided herein is at least 99%identical to SEQ ID NO: 18 or amino acids 21-144 of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of SEQ ID NO: 18. In some embodiments, the amino acid sequence of the fusion protein provided herein consists of amino acids 21-144 of SEQ ID NO: 18.
- the fusion proteins described herein can be produced by any method known in the art, including chemical synthesis and recombinant expression techniques.
- the practice of the invention employs, unless otherwise indicated, conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields within the skill of the art. These techniques are described in the references cited herein and are fully explained in the literature. See, e.g., Maniatis et al. (1982 ) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory Press; Sambrook et al. (1989) , Molecular Cloning: A Laboratory Manual , Second Edition, Cold Spring Harbor Laboratory Press; Sambrook et al.
- fusion proteins described herein can be produced and isolated using methods known in the art.
- Peptides can be synthesized, in whole or in part, using chemical methods (see, e.g., Caruthers (1980) . Nucleic Acids Res. Symp. Ser. 215; Horn (1980) ; and Banga, A.K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, PA) .
- Peptide synthesis can be performed using various solid-phase techniques (see, e.g., Roberge Science 269: 202 (1995) ; Merrifield, Methods. Enzymol.
- a recombinant expression vector is used to amplify and express the nucleic acid encoding a fusion protein disclosed herein.
- a recombinant expression vector can be a replicable DNA construct that includes synthetic or cDNA-derived DNA fragments encoding a fusion protein, operatively linked to suitable transcriptional and/or translational regulatory elements derived from mammalian, microbial, viral or insect genes.
- a viral vector is used. DNA regions are operatively linked when they are functionally related to each other.
- a promoter is operatively linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operatively linked to a coding sequence if it is positioned so as to permit translation.
- structural elements intended for use in yeast expression systems include a leader sequence enabling extracellular secretion of translated protein by a host cell.
- a polypeptide may include an N-terminal methionine residue.
- Useful expression vectors for eukaryotic hosts include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus, and cytomegalovirus.
- Useful expression vectors for bacterial hosts include known bacterial plasmids, such as plasmids from E. coli, including pCR1, pBR322, pMB9 and their derivatives, and wider host range plasmids, such as M13 and other filamentous single-stranded DNA phages.
- a fusion protein of the present disclosure is expressed from one or more vectors.
- Suitable host cells for expression of a fusion protein include prokaryotes, yeast cells, insect cells, or higher eukaryotic cells under the control of appropriate promoters.
- Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts, as well as methods of protein production are well-known in the art.
- suitable mammalian host cell lines include, but are not limited to, COS-7 (monkey kidney-derived) , L-929 (murine fibroblast-derived) , C127 (murine mammary tumor-derived) , 3T3 (murine fibroblast-derived) , CHO (Chinese hamster ovary-derived) , HeLa (human cervical cancer-derived) , BHK (hamster kidney fibroblast-derived) , HEK-293 (human embryonic kidney-derived) cell lines and variants thereof.
- COS-7 monkey kidney-derived
- L-929 murine fibroblast-derived
- C127 murine mammary tumor-derived
- 3T3 murine fibroblast-derived
- CHO Choinese hamster ovary-derived
- HeLa human cervical cancer-derived
- BHK hamster kidney fibroblast-derived
- HEK-293 human embryonic kidney-derived
- Mammalian expression vectors can comprise non-transcribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5’ or 3’ flanking non-transcribed sequences, and 5’ or 3’ non-translated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.
- expression of recombinant proteins in insect cell culture systems e.g., baculovirus
- Baculovirus systems for production of heterologous proteins in insect cells are well-known to those of skill in the art.
- a fusion protein provided herein can be co-expressed with a synthetic receptor in a cell.
- a fusion protein provided herein can be conjugated to a synthetic receptor.
- synthetic receptor refers to an engineered cell surface protein or protein complex comprising (1) a target-binding domain that can specifically bind a target molecule, and (2) a functional domain that can activate a signaling pathway in the engineered cell.
- the target-binding domain comprises an extracellular domain.
- the functional domain comprises an intracellular domain.
- the synthetic receptor further includes a transmembrane sequence.
- the synthetic receptor can be a protein complex that comprises proteins expressed from exogenous nucleic acids.
- the synthetic receptor can also be a protein complex that comprises at least one protein that is exogenously expressed, and at least one protein that is endogenously expressed.
- the engineered cell can be an immune cell, such as a T cell, a natural killer (NK) cell, a B cell, a macrophage, etc., and the functional domain can activate the immune cell, either directly or indirectly.
- NK natural killer
- the synthetic receptor can be selected from the group consisting of: a chimeric antigen receptor ( “CAR” ) , a T cell receptor ( “TCR” ) , a TCR receptor fusion construct ( “TRuC” ) , a T cell antigen coupler ( “TAC” ) , an antibody TCR receptor ( “AbTCR” ) , and a chimeric CD3 ⁇ receptor.
- the synthetic receptor is a CAR.
- the synthetic receptor is a TCR.
- the synthetic receptor is a TRuC.
- the synthetic receptor is a TAC.
- the synthetic receptor is an AbTCR.
- the synthetic receptor is a chimeric CD3 receptor.
- the synthetic receptors provided herein include a target-binding domain.
- the target-binding domain is an extracellular domain that can bind a target molecule.
- the target molecule is an antigen on a target tissue.
- the target molecule is a cancer antigen.
- the target-binding domain of a synthetic receptor provided herein can also be an epitope that can be recognized by an antibody (e.g. a bispecific or multispecific antibody) that can bind a target molecule on a target tissue, such as a cancer antigen.
- an antigen binding domain is generally derived from an antibody.
- the antigen binding domain can be an scFv or an Fab, or any suitable antigen binding fragment of an antibody (see Sadelain et al., Cancer Discov. 3: 388-398 (2013) ) .
- the extracellular antigen-binding domain is an scFv.
- Many antibodies or antigen binding domains derived from antibodies that bind to a cancer antigen are known in the art. Alternatively, such antibodies or antigen binding domains can be produced by routine methods.
- Methods of generating an antibody are well known in the art, including methods of producing a monoclonal antibody or screening a library to obtain an antigen binding polypeptide, including screening a library of human Fabs (Winter and Harris, Immunol. Today 14: 243-246 (1993) ; Ward et al., Nature 341: 544-546 (1989) ; Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1988) ; Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992) ; Borrabeck, Antibody Engineering, 2nd ed. (Oxford University Press 1995) ; Huse et al., Science 246: 1275-1281 (1989) ) .
- the antigen binding domain derived from an antibody can be human, humanized, chimeric, CDR-grafted, and the like, as desired.
- a mouse monoclonal antibody is a source antibody for generating the antigen binding domain
- such an antibody can be humanized by grafting CDRs of the mouse antibody onto a human framework (see Borrabeck, supra, 1995) , which can be beneficial for administering the synthetic receptor to a human subject.
- the antigen binding domain is an scFv.
- the generation of scFvs is well known in the art (see, for example, Huston, et al., Proc. Nat. Acad. Sci.
- a suitable cancer antigen binding activity such as an antibody
- a number cancer antigen antibodies, in particular monoclonal antibodies, are commercially available and can also be used as a source for a cancer antigen binding activity, such as an scFv, to generate a synthetic receptor.
- the target-binding domain can be an antibody fragment, derivative or mimetic thereof, where these fragments, derivatives and mimetics have the requisite binding affinity for the target molecule.
- Such antibody fragments or derivatives generally include at least the V H and V L domains of the subject antibodies, so as to retain the binding characteristics of the subject antibodies.
- An antibody fragment as used herein refers to a molecule other than an intact antibody that comprises a portion of an antibody and generally an antigen-binding site.
- antibody fragments include, but are not limited to, Fab, Fab', F (ab’) 2, Fv, single chain antibody molecules (e.g., scFv) , disulfide-linked scFv (dsscFv) , diabodies, tribodies, tetrabodies, minibodies, dual variable domain antibodies (DVD) , single variable domain antibodies (e.g., camelid antibodies, alpaca antibodies) , single variable domain of heavy chain antibodies (VHH) , nanobodies, and multispecific antibodies formed from antibody fragments.
- the target-binding domain is an Fab.
- the target-binding domain is a scFv.
- the target-binding domain comprises a single variable domain antibody.
- the target-binding domain comprises an antibody mimetic.
- An antibody mimetic can be molecules that, like antibodies, can specifically bind antigens, but that are not structurally related to antibodies.
- the antibody mimetics are usually artificial peptides within a molar mass of about 2 to 20 kDa. Nucleic acids and small molecules are sometimes considered antibody mimetics as well.
- Antibody mimetics known in the art include adnectins, affibodies, affilins, affimers, affitins, alphabodies, anticalins, aptamers, avimers, bicyclic peptides, Centyrin (J&J) , DARPins, Fynomers, Knottins, Kunitz domain peptides, monobodies, and nanoCLAMPs.
- the target-binding domain comprises antibody-like scaffolds (e.g. Owens, Nature Biotechnology 35: 602–603 (2017) ; Simeon and Chen, Protein Cell 9 (1) : 3-14 (2018) ) .
- a target-binding domain of a synthetic receptor can comprise a ligand or extracellular ligand binding domain of a receptor (see Sadelain et al., Cancer Discov. 3: 388-398 (2013) ; Sharpe et al., Dis. Model Mech. 8: 337-350 (2015) ) .
- the ligand or extracellular ligand binding domain of a receptor provides to the synthetic receptor the ability to target the cell expressing the synthetic receptor to the corresponding receptor or ligand.
- the ligand or extracellular ligand binding domain is selected such that the cell expressing the synthetic receptor is targeted to a cancer cell or tumor (see Sadelain et al., Cancer Discov.
- the ligand or extracellular ligand binding domain is selected to bind to a cancer antigen that is the corresponding receptor or ligand (see Sadelain et al., Cancer Discov. 3: 388-398 (2013) ) .
- a target-binding domain of a synthetic receptor can comprise a chimeric autoantibody receptor (CAAR) , namely, an autoantigen that can be recognized by a B cell receptor (BCR) (see Ellebrecht et al. Science 353 (6295) , 179-184 (2016) ) .
- CAAR chimeric autoantibody receptor
- BCR B cell receptor
- the antigen binding domain of the synthetic receptor is selected to bind to an antigen expressed on a cancer cell.
- a cancer antigen can be uniquely expressed on a cancer cell, or the cancer antigen can be overexpressed in a cancer cell relative to noncancerous cells or tissues.
- the cancer antigen to be bound by the synthetic receptor is chosen to provide targeting of the cell expressing the synthetic receptor over noncancerous cells or tissues.
- the cancer antigen can be a tumor antigen. Any suitable cancer antigen can be chosen based on the type of cancer exhibited by a subject (cancer patient) to be treated. It is understood that the selected cancer antigen is expressed in a manner such that the cancer antigen is accessible for binding by the synthetic receptor. Generally, the cancer antigen to be targeted by a cell expressing a synthetic receptor is expressed on the cell surface of a cancer cell. However, it is understood that any cancer antigen that is accessible for binding to a synthetic receptor is suitable for targeting the synthetic receptor expressing cell to the cancer cell.
- Suitable antigens include, but are not limited to, B-cell maturation antigen (BCMA) , mesothelin (MSLN) , prostate specific membrane antigen (PSMA) , prostate stem cell antigen (PCSA) , carbonic anhydrase IX (CAIX) , carcinoembryonic antigen (CEA) , CD5, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD70, CD74, CD123, CD133, CD138, CD33, IL3Ra2, CS1, C-Met, epithelial glycoprotein2 (EGP 2) , epithelial glycoprotein-40 (EGP-40) , epithelial cell adhesion molecule (EpCAM) , folate-binding protein (FBP) , fetal acetylcholine receptor (AChR) , folate receptor- ⁇ and ⁇ (FR ⁇ and ⁇ )
- fusion protein disclosed herein is conjugated to a synthetic receptor targeting a tumor antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- synthetic receptors provided herein include a target-binding domain that binds CD19.
- synthetic receptors provided herein include a target-binding domain that binds CD20.
- synthetic receptors provided herein include a target-binding domain that binds CD22. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds CD30. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds CD123. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds CD138. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds CD33. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds CD70. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds BCMA.
- synthetic receptors provided herein include a target-binding domain that binds CS1. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds C-Met. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds IL13Ra2. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds EGFRvIII. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds CEA. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds Her2. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds GD2.
- synthetic receptors provided herein include a target-binding domain that binds MAGE. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds GPC3. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds Mesothelin. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds PSMA. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds ROR1. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds EGFR. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds MUC1. In some embodiments, synthetic receptors provided herein include a target-binding domain that binds NY-ESO-1.
- the synthetic receptor is a CAR
- the fusion proteins provided herein can be co-expressed with a CAR in a cell.
- a fusion protein provided herein can be conjugated to a CAR.
- CARs are synthetic receptors that retarget immune cells (e.g. T cells) to tumor surface antigens (Sadelain et al., Nat. Rev. Cancer. 3 (1) : 35-45 (2003) ; Sadelain et al., Cancer Discovery 3 (4) : 388-398 (2013) ) .
- CARs are engineered receptors that provide both antigen binding and immune cell activation functions.
- CARs can be used to graft the specificity of an antibody, such as a monoclonal antibody, onto an immune cell such as a T cell, a NK cell, or a macrophage.
- First-generation receptors link an antibody-derived tumor-binding element, such as an scFv, that is responsible for antigen recognition to either CD3zeta or Fc receptor signaling domains, which trigger T-cell activation.
- the extracellular antigen-binding domain of a CAR is usually derived from a monoclonal antibody (mAb) or from receptors or their ligands. Antigen binding by the CARs triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the intracellular domain, initiating a signaling cascade required for cytolysis induction, cytokine secretion, and proliferation.
- mAb monoclonal antibody
- ITAMs immunoreceptor tyrosine-based activation motifs
- a fusion protein provided herein can be conjugated to CAR that has an antigen binding domain that binds to a cancer antigen.
- the CAR can be a “first generation, ” “second generation” or “third generation” CAR (see, for example, Sadelain et al., Cancer Discov. 3 (4) : 388-398 (2013) ; Jensen et al., Immunol. Rev. 257: 127-133 (2014) ; Sharpe et al., Dis. Model Mech. 8 (4) : 337-350 (2015) ; Brentjens et al., Clin. Cancer Res. 13: 5426-5435 (2007) ; Gade et al., Cancer Res.
- First generation CARs are typically composed of an extracellular antigen binding domain, for example, a single-chain variable fragment (scFv) , fused to a transmembrane domain, which is fused to a cytoplasmic/intracellular domain of the T cell receptor chain.
- scFv single-chain variable fragment
- First generation CARs typically have the intracellular domain from the CD3 ⁇ -chain, which is the primary transmitter of signals from endogenous T cell receptors (TCRs) .
- TCRs endogenous T cell receptors
- First generation CARs can provide de novo antigen recognition and cause activation of both CD4 + and CD8 + T cells through their CD3 ⁇ chain signaling domain in a single fusion molecule, independent of HLA-mediated antigen presentation.
- “Second-generation” CARs comprises a cancer antigen-binding domain fused to an intracellular signaling domain capable of activating immune cells such as T cells and a co-stimulatory domain designed to augment immune cell, such as T cell, potency and persistence (Sadelain et al., Cancer Discov. 3: 388-398 (2013) ) .
- CAR design can therefore combine antigen recognition with signal transduction, two functions that are physiologically borne by two separate complexes, the TCR heterodimer and the CD3 complex.
- “Second generation” CARs include an intracellular domain from various co-stimulatory molecules, for example, CD28, 4-1BB, ICOS, OX40, and the like, in the cytoplasmic tail of the CAR to provide additional signals to the cell.
- “Second generation” CARs provide both co-stimulation, for example, by CD28 or 4-1BB domains, and activation, for example, by a CD3 ⁇ signaling domain. Studies have indicated that “Second Generation” CARs can improve the anti-tumor activity of T cells.
- “Third generation” CARs provide multiple co-stimulation, for example, by comprising both CD28 and 4-1BB domains, and activation, for example, by comprising a CD3 ⁇ activation domain.
- a CAR also contains a signaling domain that functions in the immune cell expressing the CAR.
- a signaling domain can be, for example, derived from CD ⁇ or Fc receptor ⁇ (see Sadelain et al., Cancer Discov. 3: 388-398 (2013) ) .
- the signaling domain will induce persistence, trafficking and/or effector functions in the transduced immune cells such as T cells (Sharpe et al., Dis. Model Mech. 8: 337-350 (2015) ; Finney et al., J. Immunol. 161: 2791-2797 (1998) ; Krause et al., J. Exp. Med. 188: 619-626 (1998) ) .
- the signaling domain corresponds to the intracellular domain of the respective polypeptides, or a fragment of the intracellular domain that is sufficient for signaling. Exemplary signaling domains are described below in more detail.
- a CAR can comprise a signaling domain derived from a CD3 ⁇ polypeptide, for example, a signaling domain derived from the intracellular domain of CD3 ⁇ , which can activate or stimulate an immune cell, for example, a T cell.
- CD3 ⁇ comprises 3 Immune-receptor-Tyrosine-based-Activation-Motifs (ITAMs) , and transmits an activation signal to the cell, for example, a cell of the lymphoid lineage such as a T cell, after antigen is bound.
- a CD3 ⁇ polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No.
- the CD3 ⁇ polypeptide has an amino acid sequence of amino acids 52 to 164 of the CD3 ⁇ polypeptide sequence provided below, or a fragment thereof that is sufficient for signaling activity.
- An exemplary CAR is Mz, which has an intracellular domain comprising a CD3 ⁇ polypeptide comprising amino acids 52 to 164 of the CD3 ⁇ polypeptide sequence provided below.
- Another exemplary CAR is M28z, which has an intracellular domain comprising a CD3 ⁇ polypeptide comprising amino acids 52 to 164 of the CD3 ⁇ polypeptide provided below.
- Still another exemplary CAR is MBBz, which has an intracellular domain comprising a CD3 ⁇ polypeptide comprising amino acids 52 to 164 of the CD3 ⁇ polypeptide provided below.
- Yet another exemplary CAR is P28z, which has an intracellular domain derived from a CD3 ⁇ polypeptide. See GenBank NP_932170 for reference to domains within CD3 ⁇ , for example, signal peptide, amino acids 1 to 21; extracellular domain, amino acids 22 to 30; transmembrane domain, amino acids 31 to 51; intracellular domain, amino acids 52 to 164.
- a “CD3 ⁇ nucleic acid” refers to a polynucleotide encoding a CD3 ⁇ polypeptide.
- the CD3 ⁇ nucleic acid encoding the CD3 ⁇ polypeptide comprised in the intracellular domain of a CAR comprises a nucleotide sequence as set forth below.
- an intracellular domain of a CAR can further comprise at least one co-stimulatory signaling domain.
- an intracellular domain of a CAR can comprise two co-stimulatory signaling domains.
- Such a co-stimulatory signaling domain can provide increased activation of an immune cell.
- a co-stimulatory signaling domain can be derived from a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP10 polypeptide, a 2B4 polypeptide, a CD27 polypeptide, a CD30 polypeptide, a CD40 polypeptide and the like.
- CARs comprising an intracellular domain that comprises a co-stimulatory signaling region comprising 4-1BB, ICOS or DAP-10 have been described previously (see U.S. 7,446,190, which is incorporated herein by reference, which also describes representative sequences for 4-1BB, ICOS and DAP-10) .
- the intracellular domain of a CAR can comprise a co-stimulatory signaling region that comprises two co-stimulatory molecules, such as CD28 and 4-1BB (see Sadelain et al., Cancer Discov. 3 (4) : 388-398 (2013) ) , or CD28 and OX40, or other combinations of co-stimulatory ligands, as disclosed herein.
- CD28 Cluster of Differentiation 28
- CD28 is a protein expressed on T cells that provides co-stimulatory signals for T cell activation and survival.
- CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins.
- a CAR can comprise a co-stimulatory signaling domain derived from CD28.
- a CAR can include at least a portion of an intracellular/cytoplasmic domain of CD28, for example an intracellular/cytoplasmic domain that can function as a co-stimulatory signaling domain.
- a CD28 polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No.
- CD28 sequences additional to the intracellular domain can be included in a CAR of the invention.
- a CAR can comprise the transmembrane of a CD28 polypeptide.
- a CAR can have an amino acid sequence comprising the intracellular domain of CD28 corresponding to amino acids 180 to 220 of CD28, or a fragment thereof.
- a CAR can have an amino acid sequence comprising the transmembrane domain of CD28 corresponding to amino acids 153 to 179, or a fragment thereof.
- An exemplary CAR can comprise a co-stimulatory signaling domain corresponding to an intracellular domain of CD28.
- An exemplary CAR can also comprise a transmembrane domain derived from CD28.
- an exemplary CAR can comprise two domains from CD28, a co-stimulatory signaling domain and a transmembrane domain.
- a CAR has an amino acid sequence comprising the transmembrane domain and the intracellular domain of CD28 and comprises amino acids 153 to 220 of CD28.
- a CAR comprises amino acids 117 to 220 of CD28.
- Another exemplary CAR having a transmembrane domain and intracellular domain of CD28 is P28z.
- a CAR can comprise a transmembrane domain derived from a CD28 polypeptide comprising amino acids 153 to 179 of the CD28 polypeptide provided below. See GenBank NP_006130 for reference to domains within CD28, for example, signal peptide, amino acids 1 to 18; extracellular domain, amino acids 19 to 152; transmembrane domain, amino acids 153 to 179; intracellular domain, amino acids 180 to 220. It is understood that sequences of CD28 that are shorter or longer than a specific delineated domain can be included in a CAR, if desired.
- a “CD28 nucleic acid” refers to a polynucleotide encoding a CD28 polypeptide.
- the CD28 nucleic acid encoding the CD28 polypeptide comprising the transmembrane domain and the intracellular domain, for example, the co-stimulatory signaling region comprises a nucleotide sequence as set forth below.
- 4-1BB 4-1BB, also referred to as tumor necrosis factor receptor superfamily member 9, can act as a tumor necrosis factor (TNF) ligand and have stimulatory activity.
- a CAR can comprise a co-stimulatory signaling domain derived from 4-1BB.
- a 4-1BB polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No. P41273 (P41273.1, GI: 728739) or NP_001552 (NP_001552.2, GI: 5730095) or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of 4-1BB corresponding to amino acids 214 to 255, or a fragment thereof.
- a CAR can have a transmembrane domain of 4-1BB corresponding to amino acids 187 to 213, or a fragment thereof.
- An exemplary CAR is MBBz, which has an intracellular domain comprising a 4-1BB polypeptide (for example, amino acids 214 to 255 of NP_001552, SEQ ID NO: 96) . See GenBank NP_001552 for reference to domains within 4-1BB, for example, signal peptide, amino acids 1 to 17; extracellular domain, amino acids 18 to 186; transmembrane domain, amino acids 187 to 213; intracellular domain, amino acids 214 to 255.
- sequences of 4-1BB that are shorter or longer than a specific delineated domain can be included in a CAR, if desired.
- a “4-1BB nucleic acid” refers to a polynucleotide encoding a 4-1BB polypeptide.
- OX40 also referred to as tumor necrosis factor receptor superfamily member 4 precursor or CD134, is a member of the TNFR-superfamily of receptors.
- a CAR can comprise a co-stimulatory signaling domain derived from OX40.
- An OX40 polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No. P43489 (P43489.1, GI: 1171933) or NP_003318 (NP_003318.1, GI: 4507579) , provided below, or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of OX40 corresponding to amino acids 236 to 277, or a fragment thereof.
- a CAR can have an amino acid sequence comprising the transmembrane domain of OX40 corresponding to amino acids 215 to 235 of OX40, or a fragment thereof. See GenBank NP_003318 for reference to domains within OX40, for example, signal peptide, amino acids 1 to 28; extracellular domain, amino acids 29 to 214; transmembrane domain, amino acids 215 to 235; intracellular domain, amino acids 236 to 277. It is understood that sequences of OX40 that are shorter or longer than a specific delineated domain can be included in a CAR, if desired. It is also understood that an “OX40 nucleic acid” refers to a polynucleotide encoding an OX40 polypeptide.
- ICOS Inducible T-cell costimulator precursor
- CD278 is a CD28-superfamily costimulatory molecule that is expressed on activated T cells.
- a CAR can comprise a co-stimulatory signaling domain derived from ICOS.
- An ICOS polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No. NP_036224 (NP_036224.1, GI: 15029518) , provided below, or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of ICOS corresponding to amino acids 162 to 199 of ICOS.
- a CAR can have an amino acid sequence comprising the transmembrane domain of ICOS corresponding to amino acids 141 to 161 of ICOS, or a fragment thereof. See GenBank NP_036224 for reference to domains within ICOS, for example, signal peptide, amino acids 1 to 20; extracellular domain, amino acids 21 to 140; transmembrane domain, amino acids 141 to 161; intracellular domain, amino acids 162 to 199. It is understood that sequences of ICOS that are shorter or longer than a specific delineated domain can be included in a CAR, if desired. It is also understood that an “ICOS nucleic acid” refers to a polynucleotide encoding an ICOS polypeptide.
- DAP10 also referred to as hematopoietic cell signal transducer, is a signaling subunit that associates with a large family of receptors in hematopoietic cells.
- a CAR can comprise a co-stimulatory domain derived from DAP10.
- a DAP10 polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No. NP_055081.1 (GI: 15826850) , provided below, or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of DAP10 corresponding to amino acids 70 to 93, or a fragment thereof.
- a CAR can have a transmembrane domain of DAP10 corresponding to amino acids 49 to 69, or a fragment thereof. See GenBank NP_055081.1 for reference to domains within DAP10, for example, signal peptide, amino acids 1 to 19; extracellular domain, amino acids 20 to 48; transmembrane domain, amino acids 49 to 69; intracellular domain, amino acids 70 to 93. It is understood that sequences of DAP10 that are shorter or longer than a specific delineated domain can be included in a CAR, if desired. It is also understood that a “DAP10 nucleic acid” refers to a polynucleotide encoding a DAP10 polypeptide.
- CD27 (TNFRSF7) is a transmembrane receptor expressed on subsets of human CD8+ and CD4+ T-cells, NKT cells, NK cell subsets and hematopoietic progenitors and induced in FOXP3+ CD4 T-cells and B cell subsets.
- a CAR can comprise a co-stimulatory domain derived from CD27.
- a CD27 polypeptide can have an amino acid sequence corresponding to the sequence having UniProtKB/Swiss-Prot No.: P26842.2 (GI: 269849546) , provided below, or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of CD27 or a fragment thereof.
- a CAR can have a transmembrane domain of CD27 or a fragment thereof. It is understood that sequences of CD27 that are shorter or longer than a specific delineated domain can be included in a CAR, if desired. It is also understood that a “CD27 nucleic acid” refers to a polynucleotide encoding an CD27 polypeptide.
- CD30 and its ligand are members of the tumor necrosis factor receptor (TNFR) and tumor necrosis factor (TNF) superfamilies, respectively.
- TNFR tumor necrosis factor receptor
- TNF tumor necrosis factor
- CD30 in many respects, behaves similarly to Ox40 and enhances proliferation and cytokine production induced by TCR stimulation.
- a CAR can comprise a co-stimulatory domain derived from CD30.
- a CD30 polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No.: AAA51947.1 (GI: 180096) , provided below, or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of CD30 or a fragment thereof.
- a CAR can have a transmembrane domain of CD30 or a fragment thereof. It is understood that sequences of CD30 that are shorter or longer than a specific delineated domain can be included in a CAR, if desired. It is also understood that a “CD30 nucleic acid” refers to a polynucleotide encoding an CD30 polypeptide.
- CD40 CD40 and its ligand, CD40L or CD154, were first identified as instrumental in T-cell-dependent B-cell activation. The pathway is now recognized as a mechanism to activate APCs and to enhance their potential to activate T cells.
- CD154-mediated CD40 stimulation provides an important feedback mechanism for the initial co-stimulatory pathway of CD28-CD80/CD86. (Goronzy and Weyand, Arthritis research &therapy 10, no. S1 (2008) : S3. )
- a CAR can comprise a co-stimulatory domain derived from CD40.
- a CD40 polypeptide can have an amino acid sequence corresponding to the sequence having UniProtKB/Swiss-Prot No.: P25942.1 (GI: 269849546) , provided below, or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of CD40 or a fragment thereof.
- a CAR can have a transmembrane domain of CD40 or a fragment thereof. It is understood that sequences of CD40 that are shorter or longer than a specific delineated domain can be included in a CAR, if desired. It is also understood that a “CD40 nucleic acid” refers to a polynucleotide encoding an CD40 polypeptide.
- the extracellular domain of a CAR can be fused to a leader or a signal peptide that directs the nascent protein into the endoplasmic reticulum and subsequent translocation to the cell surface. It is understood that, once a polypeptide containing a signal peptide is expressed at the cell surface, the signal peptide has generally been proteolytically removed during processing of the polypeptide in the endoplasmic reticulum and translocation to the cell surface. Thus, a polypeptide such as a CAR is generally expressed at the cell surface as a mature protein lacking the signal peptide, whereas the precursor form of the polypeptide includes the signal peptide.
- a signal peptide or leader can be essential if a CAR is to be glycosylated and/or anchored in the cell membrane.
- the signal sequence or leader is a peptide sequence generally present at the N-terminus of newly synthesized proteins that directs their entry into the secretory pathway.
- the signal peptide is covalently joined to the N-terminus of the extracellular antigen-binding domain of a CAR as a fusion protein.
- the signal peptide comprises a CD8 polypeptide comprising amino acids MALPVTALLLPLALLLHAARP (SEQ ID NO: 116) . It is understood that use of a CD8 signal peptide is exemplary.
- Any suitable signal peptide can be applied to a CAR to provide cell surface expression in an immune cell (see Gierasch Biochem. 28: 923-930 (1989) ; von Heijne, J. Mol. Biol. 184 (1) : 99–105 (1985) ) .
- Particularly useful signal peptides can be derived from cell surface proteins naturally expressed in the immune cell provided herein, including any of the signal peptides of the polypeptides disclosed herein.
- any suitable signal peptide can be utilized to direct a CAR to be expressed at the cell surface of an immune cell provided herein.
- an extracellular antigen-binding domain of a CAR can comprise a linker sequence or peptide linker connecting the heavy chain variable region and light chain variable region of the extracellular antigen-binding domain.
- the linker comprises amino acids having the sequence set forth in GGGGSGGGGSGGGGS (SEQ ID NO: 1) .
- a CAR can also comprise a spacer region or sequence that links the domains of the CAR to each other.
- a spacer can be included between a signal peptide and an antigen binding domain, between the antigen binding domain and the transmembrane domain, between the transmembrane domain and the intracellular domain, and/or between domains within the intracellular domain, for example, between a stimulatory domain and a co-stimulatory domain.
- the spacer region can be flexible enough to allow interactions of various domains with other polypeptides, for example, to allow the antigen binding domain to have flexibility in orientation in order to facilitate antigen recognition.
- the spacer region can be, for example, the hinge region from an IgG, the CH 2 CH 3 (constant) region of an immunoglobulin, and/or portions of CD3 (cluster of differentiation 3) or some other sequence suitable as a spacer.
- the transmembrane domain of a CAR generally comprises a hydrophobic alpha helix that spans at least a portion of the membrane. Different transmembrane domains result in different receptor stability. After antigen recognition, receptors cluster and a signal is transmitted to the cell.
- the transmembrane domain of a CAR can be derived from another polypeptide that is naturally expressed in the immune cell.
- a CAR can have a transmembrane domain derived from CD8, CD28, CD3 ⁇ , CD4, 4-1BB, OX40, ICOS, CTLA-4, PD-1, LAG-3, 2B4, BTLA, or other polypeptides expressed in the immune cell.
- the transmembrane domain can be derived from a polypeptide that is not naturally expressed in the immune cell, so long as the transmembrane domain can function in transducing signal from antigen bound to the CAR to the intracellular signaling and/or co-stimulatory domains.
- the portion of the polypeptide that comprises a transmembrane domain of the polypeptide can include additional sequences from the polypeptide, for example, additional sequences adjacent on the N-terminal or C-terminal end of the transmembrane domain, or other regions of the polypeptide, as desired.
- CD8 Cluster of differentiation 8
- TCR T cell receptor
- CD8 binds to a major histocompatibility complex (MHC) molecule and is specific for the class I MHC protein.
- a CAR can comprise a transmembrane domain derived from CD8.
- a CD8 polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No. NP_001139345.1 (GI: 225007536) , as provided below, or fragments thereof.
- a CAR can have an amino acid sequence comprising the transmembrane domain of CD8 corresponding to amino acids 183 to 203, or fragments thereof.
- an exemplary CAR has a transmembrane domain derived from a CD8 polypeptide.
- a CAR can comprise a transmembrane domain derived from a CD8 polypeptide comprising amino acids 183 to 203.
- a CAR can comprise a hinge domain comprising amino acids 137-182 of the CD8 polypeptide provided below.
- a CAR can comprise amino acids 137-203 of the CD8 polypeptide provided below.
- a CAR can comprise amino acids 137 to 209 of the CD8 polypeptide provided below.
- CD8 nucleic acid refers to a polynucleotide encoding a CD8 polypeptide.
- CD4 Cluster of differentiation 4
- T-cell surface glycoprotein CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells.
- a CAR can comprise a transmembrane domain derived from CD4.
- CD4 exists in various isoforms. It is understood that any isoform can be selected to achieve a desired function.
- Exemplary isoforms include isoform 1 (NP_000607.1, GI: 10835167) , isoform 2 (NP_001181943.1, GI: 303522479) , isoform 3 (NP_001181944.1, GI: 303522485; or NP_001181945.1, GI: 303522491; or NP_001181946.1, GI: 303522569) , and the like.
- One exemplary isoform sequence, isoform 1, is provided below.
- a CAR can have an amino acid sequence comprising the transmembrane domain of CD4 corresponding to amino acids 397 to 418, or fragments thereof.
- CD4 nucleic acid refers to a polynucleotide encoding a CD4 polypeptide.
- regulatory T-cells are found to be efficiently engineered with a predetermined antigen-specificity via transfection of viral vectors encoding specific CAR (CAR-Tregs) .
- CAR-Tregs engineered in a non-MHC restricted manner have the advantage of widespread applications, especially in transplantation and autoimmunity (Zhang et al. (2016) Front. Immunol. 9: 2359) .
- CAR can be engineered into other types of immune cells, such as NK cells, macrophages, or B cells.
- the engineered cell is a NK cell.
- the synthetic receptor is a CAR that retargets NK cells to tumor surface antigens (see e.g., Hu et al. Acta Pharmacol Sin 39, 167–176 (2018) ) .
- CAR-NK cells can use the first generation of CAR constructs that contain CD3 ⁇ as an intracellular signaling domain or the second generation of CAR constructs that express a second signaling domain (e.g., CD28, 4-1BB) in conjunction with CD3 ⁇ .
- a second signaling domain e.g., CD28, 4-1BB
- CAR constructs are based on the activating features of NK cells.
- DNAX-activation protein 12 DAP12 is known to activate signaling for NK cells.
- DAP12 is found in cells of the myeloid lineage, such as macrophages and granulocytes, where it associates, for instance, with the triggering receptor expressed on myeloid cell members (TREM) and MDL1 (myeloid DAP12-associating lectin 1/CLEC5A) , both involved in inflammatory responses against pathogens like viruses and bacteria.
- TAM myeloid cell members
- MDL1 myeloid DAP12-associating lectin 1/CLEC5A
- DAP12 is expressed in NK cells and associates with activating receptors such as the C-type lectin receptor NKG2C, the natural cytotoxicity receptor NKp44, and the short-tailed KIR3DS1 and KIR2DS1/2/5, respectively.
- NGK2C is the dominant activating NK cell receptor for controlling CMV infection in both humans and mice. It was found that a DAP12-containing CAR generated sufficient activating signals in NK cells upon cross-linking with its Ag. et al., J Immunol 194: 3201-12 (2015) .
- a CAR can comprise a co-stimulatory domain derived from DAP12.
- a DAP12 polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No. AAD09437.1 (GI: 2905996) , provided below, or fragments thereof.
- a CAR can have a signaling domain comprising the intracellular domain of DAP12, or a fragment thereof.
- a CAR can have a transmembrane domain of DAP12, or a fragment thereof.
- DAP12 nucleic acid refers to a polynucleotide encoding a DAP12 polypeptide.
- NKG2D As the receptor NKG2D is important for NK cell activity and the NKG2D ligands are commonly overexpressed on various tumors, a unique CAR construct that contains NKG2D as the ectodomain and links signaling proteins such as DAP10 and CD3 ⁇ has been developed and can be co-expressed or conjugated with the fusion proteins disclosed herein in an engineered cell.
- These CAR-expressing NK cells have enhanced cytotoxicity against a wide spectrum of tumor subtypes, with the best responses observed in ALL, osteosarcoma, prostate carcinoma, and rhabdomyosarcoma (Chang et al., Cancer Res 2013; 73: 1777–86) .
- a human NKG2D polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No. CAA04925.1 (GI: 2980865) , provided below, or fragments thereof. It is understood that a “NKG2D nucleic acid” refers to a polynucleotide encoding a NKG2D polypeptide.
- CAR can be engineered into macrophages.
- the engineered cell is a macrophage.
- CAR-Ps Chimeric Antigen Receptors for Phagocytosis
- the cytosolic domains from MEGF10 and FcRV can trigger engulfment independently of their native extracellular domain and CAR-Ps can drive specific engulfment of antigen-coated synthetic particles and whole human cancer cells. Addition of a tandem PI3K recruitment domain can further increase cancer cell engulfment (Morrissey et al., eLife 2018; 7: e36688) .
- MEGF10 Multiple epidermal growth factor-like domains protein 10
- EMARDD EMARDD
- SR-F3 a membrane receptor involved in phagocytosis by macrophages and astrocytes of apoptotic cells.
- the intracellular domain of Megf10 has cytosolic Immunore-ceptor Tyrosine-based Activation Motifs (ITAMs) that are phosphorylated by Src family kinases.
- a CAR can comprise a transmembrane domain derived from MEGF10.
- a CAR can comprise a co-stimulatory domain derived from MEGF10.
- a MEGF10 polypeptide can have an amino acid sequence corresponding to the sequence having GenBank No.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of MEGF10, or a fragment thereof.
- a CAR can have a transmembrane domain of MEGF10, or a fragment thereof.
- a “MEGF10 nucleic acid” refers to a polynucleotide encoding a MEGF10 polypeptide.
- FcR ⁇ Activating types of IgG receptor Fc ⁇ Rs form multimeric complexes including the Fc receptor common ⁇ chain (FcR ⁇ ) that contains an intracellular tyrosine-based activating motif (ITAM) , whose activation triggers oxidative bursts, cytokine release, phagocytosis, antibody-dependent cell-mediated cytotoxicity, and degranulation.
- FcR ⁇ Fc receptor common ⁇ chain
- ITAM intracellular tyrosine-based activating motif
- a CAR can comprise a transmembrane domain derived from FcR ⁇ .
- a CAR can comprise a co-stimulatory domain derived from FcR ⁇ .
- An FcR ⁇ polypeptide can have an amino acid sequence corresponding to the sequence having NCBI Reference Sequence: NP_004097.1 (GI: 4758344) , provided below, or fragments thereof.
- a CAR can have a co-stimulatory domain comprising the intracellular domain of FcR ⁇ , or a fragment thereof.
- a CAR can have a transmembrane domain of FcR ⁇ , or a fragment thereof. It is understood that an “FcR ⁇ nucleic acid” refers to a polynucleotide encoding an FcR ⁇ polypeptide.
- CARs provided herein can include a target-binding domain as disclosed above.
- fusion proteins disclosed herein can be co-expressed with a CAR targeting a tumor antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1 in a cell.
- fusion proteins disclosed herein is conjugated to a CAR targeting a tumor antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- fusion proteins provided herein can be co-expressed or conjugated with a CAR that targets CD19 (CAR19) .
- fusion proteins provided herein can be conjugated to a CAR.
- fusion proteins provided herein can be conjugated to a CAR that binds CD19 (CAR19) .
- the amino acid sequence of CAR19 is SEQ ID NO: 74, which can be encoded by, for example, the nucleotide sequence of SEQ ID NO: 20.
- the amino acid sequence of CAR19 is SEQ ID NO: 75.
- the amino acid sequence of CAR19 is SEQ ID NO: 76.
- synthetic receptors provided herein include a target-binding domain that binds BCMA.
- the amino acid sequence of the CAR that binds BCMA is SEQ ID NO: 77.
- the amino acid sequence of the CAR that binds BCMA is SEQ ID NO: 78. In some embodiments, the amino acid sequence of the CAR that binds BCMA is SEQ ID NO: 79. In some embodiments, the amino acid sequence of the CAR that binds BCMA is SEQ ID NO: 80.
- Fusion proteins provided herein can be co-expressed with a synthetic receptor in a cell, or conjugated to a synthetic receptor.
- the synthetic receptor comprises a TCR
- fusion proteins provided herein can be co-expressed with a TCR in a cell, or conjugated to a TCR.
- the synthetic receptor can engage and activate endogenous TCR
- fusion proteins provided herein can be co-expressed or conjugated with a synthetic receptor that can engage and activate endogenous TCR.
- T cell receptors are antigen-specific molecules that are responsible for recognizing antigenic peptides presented in the context of a product of the MHC on the surface of antigen presenting cells (APCs) or any nucleated cells.
- APCs antigen presenting cells
- This system endows T cells, via their TCRs, with the potential ability to recognize the entire array of intracellular antigens expressed by a cell (including virus proteins) that are processed into short peptides, bound to an intracellular MHC molecule, and delivered to the surface as a peptide-MHC complex.
- This system allows foreign protein (e.g., mutated cancer antigen or virus protein) or aberrantly expressed protein to serve a target for T cells (e.g. Davis and Bjorkman (1988) Nature, 334, 395-402; Davis et al. (1998) Annu Rev Immunol, 16, 523-544) .
- the interaction of a TCR and a peptide-MHC complex can drive the T cell into various states of activation, depending on the affinity (or dissociation rate) of binding.
- the TCR recognition process allows a T cell to discriminate between a normal, healthy cell and, for example, one that has become transformed via a virus or malignancy, by providing a diverse repertoire of TCRs, wherein there is a high probability that one or more TCRs will be present with a binding affinity for the foreign peptide bound to an MHC molecule that is above the threshold for stimulating T cell activity (Manning and Kranz (1999) Immunology Today, 20, 417-422) .
- T cells have evolved a co-receptor system in which the cell surface molecules CD4 and CD8 bind to the MHC molecules (class II and class I, respectively) and synergize with the TCR in mediating signaling activity.
- Directed evolution can be used to generate TCRs with higher affinity for a specific peptide-MHC complex.
- Methods that can be used include yeast display (Holler et al. (2003) Nat Immunol, 4, 55-62; Holler et al. (2000) Proc Natl Acad Sci U S A, 97, 5387-92) , phage display (Li et al. (2005) Nat Biotechnol, 23, 349-54) , and T cell display (Chervin et al. (2008) J Immunol Methods, 339, 175-84) . All three approaches involve engineering, or modifying, a TCR that exhibits the normal, low affinity of the wild-type TCR, to increase the affinity for the cognate peptide-MHC complex (the original antigen that the T cells were specific for) .
- the synthetic receptor comprises a TCR
- the fusion proteins provided herein can be co-expressed with a TCR in a cell.
- a fusion protein provided herein can be conjugated to a TCR.
- the TCR comprises an alpha ( ⁇ ) chain and a beta ( ⁇ ) chain (encoded by TRAC and TRBC, respectively) .
- a human TRAC can have an amino acid sequence corresponding to UniProtKB/Swiss-Prot No.: P01848.2 (Accession: P01848.2 GI: 1431906459) .
- a human TRBC can have an amino acid sequence corresponding to the GenBank sequence ALC78509.1 (Accession: ALC78509.1 GI: 924924895) .
- the TCR comprises a gamma chain ( ⁇ ) and a delta ( ⁇ ) chain (encoded by TRGC and TRDC, respectively) .
- a human TRGC can have an amino acid sequence corresponding to UniProtKB/Swiss-Prot: P0CF51.1 (Accession: P0CF51.1 GI: 294863156) , or an amino acid sequence corresponding to UniProtKB/Swiss-Prot: P03986.2 (Accession: P03986.2 GI: 1531253869) .
- a human TRDC can have an amino acid sequence corresponding to the UniProtKB/Swiss-Prot: B7Z8K6.2 (Accession: B7Z8K6.2 GI: 294863191) .
- the extracellular regions of the ⁇ chains (or the ⁇ chains) are responsible for antigen recognition and engagement.
- Antigen binding stimulates downstream signaling through the multimeric CD3 complex that associates with the intracellular domains of the ⁇ (or ⁇ ) chains as three dimers ( ⁇ , ⁇ , ⁇ ) .
- TCRs provided herein can be genetically engineered to bind specific antigens.
- fusion protein disclosed herein can be co-expressed with a TCR targeting a tumor antigen in a cell.
- fusion protein disclosed herein can be conjugated with a TCR targeting a tumor antigen.
- the tumor antigen is selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- the synthetic receptor does not comprise both the ⁇ (or ⁇ ) chains of TCR, but can engage and activate endogenous TCR complex.
- the synthetic receptor can be a TCR receptor fusion construct ( “TRuC” ) (Baeuerle et al., Nature Communications 10: 2087 (2019) ) , a T cell antigen coupler ( “TAC” ) (Helsen et al., Nature communications 9 (1) : 3049 (2016) ) , an antibody TCR receptor ( “AbTCR” ) (Xu et al., Cell Discovery (2016) 4: 62) , or a chimeric CD3 receptor (WO2016/054520) .
- the synthetic receptor is a TRuC (Baeuerle et al., Nature Communications 10: 2087 (2019) ) .
- fusion protein disclosed herein can be co-expressed with a TRuC.
- fusion protein disclosed herein can be conjugated with a TRuC.
- TRuCs comprise an antibody-based binding domain fused to T cell receptor (TCR) subunits, and can effectively reprogram an intact TCR complex to recognize tumor surface antigens. Unlike CARs, TRuCs become a functional component of the TCR complex. TRuC-T cells have demonstrated potent anti-tumor activity in both liquid and solid tumor xenograft models.
- the target-binding domain disclosed herein can be fused to the N-terminus of human TCR ⁇ , TCR ⁇ , CD3 ⁇ , CD3 ⁇ , or CD3 ⁇ with a linker sequence, thereby providing the TCR and engineered cell with a new target specificity and the potential for HLA-A independent cell lysis.
- the target-binding domain is fused to the N-terminus of full-length human TCR ⁇ ( ⁇ -TRuC) .
- the target-binding domain is fused to the N-terminus of full-length human TCR ⁇ ( ⁇ -TRuC) .
- the target-binding domain is fused to the N-terminus of full-length human CD3 ⁇ ( ⁇ -TRuC) . In some embodiments, the target-binding domain is fused to the N-terminus of full-length human CD3 ⁇ ( ⁇ -TRuC) . In some embodiments, the target-binding domain is fused to the N-terminus of full-length human CD3 ⁇ ( ⁇ -TRuC) .
- the synthetic receptor is a TAC (Helsen et al., Nature communications 9 (1) : 3049 (2016) ) .
- fusion protein disclosed herein can be co-expressed with a TAC.
- fusion protein disclosed herein can be conjugated with a TAC.
- TAC is a chimeric receptor that triggers aggregation and activation of the endogenous TCR following binding to tumor antigens by co-opting the native TCR via the CD3 binding domain, which induces efficient antitumor responses with reduced toxicity when compared with past-generation CARs.
- TAC design mimics the TCR-CD3: co-receptor complex, and has three components: (1) an antigen-binding domain, (2) a TCR recruitment domain, and (3) a co-receptor domain (hinge, transmembrane, and cytosolic regions) .
- the TAC receptor re-directs the TCR-CD3 complex towards an antigen of choice using an interchangeable antigen binding moiety, uses an scFv to recruit the TCR-CD3 complex, and incorporates co-receptor properties by including the CD4 hinge, TM region, and cytosolic tail.
- the antigen binding domain can be any target-bind domain disclosed herein. In some embodiments, the antigen binding domain is an anti-HER2 DARPin.
- the antigen binding domain is an anti-CD19 scFV.
- a TCR recruitment domain is a CD3 ⁇ targeting domain.
- the CD3 ⁇ targeting domain is selected from the group consisting of huUCHT1, UCHT1, F6K, L2K, and OKT3.
- the co-receptor domain is a CD4 co-receptor domain.
- the co-receptor domain is a CD8 ⁇ co-receptor domain.
- the synthetic receptor is an AbTCR, which couples the antigen-binding utility of an antibody to the endogenous TCR activation pathways (Xu et al. Cell Discovery (2016) 4: 62) .
- fusion protein disclosed herein can be co-expressed with an AbTCR.
- fusion protein disclosed herein can be conjugated with an AbTCR.
- an Fab domain of an antibody is combined with the ⁇ and ⁇ chains of the TCR as the effector domain.
- the heavy chain domain of the Fab fragment is fused to a portion of the ⁇ chain of a ⁇ TCR.
- the light chain domain of the Fab fragment is fused to a portion of the ⁇ chain of a ⁇ TCR. Similar to the exogenously-expressed TCR in TCR-T cells, the AbTCR engages the endogenous CD3 complex to initiate T-cell activation. However, since the ⁇ TCR chains do not bind with the TCRs in ⁇ T-cells, AbTCR avoids the mispairing challenge of traditional ⁇ TCR-based synthetic receptors. In addition, by employing a Fab as the antigen-binding domain, the AbTCR can be used to target either peptide-MHC complexes or cell surface antigens by using TCR-mimic or conventional antibodies respectively. AbTCR-T cells can trigger antigen-specific cytokine production, degranulation, and killing of cancer cells.
- the synthetic receptor is a chimeric CD3 receptor (WO2016/054520) .
- fusion protein disclosed herein can be co-expressed with a chimeric CD3 receptor.
- fusion protein disclosed herein can be conjugated with a chimeric CD3 receptor.
- the chimeric CD3 receptors comprise an extracellular domain comprising a CD3 epitope, a transmembrane domain and an intracellular signaling domain.
- a cell that expresses the chimeric CD3 receptor can be brought into proximity with a cancer cell expressing a cancer antigen by a bispecific antibody that binds both CD3 and the cancer antigen.
- the CD3 epitope is from a CD3 ⁇ extracellular domain.
- the intracellular signaling protein is a costimulatory domain, which can comprise a 4-1BB signaling domain, a CD28 signaling domain, an ICOS signaling domain, an OX40 signaling domain, a CD27 signaling domain, a CD30 signaling domain, a CD150 signaling domain, a DAP-10 signaling domain, an NKG2D signaling domain, or a portion or combination thereof.
- the intracellular domain can further comprise a T cell receptor ⁇ chain.
- the chimeric CD3 receptor can further include a transmembrane domain.
- the transmembrane domain can be a CD8 transmembrane domain, a CD28 transmembrane domain, an FcR transmembrane domain, or a CD3 ⁇ transmembrane domain. (WO2016/054520. )
- nucleic acids that encode the fusion proteins disclosed herein.
- nucleic acids that encode a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion protein binds a MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- nucleic acids that encode a fusion protein comprising an HLA-E-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- nucleic acids that encode a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof.
- the fusion protein does not have an MHC heavy chain. In some embodiments, the fusion protein does not have an HLA-E heavy chain.
- the fusion protein does not have an HLA-A heavy chain, an HLA-B heavy chain, an HLA-C heavy chain, an HLA-E heavy chain, an HLA-F heavy chain, or an HLA-G heavy chain.
- the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids.
- the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids.
- Various embodiments of the fusion proteins encoded by the nucleic acids provided herein are provided in Section 5.2 above.
- nucleic acids comprising (i) a first fragment encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and (ii) a second fragment encoding a synthetic receptor.
- the synthetic receptor can be any synthetic receptor disclosed herein.
- the synthetic receptor can be selected from the group consisting of a chimeric antigen receptor (CAR) , a T cell receptor (TCR) , a TCR receptor fusion construct (TRuC) , a T cell antigen coupler (TAC) , an antibody TCR receptor (AbTCR) , and a chimeric CD3 receptor.
- the synthetic receptor is a CAR
- nucleic acids provided herein comprise a first fragment encoding a fusion protein as disclosed herein that comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second fragment encoding a CAR, wherein the second fragment is operatively linked to the first fragment.
- the CAR can be any CAR disclosed herein or otherwise known in the art.
- the CAR comprises an antigen-binding domain that specifically binds a tumor antigen.
- the synthetic receptor is a TCR
- nucleic acids provided herein comprise a first fragment encoding a fusion protein as disclosed herein that comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second fragment encoding a TCR, wherein the second fragment is operatively linked to the first fragment.
- the TCR can be any TCR disclosed herein or otherwise known in the art.
- the TCR comprises an antigen-binding domain that specifically binds a tumor antigen.
- the synthetic receptor is a TRuc
- nucleic acids provided herein comprise a first fragment encoding a fusion protein as disclosed herein that comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second fragment encoding a TRuc, wherein the second fragment is operatively linked to the first fragment.
- the TRuc comprises an antigen-binding domain that specifically binds a tumor antigen.
- the synthetic receptor is a TAC
- nucleic acids provided herein comprise a first fragment encoding a fusion protein as disclosed herein that comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second fragment encoding a TAC, wherein the second fragment is operatively linked to the first fragment.
- the TAC comprises an antigen-binding domain that specifically binds a tumor antigen.
- the synthetic receptor is an AbTCR
- nucleic acids provided herein comprise a first fragment encoding a fusion protein as disclosed herein that comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second fragment encoding an AbTCR, wherein the second fragment is operatively linked to the first fragment.
- the AbTCR comprises an antigen-binding domain that specifically binds a tumor antigen.
- the synthetic receptor is a chimeric CD3 receptor
- nucleic acids provided herein comprise a first fragment encoding a fusion protein as disclosed herein that comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second fragment encoding a chimeric CD3 receptor, wherein the second fragment is operatively linked to the first fragment.
- the chimeric CD3 receptor comprises an antigen-binding domain that specifically binds a tumor antigen.
- nucleic acids provided herein comprise a first fragment encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide, and a second fragment encoding a synthetic receptor, wherein the first and second fragments are connected via a polynucleotide encoding a self-cleaving peptide. In some embodiments, the first and second fragments are connected via a polynucleotide encoding a 2A peptide.
- 2A peptides also known as 2A self-cleaving peptides, include a class of 18-22 amino acids-long peptides and can be used for bicistronic or multicistronic expression of protein sequences (see Szymczak et al., Expert Opin. Biol. Therapy 5 (5) : 627-638 (2005) ; Liu et al. (2017) . Scientific Reports 7 (1) : 2193) .
- 2A peptides include, for example, P2A peptide, T2A peptide, F2A peptide, or E2A peptide.
- An exemplary P2A sequence is (GSG) ATNFSLLKQAGDVEENPGPM (SEQ ID NO: 105) .
- An exemplary T2A sequence is (GSG) EGRGSLLTCGDVEENPGP (SEQ ID NO: 106) .
- An exemplary E2A sequence is (GSG) QCTNYALLKLAGDVESNPGP (SEQ ID NO: 107) .
- An exemplary F2A sequence is (GSG) VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 108) .
- the sequence “GSG” (Gly-Ser-Gly) on the N-terminal of a 2A peptide is optional.
- nucleic acids provided herein comprise a first fragment encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide, and a second fragment encoding a synthetic receptor, wherein the first and second fragments are connected via a polynucleotide encoding a 2A peptide, and wherein the nucleic acids encode the synthetic receptor, the 2A linker, the fusion protein, from N-terminus to C-terminus.
- the nucleic acids provided herein encode the fusion protein, the 2A linker, the synthetic receptor, from N-terminus to C-terminus.
- nucleic acids provided herein comprise a first fragment encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide, and a second fragment encoding a CAR, wherein the first and second fragments are connected via a polynucleotide encoding a 2A peptide, and wherein the nucleic acids encode the CAR, the 2A linker, the fusion protein, from N-terminus to C-terminus.
- the nucleic acids provided herein encode the fusion protein, the 2A linker, the CAR, from N-terminus to C-terminus.
- nucleic acids provided herein comprise a first fragment encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide, and a second fragment encoding a synthetic receptor, wherein the first and second fragments are connected via an IRES sequence.
- An “internal ribosome entry site” or “IRES” refers to an element that promotes direct internal ribosome entry to the initiation codon, such as ATG, of a cistron (a protein encoding region) , thereby leading to the cap-independent translation of the gene. See, e.g., Jackson et al., 1990. Trends Biochem Sci 15 (12) : 477-83) and Jackson and Kaminski. 1995.
- nucleic acids provided herein have the first fragment, the IRES sequence, and the second fragment, from 5’ end to 3’ end. In some embodiments, nucleic acids provided herein have the second fragment, the IRES fragment, the first fragment, from 5’ end to 3’ end.
- nucleic acids provided herein encode a fusion protein having an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18.
- the amino acid sequence of the fusion protein provided herein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18.
- nucleotide sequence of nucleic acids provided herein is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identical to SEQ ID NO: 6 or 12. In some embodiments, the nucleotide sequence of nucleic acids provided herein is SEQ ID NO: 6, or 12.
- the nucleotide sequence of nucleic acid provided herein is at least 85%identical to SEQ ID NO: 6. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 90%identical to SEQ ID NO: 6. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 95%identical to SEQ ID NO: 6. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 98%identical to SEQ ID NO: 6. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 99%identical to SEQ ID NO: 6. In some embodiments, the nucleotide sequence of nucleic acid provided herein is SEQ ID NO: 6.
- the nucleotide sequence of nucleic acid provided herein is at least 85%identical to SEQ ID NO: 12. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 90%identical to SEQ ID NO: 12. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 95%identical to SEQ ID NO: 12. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 98%identical to SEQ ID NO: 12. In some embodiments, the nucleotide sequence of nucleic acid provided herein is at least 99%identical to SEQ ID NO: 12. In some embodiments, the nucleotide sequence of nucleic acid provided herein is SEQ ID NO: 12.
- variants of the specific nucleic acids provided herein are also contemplated.
- the variants can contain alterations in the coding regions, non-coding regions, or both.
- a nucleic acid variant contains alterations which produce silent substitutions, additions, or deletions, but does not alter the properties or activities of the encoded polypeptide.
- a nucleic acid variant comprises silent substitutions that results in no change to the amino acid sequence of the polypeptide (due to the degeneracy of the genetic code) .
- Nucleic acid variants can be produced for a variety of reasons, for example, to optimize codon expression for a particular host (e.g., change codons in the human mRNA to those preferred by a bacterial host such as E. coli) .
- a nucleic acid variant comprises at least one silent mutation in a non-coding or a coding region of the sequence.
- a nucleic acid variant is produced to modulate or alter expression (or expression levels) of the encoded nucleic acid. In some embodiments, a nucleic acid variant is produced to increase expression of the encoded polypeptide. In some embodiments, a nucleic acid variant is produced to decrease expression of the encoded polypeptide. In some embodiments, a nucleic acid variant has increased expression of the encoded polypeptide as compared to a parental nucleic acid. In some embodiments, a nucleic acid variant has decreased expression of the encoded polypeptide as compared to a parental nucleic acid.
- nucleic acids provided herein can be codon optimized to increase efficiency of expression of the fusion protein in a given. Codon optimization can be used to achieve higher levels of expression in a given cell. Factors that are involved in different stages of protein expression include codon adaptability, mRNA structure, and various cis-elements in transcription and translation. Any suitable codon optimization methods or technologies that are known to one skilled in the art can be used to modify the nucleic acids provided herein.
- codon optimization methods are well known, including commercially available codon optimization services, for example, OptimumGene TM (GenScript; Piscataway, NJ) , Encor optimization (EnCor Biotechnology; Gainseville FL) , Blue Heron (Blue Heron Biotech; Bothell, WA) , and the like.
- OptimumGene TM GeneScript; Piscataway, NJ
- Encor optimization EnCor Biotechnology; Gainseville FL
- Blue Heron Blue Heron Biotech; Bothell, WA
- multiple codon optimizations can be performed based on different algorithms, and the optimization results blended to generate a codon optimized nucleic acid encoding a polypeptide.
- a nucleic acid is isolated. In some embodiments, a nucleic acid is substantially pure.
- the vector can be an expression vector.
- the vector can be a viral vector.
- the vector is a retroviral vector, for example, a gamma retroviral vector, which is employed for the introduction of the nucleic acids described herein into a target cell.
- the vector can be a lentiviral vector.
- the vector can be an adenoviral vector.
- the vector can be an adeno-associated viral vector.
- the vectors and constructs can optionally be designed to include a reporter.
- Nucleic acids provided herein can be prepared, manipulated and/or expressed using any of a variety of well-established techniques known and available in the art.
- vectors are plasmid, autonomously replicating sequences, and transposable elements.
- Exemplary transposon systems such as Sleeping Beauty and PiggyBac can be used, which can be stably integrated into the genome (e.g., Ivics et al., Cell, 91 (4) : 501–510 (1997) ; et al., (2007) Nucleic Acids Research. 35 (12) : e87) .
- Additional exemplary vectors include, without limitation, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosome (YAC) , bacterial artificial chromosome (BAC) , or P1-derived artificial chromosome (PAC) , bacteriophages such as lambda phage or M13 phage, and animal viruses.
- artificial chromosomes such as yeast artificial chromosome (YAC) , bacterial artificial chromosome (BAC) , or P1-derived artificial chromosome (PAC)
- bacteriophages such as lambda phage or M13 phage
- animal viruses include, without limitation, retrovirus (including lentivirus) , adenovirus, adeno-associated virus, herpesvirus (e.g., herpes simplex virus) , poxvirus, baculovirus, papillomavirus, and papovavirus (e.g., SV40) .
- expression vectors are pClneo vectors (Promega) for expression in mammalian cells; pLenti4/V5-DEST TM , pLenti6/V5-DEST TM , and pLenti6.2/V5-GW/lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells.
- coding sequences of fusion proteins disclosed herein can be ligated into such expression vectors for their expression in mammalian cells.
- the vector is an episomal vector or a vector that is maintained extrachromosomally.
- episomal vector refers to a vector that is able to replicate without integration into host’s chromosomal DNA and without gradual loss from a dividing host cell also meaning that said vector replicates extrachromosomally or episomally.
- the vector is engineered to harbor the sequence coding for the origin of DNA replication or “ori” from a lymphotrophic herpes virus or a gamma herpesvirus, an adenovirus, SV40, a bovine papilloma virus, or a yeast, specifically a replication origin of a lymphotrophic herpes virus or a gamma herpesvirus corresponding to oriP of EBV.
- the lymphotrophic herpes virus may be Epstein Barr virus (EBV) , Kaposi's sarcoma herpes virus (KSHV) , Herpes virus saimiri (HS) , or Marek's disease virus (MDV) .
- Epstein Barr virus (EBV) and Kaposi's sarcoma herpes virus (KSHV) are also examples of a gamma herpesvirus.
- the host cell comprises the viral replication transactivator protein that activates the replication.
- “Expression control sequences, ” “control elements, ” or “regulatory sequences” present in an expression vector are those non-translated regions of the vector-origin of replication, selection cassettes, promoters, enhancers, translation initiation signals (Shine Dalgarno sequence or Kozak sequence) introns, a polyadenylation sequence, 5' and 3' untranslated regions-which interact with host cellular proteins to carry out transcription and translation.
- Such elements can vary in their strength and specificity.
- any number of suitable transcription and translation elements including ubiquitous promoters and inducible promoters can be used.
- Illustrative ubiquitous expression control sequences that can be used in present disclosure include, but are not limited to, a cytomegalovirus (CMV) immediate early promoter, a viral simian virus 40 (SV40) promoter (e.g., early or late) , a Moloney murine leukemia virus (MoMLV) LTR promoter, a Rous sarcoma virus (RSV) LTR, a herpes simplex virus (HSV) (thymidine kinase) promoter, H5, P7.5, and P11 promoters from vaccinia virus, an elongation factor 1-alpha (EF1a) promoter, early growth response 1 (EGR1) , ferritin H (FerH) , ferritin L (FerL) , Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) , eukaryotic translation initiation factor 4A1 (EIF4A1) , heat shock 70kDa protein 5 (H
- inducible promoters/systems include, but are not limited to, steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone) , metallothionine promoter (inducible by treatment with various heavy metals) , MX-1 promoter (inducible by interferon) , the “GeneSwitch” mifepristone-regulatable system (Sirin et al., 2003, Gene, 323: 67) , the cumate inducible gene switch (WO 2002/088346) , tetracycline-dependent regulatory systems, etc.
- steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone)
- metallothionine promoter inducible by treatment with various heavy metals
- MX-1 promoter inducible by interfer
- genetically engineered cells expressing the fusion proteins disclosed herein.
- Provided herein are also genetically engineered cells comprising the nucleic acids disclosed herein.
- provided herein are also genetically engineered cells comprising the vectors disclosed herein.
- provided herein are genetically engineered cells expressing a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion protein binds an MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- provided herein are genetically engineered cells expressing a fusion protein comprising an HLA-E-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- genetically engineered cells expressing a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof.
- genetically engineered cells comprising a nucleic acid encoding a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion protein binds an MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- genetically engineered cells comprising a nucleic acid encoding a fusion protein comprising an HLA-E-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- genetically engineered cells comprising a nucleic acid encoding a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof.
- the fusion protein has less than 500 amino acids. In some embodiments, the fusion protein has less than 400, less than 300 amino acids, or less than 200 amino acids. In some embodiments, the fusion protein has about 100 to about 200, about 120 to about 180, about 120 to about 160 amino acids, or about 140 to about 160 amino acids. In some embodiments, the fusion protein lacks an MHC heavy chain. In some embodiments, the fusion protein lacks an HLA-A heavy chain, an HLA-B heavy chain, an HLA-C heavy chain, an HLA-E heavy chain, an HLA-F heavy chain, or an HLA-G heavy chain. In some embodiments, the fusion protein lacks an HLA-E heavy chain. Various embodiments of the fusion proteins are provided in the section above.
- the cells disclosed herein are genetically engineered to express a fusion protein that comprises a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion protein binds an MHC heavy chain to form a stable MHC complex on the cell surface.
- the fusion protein binds an endogenously expressed MHC heavy chain to form a stable MHC complex on the cell surface.
- the MHC complex can bind an inhibitory receptor of an immune cell to inhibit the immune cell.
- stable MHC complexes that comprise the fusion protein disclosed herein and a MHC heavy chain.
- the MHC heavy chain can be an endogenously expressed.
- stable HLA-A complexes that comprise the fusion protein disclosed herein and an HLA-A heavy chain, wherein the fusion protein comprises a HLA-A restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- stable HLA-B complexes that comprise the fusion protein disclosed herein and an HLA-B heavy chain, wherein the fusion protein comprises a HLA-B restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- stable HLA-C complexes that comprise the fusion protein disclosed herein and an HLA-C heavy chain, wherein the fusion protein comprises a HLA-C restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- stable HLA-E complexes that comprise the fusion protein disclosed herein and an HLA-E heavy chain, wherein the fusion protein comprises a HLA-E restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- stable HLA-F complexes that comprise the fusion protein disclosed herein and an HLA-F heavy chain, wherein the fusion protein comprises a HLA-F restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- stable HLA-G complexes that comprise the fusion protein disclosed herein and an HLA-G heavy chain, wherein the fusion protein comprises a HLA-G restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- stable CD1 complexes that comprise the fusion protein disclosed herein and a CD1 heavy chain, wherein the fusion protein comprises a CD1 restricted presenting molecule covalently linked to a ⁇ 2M peptide via a linker.
- stable MR1 complexes that comprise the fusion protein disclosed herein and an MR1 heavy chain, wherein the fusion protein comprises an MR1 restricted presenting molecule covalently linked to a ⁇ 2M peptide via a linker.
- stable FcRn complexes that comprise the fusion protein disclosed herein and an FcRn heavy chain, wherein the fusion protein comprises an FcRn restricted presenting molecule covalently linked to a ⁇ 2M peptide via a linker.
- stable UL18 complexes that comprise the fusion protein disclosed herein and a UL18 protein, wherein the fusion protein comprises a UL18 restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- an MHC complex can be detected by any methods disclosed herein or otherwise known in the art.
- the co-localization of the fusion protein disclosed herein and the MHC heavy chain in the MHC complex can be detected using ⁇ 2M co-immunoprecipitation (Lee et al., J Immunol 1998; 160: 4951-60) .
- the interaction of MHC heavy chain and the fusion protein disclosed herein in the MHC complex can be detected by surface plasmon resonance technology (SPR) (Goodridge et al., J. Immunol. 2010; 184 (11) : 6199-6208) .
- SPR surface plasmon resonance technology
- the fusion protein and the MHC heavy chain can each be labeled with different fluorescent labels, and the co-localization of MHC heavy chain and the fusion protein disclosed herein in the MHC complex can be detected by microscopy or flow cytometry.
- assays that are used to detect protein-protein interactions can be used for detecting the MHC complex, including, for example, pull-down assays, crosslinking, label transfer, far-western blot analysis, protein affinity purification, two hybrid assays (yeast, mammalian) , Forster Resonance Energy Transfer (FRET) , gel-shift assays, etc. (See e.g. et al.
- the genetically engineered cells disclosed herein further express a synthetic receptor that comprises (1) a target-binding domain that can specifically bind a target molecule, and (2) a functional domain that can activate a signaling pathway in the engineered cell.
- the synthetic receptor can be a CAR, a TCR, a TRuC, a TAC, an AbTCR, or a chimeric CD3 receptor.
- the genetically engineered cells disclosed herein further express a CAR.
- the genetically engineered cells disclosed herein further express a TCR.
- the genetically engineered cells disclosed herein further express a TRuC.
- the genetically engineered cells disclosed herein further express a TAC.
- the genetically engineered cells disclosed herein further express an AbTCR.
- the genetically engineered cells disclosed herein further express a chimeric CD3 receptor.
- the synthetic receptor is a CAR.
- the CAR can be any CAR disclosed herein or otherwise known in the art.
- the CAR comprises an antigen-binding domain that specifically binds a tumor antigen.
- provided herein are also genetically engineered cells expressing a fusion protein disclosed herein and a CAR.
- genetically engineered cells provided herein comprise a nucleic acid that comprises a first fragment encoding a fusion protein, and a second fragment encoding a CAR. The first and second fragments of the nucleic acid can be connected via a polynucleotide encoding a 2A peptide.
- the first and second fragments of the nucleic acid can also be connected with an IRES sequence.
- genetically engineered cells provided herein comprise a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second nucleic acid encoding a CAR.
- the synthetic receptor is a TCR.
- the TCR can be any TCR disclosed herein or otherwise known in the art.
- the TCR comprises an antigen-binding domain that specifically binds a tumor antigen.
- provided herein are also genetically engineered cells expressing a fusion protein disclosed herein and a TCR.
- genetically engineered cells provided herein comprise a nucleic acid that comprises a first fragment encoding a fusion protein, and a second fragment encoding a TCR. The first and second fragments of the nucleic acid can be connected via a polynucleotide encoding a 2A peptide.
- the first and second fragments of the nucleic acid can also be connected with an IRES sequence.
- genetically engineered cells provided herein comprise a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second nucleic acid encoding a TCR.
- the synthetic receptor is a TRuC.
- the TRuC can be any TRuC disclosed herein or otherwise known in the art.
- the TRuC comprises an antigen-binding domain that specifically binds a tumor antigen.
- provided herein are also genetically engineered cells expressing a fusion protein disclosed herein and a TRuC.
- genetically engineered cells provided herein comprise a nucleic acid that comprises a first fragment encoding a fusion protein, and a second fragment encoding a TRuC. The first and second fragments of the nucleic acid can be connected via a polynucleotide encoding a 2A peptide.
- the first and second fragments of the nucleic acid can also be connected with an IRES sequence.
- genetically engineered cells provided herein comprise a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second nucleic acid encoding a TRuC.
- the synthetic receptor is a TAC.
- the TAC can be any TAC disclosed herein or otherwise known in the art.
- the TAC comprises an antigen-binding domain that specifically binds a tumor antigen.
- provided herein are also genetically engineered cells expressing a fusion protein disclosed herein and a TAC.
- genetically engineered cells provided herein comprise a nucleic acid that comprises a first fragment encoding a fusion protein, and a second fragment encoding a TAC. The first and second fragments of the nucleic acid can be connected via a polynucleotide encoding a 2A peptide.
- the first and second fragments of the nucleic acid can also be connected with an IRES sequence.
- genetically engineered cells provided herein comprise a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second nucleic acid encoding a TAC.
- the synthetic receptor is an AbTCR.
- the AbTCR can be any AbTCR disclosed herein or otherwise known in the art.
- the AbTCR comprises an antigen-binding domain that specifically binds a tumor antigen.
- provided herein are also genetically engineered cells expressing a fusion protein disclosed herein and an AbTCR.
- genetically engineered cells provided herein comprise a nucleic acid that comprises a first fragment encoding a fusion protein, and a second fragment encoding an AbTCR. The first and second fragments of the nucleic acid can be connected via a polynucleotide encoding a 2A peptide.
- the first and second fragments of the nucleic acid can also be connected with an IRES sequence.
- genetically engineered cells provided herein comprise a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second nucleic acid encoding an AbTCR.
- the synthetic receptor is a chimeric CD3 receptor.
- the chimeric CD3 receptor can be any chimeric CD3 receptor disclosed herein or otherwise known in the art.
- the chimeric CD3 receptor comprises an antigen-binding domain that specifically binds a tumor antigen.
- provided herein are also genetically engineered cells expressing a fusion protein disclosed herein and a chimeric CD3 receptor.
- genetically engineered cells provided herein comprise a nucleic acid that comprises a first fragment encoding a fusion protein, and a second fragment encoding a chimeric CD3 receptor.
- the first and second fragments of the nucleic acid can be connected via a polynucleotide encoding a 2A peptide.
- the first and second fragments of the nucleic acid can also be connected with an IRES sequence.
- genetically engineered cells provided herein comprise a nucleic acid encoding a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker, and a second nucleic acid encoding a chimeric CD3 receptor.
- the cells provided herein are also engineered to reduce the endogenous expression of a Class I MHC molecule or an MHC-like molecule on cell surface.
- the inhibition of expression of Class I MHC molecules and/or MHC-like molecules on the surface of donor cells can reduce or eliminate allogeneic antigen presentation on the donor cells and help escape the recognition and clearance of the donor cell by host T cells, and is therefore advantageous for improving the compatibility of allografts.
- removal of Class I MHC molecules from the donor T cell can eliminate the “non-self” antigen presentation of the allogeneic donor cell and therefore protect it from the host immune system, especially CD8+ T cells (WO2015136001) .
- the cells provided herein are engineered to reduce the endogenous expression of a Class I MHC molecule or an MHC-like molecule.
- the cells disclosed herein lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface.
- the cells disclosed herein lack endogenous expression of a Class I MHC molecule on the cell surface.
- the cells disclosed herein lack endogenous expression of a classical Class I MHC molecule on the cell surface.
- the cells disclosed herein lack endogenous expression of a nonclassical Class I MHC molecule on the cell surface.
- the cells disclosed herein lack endogenous expression of an MHC-like molecule on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of a heavy chain of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, or any combination thereof on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of HLA-A heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of HLA-B heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of HLA-C heavy chain on the cell surface.
- the cells disclosed herein lack endogenous expression of HLA-E heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of HLA-F heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of HLA-G heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of HLA-A heavy chain, HLA-B heavy chain, and HLA-C heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of HLA-E heavy chain, HLA-F heavy chain, and HLA-G heavy chain on the cell surface.
- the cells disclosed herein lack endogenous expression of heavy chains of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of at least an MHC-like molecule on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of CD1 heavy chain, MR1 heavy chain, FcRN heavy chain, UL18, or any combination thereof on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of CD1 heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of MR1 heavy chain on the cell surface.
- the cells disclosed herein lack endogenous expression of FcRn heavy chain on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of UL18 on the cell surface. In some embodiments, the cells disclosed herein lack endogenous expression of CD1 heavy chain, MR1 heavy chain, FcRn heavy chain and UL18 on the cell surface.
- the cells disclosed herein lack endogenous expression of ⁇ 2M on the cell surface. Because ⁇ 2M is an indispensable structural component of a variety of MHC complexes having different heavy chains, inhibition of ⁇ 2M expression can lead to a reduction or elimination of Class I MHC molecules and some MHC-like molecules on the surface of the engineered cell.
- the cells disclosed herein are genetically engineered to (1) express a fusion protein disclosed herein that comprises a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, and (2) lack endogenous expression of ⁇ 2M.
- the fusion protein can be any fusion protein disclosed herein.
- the fusion protein comprises an HLA-E-restricted presenting peptide, and forms a complex with an endogenous HLA-E heavy chain that can be recognized by an inhibitory receptor of an immune cell, such as the NKG2A receptor on NK cells.
- the formation of the MHC complex can be measured by co-localization of the fusion protein and the heavy chain on the cell surface, and the MHC complex comprises the fusion protein disclosed herein, which can be detected by using an anti- ⁇ 2M antibody, and the endogenous MHC heavy chain, which can be detected by an antibody that recognizes the heavy chain.
- the antibody clone W6/32 can be used to detect HLA-ABC; the antibody clone 3D12 can be used to detect HLA-E; and the antibody clone can be used to detect ⁇ 2M.
- Cells disclosed herein that lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface means that the level of endogenous expression of the molecule at the cell surface is reduced significantly compared to a non-engineered cell.
- the endogenous expression of the molecule at the cell surface is reduced by at least 50%compared to a non-engineered cell.
- the endogenous expression of the molecule at the cell surface is reduced by at least 60%compared to a non-engineered cell.
- the endogenous expression of the molecule at the cell surface is reduced by at least 70%compared to a non-engineered cell.
- the endogenous expression of the molecule at the cell surface is reduced by at least 80%compared to a non-engineered cell. In some embodiments, the endogenous expression of the molecule at the cell surface is reduced by at least 90%compared to a non-engineered cell. In some embodiments, the endogenous expression of the molecule at the cell surface is reduced by at least 95%compared to a non-engineered cell. In some embodiments, the endogenous expression of the molecule at the cell surface is not detectable. For example, in some embodiments, the Class I MHC molecule or MHC-like molecule cannot be detected by Western Blot in the cell membrane fraction of the cells disclosed herein, or cannot be detected by immunofluorescence on the cell membrane of cells. In some embodiments, the cells provided herein are engineered to delete (or knock out) the gene encoding the Class I MHC molecule or MHC-like molecule.
- provided herein are a population of genetically engineered cells described herein, wherein at least 50%cells lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface. In some embodiments, provided herein are a population of genetically engineered cells described herein, wherein at least 60%cells lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface. In some embodiments, provided herein are a population of genetically engineered cells described herein, wherein at least 75%cells lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface.
- provided herein are a population of genetically engineered cells described herein, wherein at least 80%cells lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface. In some embodiments, provided herein are a population of genetically engineered cells described herein, wherein at least 85%cells lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface. In some embodiments, provided herein are a population of genetically engineered cells described herein, wherein at least 90%cells lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface. In some embodiments, provided herein are a population of genetically engineered cells described herein, wherein at least 95%cells lack endogenous expression of a Class I MHC molecule or an MHC-like molecule on the cell surface.
- the genetically engineered cell provided herein can be of any type.
- the cell is suitable for transplantation.
- the cell is suitable for allogeneic transplantation.
- the cell is selected from the group consisting of a stem cell, a pluripotent cell, a progenitor cells, a hematopoietic stem and/or progenitor cell, a CD34+ mobilized peripheral blood cell, a CD34+ cord blood cell, a CD34+bone marrow cell, a hepatocyte, a somatic cell, an immune cell, and a non-transformed cell.
- the cell is a stem cell.
- the cell is a pluripotent cell.
- the cell is a progenitor cell. In some embodiments, the cell is a hematopoietic stem and/or progenitor cell. In some embodiments, the cell is a CD34+ mobilized peripheral blood cell. In some embodiments, the cell is a CD34+ cord blood cell. In some embodiments, the cell is a CD34+ bone marrow cell. In some embodiments, the cell is a hepatocyte. In some embodiments, the cell is a somatic cell. In some embodiments, the cell is a non-transformed cell.
- the cell provided herein is a stem cell.
- the cell can be a somatic cell.
- the cell can be a non-pluripotent cell.
- the cell can be an incompletely or partially pluripotent stem cell.
- the cell can be a multipotent cell.
- the cell can be an oligopotent cell,
- the cell can be a unipotent cell.
- the cell can be a terminally differentiated cell.
- Pluripotent cells suitable for use in particular embodiments include, but are not limited to, naturally-occurring stem cells, embryonic stem cells, or induced pluripotent cells (iPSCs) .
- iPSCs induced pluripotent cells
- Provided herein are also a mixed population of cells combining any of the cells mentioned above.
- a population of cells provided herein can comprise cells undergoing reprogramming, which comprise pluripotent cells, partially pluripotent cells, and non-pluripotent cells, such as fully differentiated cells.
- the cell provided herein is an adult stem/progenitor cells. In some embodiments, the cell provided herein is a neonatal stem/progenitor cells. In some embodiments, the cell is selected from the group consisting of: a mesodermal stem/progenitor cell, an endodermal stem/progenitor cell, and an ectodermal stem/progenitor cell. In some embodiments, the cell is a mesodermal stem/progenitor cell. In some embodiments, the cell is an endodermal stem/progenitor cell. In some embodiments, the cell is an ectodermal stem/progenitor cell.
- mesodermal stem/progenitor cells include, but are not limited to: mesodermal stem/progenitor cells, endothelial stem/progenitor cells, bone marrow stem/progenitor cells, umbilical cord stem/progenitor cells, adipose tissue derived stem/progenitor cells, hematopoietic stem/progenitor cells (HSCs) , mesenchymal stem/progenitor cells, muscle stem/progenitor cells, kidney stem/progenitor cells, osteoblast stem/progenitor cells, chondrocyte stem/progenitor cells, and the like.
- the cell is a mesodermal stem/progenitor cell.
- the cell is an endothelial stem/progenitor cell. In some embodiments, the cell is a bone marrow stem/progenitor cell. In some embodiments, the cell is an umbilical cord stem/progenitor cell. In some embodiments, the cell is an adipose tissue derived stem/progenitor cell. In some embodiments, the cell is an hematopoietic stem/progenitor cell (HSC) . In some embodiments, the cell is a mesenchymal stem/progenitor cell. In some embodiments, the cell is a muscle stem/progenitor cell. In some embodiments, the cell is a kidney stem/progenitor cell. In some embodiments, the cell is an osteoblast stem/progenitor cell. In some embodiments, the cell is a chondrocyte stem/progenitor cell.
- HSC hematopoietic stem/progenitor cell
- ectodermal stem/progenitor cells include, but are not limited to neural stem/progenitor cells, retinal stem/progenitor cells, skin stem/progenitor cells, and the like.
- the cell is a neural stem/progenitor cell.
- the cell is a retinal stem/progenitor cell.
- the cell is a skin stem/progenitor cell.
- endodermal stem/progenitor cells include, but are not limited to liver stem/progenitor cells, pancreatic stem/progenitor cells, epithelial stem/progenitor cells, and the like.
- the cell is an endodermal stem/progenitor cell.
- the cell is a liver stem/progenitor cell.
- the cell is a pancreatic stem/progenitor cell.
- the cell is an epithelial stem/progenitor cell.
- the cell provided herein is selected from the group consisting of: pancreatic islet cells, CNS cells, PNS cells, cardiac muscle cells, skeletal muscle cells, smooth muscle cells, hematopoietic cells, bone cells, liver cells, an adipose cells, renal cells, lung cells, chondrocyte, skin cells, follicular cells, vascular cells, epithelial cells, immune cells, endothelial cells, and the like.
- the cell is a pancreatic islet cell.
- the cell is a CNS cell.
- the cell is a PNS cell.
- the cell is a cardiac muscle cell.
- the cell is a skeletal muscle cell.
- the cell is a smooth muscle cell. In some embodiments, the cell is a hematopoietic cell. In some embodiments, the cell is a bone cell. In some embodiments, the cell is a liver cell. In some embodiments, the cell is an adipose cell. In some embodiments, the cell is a renal cell. In some embodiments, the cell is a lung cell. In some embodiments, the cell is a chondrocyte. In some embodiments, the cell is a skin cell. In some embodiments, the cell is a follicular cell. In some embodiments, the cell is a vascular cell. In some embodiments, the cell is an epithelial cell. In some embodiments, the cell is am endothelial cell.
- the cell provided herein is an immune cell.
- the cell can be a leukocyte.
- a leukocyte is a karyocyte developed from a hematopoietic stem cell and plays important roles in the hematopoietic system and the lymphatic system.
- Leukocytes includes myeloid cells, lymphoid cells, granulocytes (such as neutrophils, eosinophils, basophils) , lymphocytes (such as T cells, B cells, NK cells, NKT cells) , plasma cells, dendritic cells, monocytes and cells differentiated therefrom such as a macrophage.
- the cell provided herein is a leukocyte.
- the cell provided herein is a myeloid cell. In some embodiments, the cell provided herein is a lymphoid cells. In some embodiments, the cell provided herein is a granulocyte. In some embodiments, the cell provided herein is a neutrophil. In some embodiments, the cell provided herein is an eosinophil. In some embodiments, the cell provided herein is a basophil. In some embodiments, the cell provided herein is a T cell. In some embodiments, the cell provided herein is a B cell. In some embodiments, the cell provided herein is a plasma cell. In some embodiments, the cell provided herein is an NK cell. In some embodiments, the cell provided herein is an NKT cell. In some embodiments, the cell provided herein is a dendritic cell. In some embodiments, the cell provided herein is a monocyte. In some embodiments, the cell provided herein is a macrophage.
- the cell provided herein is a tumor-infiltrating lymphocyte (TIL) .
- TIL tumor-infiltrating lymphocyte
- a population of the cells disclosed herein can be a homogenous population of cells.
- the population of cells can be a heterogeneous population of cells.
- the population of cells can be a heterogeneous population of cells comprising any combination of the cells disclosed herein.
- T cells provided herein can be used in allogeneic transplantation.
- some CAR-T cells disclosed herein can be universal CAR-Ts that can be used in allogeneic transplantation for cancer treatment.
- provided herein is a genetically engineered T cell that expresses the fusion protein disclosed herein.
- provided herein is a genetically engineered T cell that comprises the nucleic acid disclosed herein.
- provided herein is a CAR-T cell.
- the genetically engineered cell provided herein is a universal lymphocyte, namely, a lymphocyte that can be applied to allotransplantation, which either does not produce or produces a controlled GvHD reaction.
- a GvHD (graft-versus-host disease) reaction refers to the medical complication following transplantation of tissues having immunologically active cells, wherein the immunologically active cells in the graft tissue recognize the recipient’s healthy tissue as foreign and initiate an immune response against the recipient’s healthy tissues.
- GvHD can be clinically controlled by drug intervention and does not threaten life; but severe GvHD can be life-threatening.
- GvHD is a particular concern for allogeneic CAR-T therapies, as the allogeneic T cells might recognize not only the cancer but also the noncancerous tissues in the recipient as non-self and attack such noncancerous tissues.
- TCR T-Cell Receptor
- TCR is a transmembrane octamer on T cells composed of a TCR dimer and various subunits of CD3.
- TCR is responsible for antigen recognition by T cells, which is required for T cell activation.
- Components of the TCR receptor include ⁇ and ⁇ subunits of TCR, and ⁇ , ⁇ , ⁇ , ⁇ or ⁇ subunits of CD3. Removal of a functional TCR component from the donor T cell can prevent the donor T cell from attacking host cells.
- T cells provided herein also lack the expression of a component of the TCR complex.
- at least one gene encoding a component of the TCR is inactivated in the T cells provided herein.
- the gene encoding ⁇ subunit of TCR (e.g. TRAC) is inactivated in the T cells provided herein.
- a human TRAC can have an amino acid sequence corresponding to UniProtKB/Swiss-Prot No.: P01848.2 (Accession: P01848.2 GI: 1431906459) .
- the gene encoding ⁇ subunit of TCR (e.g. TRBC) is inactivated in the T cells provided herein.
- a human TRBC can have an amino acid sequence corresponding to the GenBank sequence ALC78509.1 (Accession: ALC78509.1 GI: 924924895) .
- the gene encoding the ⁇ subunit of CD3 is inactivated in the T cells provided herein.
- a human ⁇ subunit of CD3 can have an amino acid sequence corresponding to the sequence having NCBI Reference Sequence: NP_000723.1 (Accession: NP_000723.1 GI: 4502669; Isoform A) or NCBI Reference Sequence: NP_001035741.1 (Accession: NP_001035741.1 GI: 98985801; Isoform B) .
- the gene encoding the ⁇ subunit of CD3 is inactivated in the T cells provided herein.
- a human ⁇ subunit of CD3 can have an amino acid sequence corresponding to the sequence having UniProtKB/Swiss-Prot: P07766.2 (Accession: P07766.2 GI: 1345708) .
- the gene encoding the ⁇ subunit of CD3 is inactivated in the T cells provided herein.
- a human ⁇ subunit of CD3 can have an amino acid sequence corresponding to the sequence having NCBI Reference Sequence: NP_000064.1 (Accession: NP_000064.1 GI: 4557429) .
- the gene encoding the ⁇ subunit of CD3 is inactivated in the T cells provided herein.
- a human the ⁇ subunit of CD3 can have an amino acid sequence corresponding to the sequence having UniProtKB/Swiss-Prot: P20963.1 (Accession: P20963.1 GI: 23830999) .
- the gene encoding the ⁇ subunit of CD3 is inactivated in the T cells provided herein.
- a human ⁇ subunit of CD3 can have an amino acid sequence corresponding to the sequence having UniProt Identifier P20963-2.
- T cells expressing the fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the T cells further express a CAR, and wherein the endogenous genes encoding ⁇ 2M and ⁇ subunit of TCR are inactivated in the T cells.
- the fusion protein can be any fusion protein disclosed herein.
- the CAR can be any CAR disclosed herein or otherwise known in the art.
- the fusion protein comprises human ⁇ 2M covalently linked to a presenting peptide via a (G4S) 3 linker, wherein the presenting peptide is HLA-E restricted and is an 8-10 amino acid fragment of a signal peptide of a Class I MHC molecule.
- the CAR comprises an antigen-binding domain that specifically binds a tumor antigen (e.g. CD19) .
- compositions comprising the cells disclosed herein.
- the pharmaceutical composition comprises an effective amount of a cell disclosed herein and a pharmaceutically acceptable carrier.
- the cells disclosed herein and compositions comprising the cells can be conveniently provided in sterile liquid preparations, for example, typically isotonic aqueous solutions with cell suspensions, or optionally as emulsions, dispersions, or the like, which are typically buffered to a selected pH.
- the compositions can comprise carriers, for example, water, saline, phosphate buffered saline, and the like, suitable for the integrity and viability of the cells, and for administration of a cell composition.
- Sterile injectable solutions can be prepared by incorporating cells disclosed herein in a suitable amount of the appropriate solvent with various amounts of the other ingredients, as desired.
- Such compositions can include a pharmaceutically acceptable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, dextrose, or the like, that are suitable for use with a cell composition and for administration to a subject such as a human.
- Suitable buffers for providing a cell composition are well known in the art. Any vehicle, diluent, or additive used is compatible with preserving the integrity and viability of the cells disclosed herein.
- compositions will generally be isotonic, that is, they have the same osmotic pressure as blood and lacrimal fluid.
- the desired isotonicity of the cell compositions provided herein can be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, or other inorganic or organic solutes.
- Sodium chloride is preferred particularly for buffers containing sodium ions.
- One particularly useful buffer is saline, for example, normal saline.
- the components of the compositions should be selected to be chemically inert and will not affect the viability or efficacy of the cells disclosed herein and will be compatible for administration to a subject, such as a human.
- the skilled artisan can readily determine the amount of cells and optional additives, vehicles, and/or carrier in compositions to be administered in methods of the invention.
- the cells disclosed herein can be administered in any physiologically acceptable vehicle. Suitable doses for administration are described herein.
- a cell population comprising cells disclosed herein can comprise a purified population of cells. Those skilled in the art can readily determine the percentage of cells in a cell population using various well-known methods, as described herein.
- the ranges of purity in cell populations comprising genetically modified cells provided herein can be from about 20%to about 25%, from about 25%to about 30%, from about 30%to about 35%, from about 35%to about 40%, from about 40%to about 45%, from about 45%to about 50%, from about 55%to about 60%, from about 65%to about 70%, from about 70%to about 75%, from about 75%to about 80%, from about 80%to about 85%; from about 85%to about 90%, from about 90%to about 95%, or from about 95 to about 100%.
- the ranges of purity in cell populations comprising genetically modified cells provided herein can be from about 20%to about 30%, from about 20%to about 50%, from about 20%to about 80%, from about 20%to about 100%, from about 50%to about 80%, or from about 50%to about 100%. Dosages can be readily adjusted by those skilled in the art; for example, a decrease in purity may require an increase in dosage.
- kits for preparation of cells disclosed herein comprises one or more vectors for generating a genetically engineered cell, such as a T cell, that expresses a fusion protein disclosed herein for allogeneic transplant.
- the kits can be used to generate genetically engineered cells from non-autologous cells to be administered to a compatible subject.
- the kits can comprise cells disclosed herein, for example, non-autologous cells, for administration to a subject.
- the kits comprise the cells disclosed herein in one or more containers.
- methods of genetically engineering a cell for an allogeneic transplant comprising transducing the cell with a nucleic acid disclosed herein.
- methods of genetically engineering a cell for an allogeneic transplant comprising transducing the cell with a vector comprising a nucleic acid disclosed herein.
- the nucleic acid encodes a fusion protein disclosed herein.
- methods provided herein comprise transducing a cell with a nucleic acid encoding a fusion protein, wherein the fusion protein comprises a presenting peptide and a ⁇ 2M peptide covalently linked via a linker.
- kits for genetically engineering a cell for an allogeneic transplant comprising transducing the cell with a nucleic acid that encodes a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the fusion protein binds a MHC heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell.
- provided herein are methods of genetically engineering a cell for an allogeneic transplant, comprising transducing the cell with a nucleic acid that encodes a fusion protein comprising an HLA-E-restricted presenting peptide covalently linked to a ⁇ 2M peptide via a linker.
- methods of genetically engineering a cell for an allogeneic transplant comprising transducing the cell with a nucleic acid that encodes a fusion protein comprising a presenting peptide covalently linked to a ⁇ 2M peptide via a linker, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof.
- the fusion protein does not have an MHC heavy chain. In some embodiments, the fusion protein does not have an HLA-E heavy chain. In some embodiments, the fusion protein does not have an HLA-A heavy chain, an HLA-B heavy chain, an HLA-C heavy chain, an HLA-E heavy chain, an HLA-F heavy chain, or an HLA-G heavy chain. In some embodiments, the fusion protein has less than 500 amino acids, less than 400 amino acids, less than 300 amino acids, or less than 200 amino acids. In some embodiments, the fusion protein has about 100 to about 300 amino acids, about 100 to about 200 amino acids, about 120 to about 180 amino acids, about 120 to about 160 amino acids, or about 140 to about 160 amino acids. Various embodiments of the fusion proteins encoded by the nucleic acids provided herein are provided in Section 5.2 above.
- the cells disclosed herein can be subjected to conditions that favor maintenance or expansion of cells as well known in the art.
- stem cells or immune cells can be subjected to conditions that favor maintenance or expansion of cells as well known in the art.
- the cells disclosed herein e.g. stem cells or immune cells
- the cells can optionally be cryopreserved after isolation and/or genetic engineering, and/or expansion of genetically engineered cells (see Kaiser et al., supra, 2015) ) .
- Methods for cyropreserving cells are well known in the art (see, for example, Freshney, Culture of Animal Cells: A Manual of Basic Techniques, 4th ed., Wiley-Liss, New York (2000) ; Harrison and Rae, General Techniques of Cell Culture, Cambridge University Press (1997) ) .
- one or more nucleic acids encoding the fusion protein is introduced into the target cell using a suitable expression vector.
- the target cells e.g. stem cells or immune cells
- the target cells are transduced with one or more nucleic acids encoding a fusion protein, or a synthetic receptor and a fusion protein.
- the synthetic receptor and fusion protein encoding nucleic acids can be on separate vectors or on the same vector, as desired.
- a nucleic acid encoding a synthetic receptor or a fusion protein disclosed herein can be cloned into a suitable vector, such as a retroviral vector, and introduced into the target cell using well known molecular biology techniques (see Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999) ) .
- a suitable vector such as a retroviral vector
- Any vector suitable for expression in a cell of the invention particularly a human immune cell or a stem cell, can be used.
- the vectors contain suitable expression elements such as promoters that provide for expression of the encoded nucleic acids in the target cell.
- cells can optionally be activated to increase transduction efficiency (see Parente-Pereira et al., J. Biol. Methods 1 (2) e7 (doi 10.14440/jbm. 2014.30) (2014) ; Movassagh et al., Hum. Gene Ther. 11: 1189-1200 (2000) ; Rettig et al., Mol. Ther. 8: 29-41 (2003) ; Agarwal et al., J. Virol. 72: 3720-3728 (1998) ; Pollok et al., Hum. Gene Ther. 10: 2221-2236 (1998) ; Quinn et al., Hum. Gene Ther. 9: 1457-1467 (1998) ; see also commercially available methods such as Dynabeads TM human T cell activator products, Thermo Fisher Scientific, Waltham, MA) .
- the vector is a retroviral vector, for example, a gamma retroviral or lentiviral vector, which is employed for the introduction of a fusion protein and/or synthetic receptor into the target cell.
- a retroviral vector is generally employed for transduction.
- any suitable viral vector or non-viral delivery system can be used.
- Combinations of a retroviral vector and an appropriate packaging line are also suitable, where the capsid proteins will be functional for infecting human cells.
- Various amphotropic virus-producing cell lines are known, including, but not limited to, PA12 (Miller et al., Mol. Cell. Biol.
- Non-amphotropic particles are suitable too, for example, particles pseudotyped with VSVG, RD114 or GALV envelope and any other known in the art (Relander et al., Mol. Therap. 11: 452-459 (2005) ) .
- Possible methods of transduction also include direct co-culture of the cells with producer cells (for example, Bregni et al., Blood 80: 1418-1422 (1992) ) , or culturing with viral supernatant alone or concentrated vector stocks with or without appropriate growth factors and polycations (see, for example, Xu et al., Exp. Hemat. 22: 223-230 (1994) ; Hughes, et al. J. Clin. Invest. 89: 1817-1824 (1992) ) .
- the chosen vector exhibits high efficiency of infection and stable integration and expression (see, for example, Cayouette et al., Human Gene Therapy 8: 423-430 (1997) ; Kido et al., Current Eye Research 15: 833-844 (1996) ; Bloomer et al., J. Virol. 71: 6641-6649 (1997) ; Naldini et al., Science 272: 263 267 (1996) ; and Miyoshi et al., Proc. Natl. Acad. Sci. U.S.A. 94: 10319-10323 (1997) ) .
- viral vectors that can be used include, for example, adenoviral, lentiviral, and adeno-associated viral vectors, vaccinia virus, a bovine papilloma virus derived vector, or a herpes virus, such as Epstein-Barr Virus (see, for example, Miller, Hum. Gene Ther. 1 (1) : 5-14 (1990) ; Friedman, Science 244: 1275-1281 (1989) ; Eglitis et al., BioTechniques 6: 608-614 (1988) ; Tolstoshev et al., Current Opin. Biotechnol.
- Epstein-Barr Virus see, for example, Miller, Hum. Gene Ther. 1 (1) : 5-14 (1990) ; Friedman, Science 244: 1275-1281 (1989) ; Eglitis et al., BioTechniques 6: 608-614 (1988) ; Tolstoshev et al., Current Opin. Biotechno
- Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med. 323: 370 (1990) ; Anderson et al., U.S. Pat. No. 5,399,346) .
- a vector is a retroviral vector.
- retroviral vectors for expression in T cells or other immune cells, including engineered T cells has been described (see Scholler et al., Sci. Transl. Med. 4: 132-153 (2012; Parente-Pereira et al., J. Biol. Methods 1 (2) : e7 (1-9) (2014) ; Lamers et al., Blood 117 (1) : 72-82 (2011) ; Reviere et al., Proc. Natl. Acad. Sci. USA 92: 6733-6737 (1995) ) .
- the vector is an SGF retroviral vector such as an SGF ⁇ -retroviral vector, which is Moloney murine leukemia-based retroviral vector.
- SGF vectors have been described previously (see, for example, Wang et al., Gene Therapy 15: 1454-1459 (2008) ) .
- the vectors used herein employ suitable promoters for expression in a particular host cell.
- the promoter can be an inducible promoter or a constitutive promoter.
- the promoter of an expression vector provides expression in a stem cell, such as a hematopoietic stem cell.
- the promoter of an expression vector provides expression in an immune cell, such as a T cell.
- Non-viral vectors can be used as well, so long as the vector contains suitable expression elements for expression in the target cell.
- Some vectors, such as retroviral vectors can integrate into the host genome.
- targeted integration can be implemented using technologies such as a nuclease, transcription activator-like effector nucleases (TALENs) , Zinc-finger nucleases (ZFNs) , and/or clustered regularly interspaced short palindromic repeats (CRISPRs) , homologous recombination, non-homologous end joining, microhomology-mediated end joining, homology-mediated end joining and the like (Gersbach et al., Nucl. Acids Res. 39: 7868-7878 (2011) ;ieri, et al. Cell Death Dis. 6: e1831. (Jul 23 2015) ; Sontheimer, Hum. Gene Ther. 26 (7) : 413-424 (2015) ; Yao et al. Cell Research volume 27, pages 801–814 (2017) ) .
- TALENs transcription activator-like effector nucleases
- ZFNs Zinc-finger nucleases
- CRISPRs clustered regularly inters
- the vectors and constructs can optionally be designed to include a reporter.
- the vector can be designed to express a reporter protein, which can be useful to identify cells comprising the vector or nucleic acids provided on the vector, such as nucleic acids that have integrated into the host chromosome.
- the reporter can be expressed as a bicistronic or multicistronic expression construct with the fusion protein or synthetic receptor.
- reporter proteins include, but are not limited to, fluorescent proteins, such as mCherry, green fluorescent protein (GFP) , blue fluorescent protein, for example, EBFP, EBFP2, Azurite, and mKalama1, cyan fluorescent protein, for example, ECFP, Cerulean, and CyPet, and yellow fluorescent protein, for example, YFP, Citrine, Venus, and YPet.
- fluorescent proteins such as mCherry, green fluorescent protein (GFP) , blue fluorescent protein, for example, EBFP, EBFP2, Azurite, and mKalama1
- cyan fluorescent protein for example, ECFP, Cerulean, and CyPet
- yellow fluorescent protein for example, YFP, Citrine, Venus, and YPet.
- Assays can be used to determine the transduction efficiency of a fusion protein disclosed herein or a synthetic receptor using routine molecular biology techniques. If a marker has been included in the construct, such as a fluorescent protein, gene transfer efficiency can be monitored by FACS analysis to quantify the fraction of transduced (for example, GFP + ) immune cells, such as T cells, and/or by quantitative PCR. Using a well-established cocultivation system (Gade et al., Cancer Res. 65: 9080-9088 (2005) ; Gong et al., Neoplasia 1: 123-127 (1999) ; Latouche et al., Nat. Biotechnol.
- fibroblast AAPCs expressing cancer antigen vs. controls
- transduced immune cells such as T cells, expressing a synthetic receptor (e.g. CAR) (cell supernatant LUMINEX (Austin TX) assay for IL-2, IL-4, IL-10, IFN- ⁇ , TNF- ⁇ , and GM-CSF) , T cell proliferation (by carboxyfluorescein succinimidyl ester (CFSE) labeling) , and T cell survival (by Annexin V staining) .
- CAR cell supernatant LUMINEX (Austin TX) assay for IL-2, IL-4, IL-10, IFN- ⁇ , TNF- ⁇ , and GM-CSF)
- T cell proliferation by carboxyfluorescein succinimidyl ester (CFSE) labeling
- CFSE carboxyfluorescein succinimidyl ester
- T cell survival by Annexin V staining
- T cells can be exposed to repeated stimulation by cancer antigen positive target cells, and it can be determined whether T cell proliferation and cytokine response remain similar or diminished with repeated stimulation.
- the cancer antigen CAR constructs can be compared side by side under equivalent assay conditions.
- Cytotoxicity assays with multiple E: T ratios can be conducted using chromium-release assays.
- a nucleic acid encoding the fusion protein and/or synthetic receptor can also be provided in other types of vectors more suitable for genetic manipulation, such as for expression of various constructs in a bacterial cell such as E. coli.
- vectors can be any of the well known expression vectors, including commercially available expression vectors (see in Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory, New York (2001) ; and Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999) .
- methods provided herein include inactivating at least one gene encoding a Class I MHC molecule or an MHC-like molecule in the immune cell.
- the Class I MHC molecule is selected from the group consisting of heavy chains of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G.
- methods provided herein include inactivating the gene encoding ⁇ 2M.
- methods provided herein include inactivating a gene encoding an MHC-like molecule selected from the group consisting of CD1 heavy chain, MR1 heavy chain, FcRN heavy chain and UL18.
- Gene inactivation can be done using any methods disclosed herein or otherwise known in the art.
- the gene is inactivated DNA cleavage and repair, base editing, RNA interference, or RNA editing.
- the gene is inactivated by DNA cleavage using a rare endonuclease selected from the group consisting of a RNA-directed endonuclease, a TAL nuclease, a homing endonuclease, a zinc-finger nuclease, and a Mega-TAL nuclease.
- the gene is inactivated by DNA cleavage and repair.
- the DNA cleavage and repair is performed by using a CRISPR-Cas system.
- the CRISPR-Cas system is a CRISPR-Cas9 system.
- methods provided herein comprise inactivating a gene by base editing.
- Accurate site-directed change and transformation among adenine (A) , guanine (G) , cytosine (C) , thymine (T) , or uracil (U) at a certain specific site in a nucleic acid (DNA or RNA) result in the base at the specific site changing from one base to another base.
- methods provided herein comprise inactivating a gene by prime editing. It’s a “search-and-replace” genome editing technique that mediates targeted insertions, deletions, and all possible base-to-base conversions. And, it can combine different types of edits with one another.
- a primer editing process can include the following steps: first, an engineered prime editing guide RNA (pegRNA) that both specifies the target site and contains the desired edit (s) engages the prime editor protein.
- pegRNA engineered prime editing guide RNA
- This primer editor protein consists of a Cas9 nickase fused to a reverse transcriptase. The Cas9 nickase part of the protein is guided to the DNA target site by the pegRNA.
- the reverse transcriptase domain uses the pegRNA to template reverse transcription of the desired edit, directly polymerizing DNA onto the nicked target DNA strand.
- the edited DNA strand replaces the original DNA strand, creating a heteroduplex containing one edited strand and one unedited strand.
- the editor guides resolution of the heteroduplex to favor copying the edit onto the unedited strand, completing the process (Anzalone et al. Nature (2019) doi: 10.1038/s41586-019-1711-4) .
- methods provided herein comprise inactivating a gene by RNA interference.
- RNA interference can be adopted for reducing or silencing the expression of a target gene.
- the degradation of a target gene mRNA (or its stability is interfered) is specifically induced or the translation efficiency of the target gene mRNA is inhibited by expressing a double-stranded RNA or an antisense RNA homologous to the target gene mRNA.
- methods provided herein comprise inactivating a gene by DNA cleavage and repair.
- DNA cleavage refers to a method that one or two DNA strands at a double-stranded DNA target sequence site break.
- DNA cleavage can be done, for example, by using a ribonuclease, an FokI endonuclease, a Cas protein and the like.
- the cell repairs the cleavage site, for example, by a non-homologous end joining (NHEJ) or homologous recombination (HR) .
- NHEJ non-homologous end joining
- HR homologous recombination
- the sequence near the cleavage site can be changed, and errors such as insertion and deletion mutations may occur. If the cleavage site is in an exon region or a regulatory region of a gene, the expression of the gene can be reduced and eliminated.
- Zinc-finger nuclease ZaFN
- methods provided herein comprise inactivating a gene by using Zinc-finger nuclease (ZFN) .
- ZFN Zinc-finger nuclease
- a zinc-finger nuclease consists of a DNA recognition domain and a non-specific endonuclease.
- the DNA recognition domain consists of a series of Cys2-His2 zinc-finger proteins linked in series, and each zinc-finger unit includes about 30 amino acids for specifically binding to DNA.
- the non-specific endonuclease is a FokI endonuclease which forms a dimer to cleave the DNA.
- TALEN TAL Nuclease
- methods provided herein comprise inactivating a gene by using TALEN.
- TALEN is a transcription activator-like effector nuclease.
- the TALE protein is a core component of a DNA binding domain, and generally consists of a plurality of basic repeat units linked in series. The designed and combined series of units can specifically recognize a DNA sequence, and cleave a specific DNA sequence by coupling the FokI endonuclease.
- methods provided herein comprise inactivating a gene by using the CRISPR/Cas system.
- a CRISPR/Cas system is a nuclease system consisting of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR binding proteins (i.e., Cas proteins) , which can cleave nearly all genomic sequences adjacent to protospacer-adjacent motifs (PAM) in eukaryocytes (Cong et al. Science 2013. 339: 819-823) .
- CRISPR/Cas system is a nuclease system consisting of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR binding proteins (i.e., Cas proteins) , which can cleave nearly all genomic sequences adjacent to protospacer-adjacent motifs (PAM) in eukaryocytes (Cong et al. Science 2013. 339: 819-823) .
- CRISPR/Cas system is used to refer collectively to transcripts involving CRISPR-related ( “Cas” ) genes, as well as other elements involving the expression thereof or directing the activity thereof, including sequences encoding a Cas gene, tracr (trans-activated CRISPR) sequences (for example, tracrRNA or active partial tracrRNA) , tracr pairing sequences (in the background of an endogenous CRISPR system, cover “direct repeats” and processed partial direct repeats) , guide sequences, or other sequences from the CRISPR locus and transcripts.
- the CRISPR system is characterized as an element that facilitates the formation of a CRISPR complex at a site of a target sequence (also called a protospacer in the endogenous CRISPR system) .
- the formation of the CRISPR complex results in the cleavage of one chain or two chains in or near the target sequence (for example, within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs) .
- the tracr sequence (which may comprise or consist of all or part of a wild-type tracr sequence (for example, about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85 or more nucleotides of the wild-type tracr sequence) ) may also form part of the CRISPR complex, for example, by hybridizing along at least a part of the tracr sequence to all or part of the tracr pairing sequence operably linked to the guide sequence.
- the tracr sequence is sufficiently complementary to a tracr pairing sequence to hybridize and participate in the formation of a CRISPR complex.
- the tracr sequence has at least 50%, 60%, 70%, 80%, 90%, 95%, or 99%sequence complementarity along the length of the tracr pairing sequence when performing an optimal comparison.
- one or more vectors that drive expression of one or more elements of the CRISPR system are introduced into a host cell such that the expression of the elements of the CRISPR system directs the formation of the CRISPR complex at one or more target sites.
- the tracr pairing sequence has sufficient complementarity with the tracr sequence to facilitate formation of the CRISPR complex at the target sequence, wherein the CRISPR complex comprises a tracr pairing sequence that is hybridized to the tracr sequence.
- the degree of complementarity is in terms of an optimal alignment of the tracr pairing sequence and the tracr sequence along the length of the shorter of the two sequences.
- the optimal alignment can be determined by any suitable alignment algorithm, and the effects of a secondary structure can be further taken into account, for example, the self-complementarity within the tracr sequence or tracr pairing sequence.
- the degree of complementarity between the tracr sequence and the tracr pairing sequence along the length of the shorter of the two is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher.
- the tracr sequence has about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50 or more nucleotides in sequence.
- Cas protein examples include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12) , Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4 homologues, or modified forms thereof.
- the Cas protein is a Cas9 protein.
- Cas9 also known as Csn1
- Csn1 is a giant protein involved in both crRNA biosynthesis and the destruction of invading DNA. Cas9 has been described in different bacterial species such as S.thermophiles, Listeria innocua (Gasiunas, Barrangou et al. 2012; Jinek, Chylinski et al. 2012) and S. Pyogenes (Deltcheva, Chylinski et al. 2011) .
- the giant Cas9 protein (more than 1200 amino acids) contains two predicted nuclease domains, namely, an HNH (McrA-like) nuclease domain located in the middle of the protein and a split RuvC-like nuclease domain (RNAase H-fold) (Makarova, Grishin et al. (2006) ) .
- a Cas9 variant may be a Cas9 endonuclease that is not naturally found in nature and is obtained by protein engineering or by random mutagenesis.
- the Cas9 variant according to the present invention can be obtained by mutations such as deletion, insertion or substitution of at least one residue in the amino acid sequence of the S.
- the Cas9 protein is Streptococcus pneumoniae, S. pyogenes, or S. thermophiles Cas9, and may include mutated Cas9 derived from these organisms, or variants linking other amino acid sequences to Cas9, for example, the variant linking the FokI enzyme to Cas9.
- Cas9 are known; for example, the amino acid sequence of the Streptococcus pyogenes Cas9 protein can be found in the SwissProt database under the accession number Q99ZW2, the amino acid sequence of the Neisseria meningitides Cas9 protein can be found in the UniProt database under the number A1IQ68, the amino acid sequence of the S. thermophiles Cas9 protein can be found in the UniProt database under the number Q03LF7, and the amino acid sequence of the Staphylococcus aureus Cas9 protein can be found in the UniProt database under the number J7RUA5.
- the genetically engineered cells provided herein can be used in allogeneic transplant, and are less likely to be rejected by the recipient’s immune system, at least because the fusion proteins expressed on the cells can form MHC complexes that engage the inhibitory receptors on the recipient’s immune cells to prevent their activation against the allogeneic transplant.
- a genetically engineered cell in an allogeneic transplant wherein the cell expresses a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker.
- methods of providing an allogeneic cell transplant to a subject in need thereof comprising administering a therapeutically effective amount of a genetically engineered cell to the subject, wherein the cell expresses a fusion protein comprising a presenting peptide and a ⁇ 2M peptide covalently linked via a linker.
- the genetically engineered cell can be any genetically engineered cell disclosed herein in section 5.5.
- the fusion protein can be any fusion protein disclosed herein in section 5.2.
- provided herein are uses of a genetically engineered cell in an allogeneic transplant, wherein the cell comprises a nucleic acid disclosed herein.
- Provided herein are also methods of providing an allogeneic cell transplant in a subject in need thereof, comprising administering a therapeutically effective amount of a genetically engineered cell to the subject, wherein the cell comprises a nucleic acid disclosed herein.
- the subject receiving the treatment is a human. In some embodiments, the subject is a human in need of an allogeneic transplant.
- fusion proteins nucleic acids, cells, and the methods of their production are disclosed in detail in sections above.
- the cell comprises a nucleic acid encoding a fusion protein comprising a HLA-E-restricted presenting peptide covalently linked to human ⁇ 2M via a (G4S) 3 linker.
- the fusion protein can bind an endogenously expressed HLA-E heavy chain to form an HLA-E complex on the surface of the genetically engineered cell, which can engage an inhibitory receptor (e.g. NKG2A) on an immune cell (e.g. NK cell) to inhibit its potentially cytotoxic activity against the genetically engineered cells.
- an inhibitory receptor e.g. NKG2A
- an immune cell e.g. NK cell
- provided herein are methods of administering a therapeutically effective amount of the genetically engineered cells disclosed herein to a subject in need of such cells as an allogeneic transplant.
- Provided herein are also uses of the genetically engineered cells disclosed herein for preparing an allogeneic transplant.
- An allogeneic transplant comprising the cells provided herein is less likely to be rejected by the recipient, at least because the fusion protein expressed in the cells provides a mechanism for inhibiting a potential allogeneic immune response.
- provided herein are methods of providing an allogeneic transplant to a subject in need thereof by administering a therapeutically effective amount of cells provided herein to the subject.
- provided herein are methods of reducing the likelihood that cells administered to a subject trigger an allogeneic immune response in the subject. In some embodiments, provided herein are methods of reducing an allogeneic response in a subject. In some embodiments, methods provided herein reduce the occurrence of allograft rejection.
- the subject in need of administration of cells is suffering from a disorder.
- the subject can be suffering from a disorder in which the particular cells are decreased in function or number, and it is therefore desirable to administer functional cells obtained from a healthy or normal individual in which the particular cells are functioning properly and to administer an adequate number of those healthy cells to the individual to restore the function provided by those cells (e.g., hormone producing cells which have decreased in cell number or function, immune cells winch have decreased in cell number or function, etc. ) .
- the healthy cells can be engineered as disclosed herein to decrease the likelihood of host rejection of the healthy cells.
- the disorder is a genetic disorder.
- the disorder is an infection.
- the disorder is HIV infection or AIDS.
- the disorder is cancer.
- Methods disclosed herein can be particularly helpful in regenerative medicine.
- patients in need of a stem cell transplant can benefit from the genetically engineered cells disclosed herein.
- methods of providing an allogeneic stem cell to a subject in need thereof by administering a therapeutically effective amount of the stem cells provided herein to the subject are also uses of the genetically engineered stem cells disclosed herein for preparing a stem cell transplant.
- the genetically engineered stem cells are differentiated into the desired cell type before being administered to a subject in need thereof.
- people who can benefit from these cell therapies include those with spinal cord injuries, type 1 diabetes, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, heart disease, stroke, burns, cancer and osteoarthritis.
- provided herein are methods of treating a subject that can be benefit from an allogenic cell therapy by administering a therapeutically effective amount of the cells provided herein to the subject.
- the subject can have spinal cord injuries, type 1 diabetes, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, heart disease, stroke, burns, cancer or osteoarthritis.
- the genetically engineered cells can be expanded before being administered to a subject in need thereof.
- the cells are administered as a population of cells expressing the fusion protein described herien.
- the cells to be administered can be purified or enriched.
- the subject is in need of an organ transplantation, and the allogeneic organ transplant can be developed using a genetically engineered stem cell disclosed herein.
- provided herein are also methods of providing an allogenic organ transplant by culturing the genetically engineered stem cells disclosed herein under appropriate conditions that allow the development of the organ.
- provided herein are methods of providing hematopoietic stem and/or progenitor cells to a subject in need thereof by administering a therapeutically effective amount of the genetically engineered cells provided herein to the subject in need thereof, wherein the cells are hematopoietic stem and/or progenitor cells.
- the subject might be in need of a bone marrow transplant, and provided herein are also uses of the genetically engineered cells disclosed herein for preparing a bone marrow transplant.
- the genetically engineered hematopoietic stem and/or progenitor cells can be CD34+ mobilized peripheral blood cells, CD34+ cord blood cells, or CD34+ bone marrow cells.
- provided herein are methods of treating cancer by administering a therapeutically effective amount of the cells provided herein to the subject in need thereof.
- Provided herein are also uses of the genetically engineered cells disclosed herein in cancer treatment.
- Provided herein are also uses of the genetically engineered cells disclosed herein for the preparation of a medicament for the treatment of cancer.
- the cell can be an immune cell.
- the cell can be a leukocyte, including, for example, myeloid cells, lymphoid cells, granulocytes (such as neutrophils, eosinophils, basophils) , lymphocytes (such as T cells, B cells, NK cells, NKT cells) , plasma cells, dendritic cells, monocytes, or cells differentiated therefrom such as a macrophage.
- a leukocyte including, for example, myeloid cells, lymphoid cells, granulocytes (such as neutrophils, eosinophils, basophils) , lymphocytes (such as T cells, B cells, NK cells, NKT cells) , plasma cells, dendritic cells, monocytes, or cells differentiated therefrom such as a macrophage.
- granulocytes such as neutrophils, eosinophils, basophils
- lymphocytes such as T cells, B cells, NK cells, NKT cells
- plasma cells dendritic cells, mon
- provided herein are methods of treating cancer by administering a therapeutically effective amount of the genetically engineered NK cells provided herein to the subject in need thereof. In some embodiments, provided herein are methods of treating cancer by administering a therapeutically effective amount of the genetically engineered macrophages provided herein to the subject in need thereof.
- the methods can include administering a cancer-antigen specific immune cell to a subject in need thereof, wherein the cell recombinantly expresses a fusion protein disclosed herein and a synthetic receptor comprising an antigen binding domain that specifically binds the cancer antigen.
- the cancer antigen can be any cancer antigen disclosed herein or otherwise known in the art.
- the cancer antigen is selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- the synthetic receptor is a CAR, a TCR, a TRuC, a TAC, an AbTCR, or a chimeric CD3 receptor.
- provided herein are also uses of the genetically engineered T cells disclosed herein in preparation of a medicament for cancer treatment, wherein the genetically engineered T cells express a synthetic receptor.
- the genetically engineered T cells express a CAR.
- the genetically engineered T cells express a TCR.
- the genetically engineered T cells express a TRuC.
- the genetically engineered T cells express a TAC.
- the genetically engineered T cells express an AbTCR.
- the genetically engineered T cells express a chimeric CD3 receptor.
- immune cells provided herein can be used in allogeneic transplantation.
- the immune cell can be a leukocyte, including, for example, myeloid cells, lymphoid cells, granulocytes (such as neutrophils, eosinophils, basophils) , lymphocytes (such as T cells, B cells, NK cells, NKT cells) , plasma cells, dendritic cells, monocytes, or cells differentiated therefrom such as a macrophage.
- leukocyte including, for example, myeloid cells, lymphoid cells, granulocytes (such as neutrophils, eosinophils, basophils) , lymphocytes (such as T cells, B cells, NK cells, NKT cells) , plasma cells, dendritic cells, monocytes, or cells differentiated therefrom such as a macrophage.
- provided herein are methods of treating cancer in a subject by administering a therapeutically effective amount of the T cells provided herein to the subject in need thereof.
- provided herein are methods of treating cancer in a subject by administering a therapeutically effective amount of the CAR-T cells provided herein to the subject in need thereof.
- Provided herein are also uses of the genetically engineered T cells disclosed herein in cancer treatment.
- Provided herein are also uses of the genetically engineered T cells disclosed herein in preparation of a medicament for cancer treatment.
- the methods can be used to treat cancer or reduce tumor burden in a subject.
- the methods provided herein are used to treat cancer.
- a method of treating cancer can include any effect that ameliorates a sign or symptom associated with cancer.
- signs or symptoms include, but are not limited to, reducing tumor burden, including inhibiting growth of a tumor, slowing the growth rate of a tumor, reducing the size of a tumor, reducing the number of tumors, eliminating a tumor, all of which can be measured using routine tumor imaging techniques well known in the art.
- Other signs or symptoms associated with cancer include, but are not limited to, fatigue, pain, weight loss, and other signs or symptoms associated with various cancers.
- the methods of the invention can reduce tumor burden.
- administration of the cells of the invention can reduce the number of tumor cells, reduce tumor size, and/or eradicate the tumor in the subject.
- the immune cells are administered to a subject in need of cancer treatment.
- the subject can be a mammal, in particular a human.
- the subject is a human.
- Suitable human subjects for therapy include those with “advanced disease” or “high tumor burden” who bear a clinically measurable tumor.
- a clinically measurable tumor is one that can be detected on the basis of tumor mass, for example, by palpation, CAT scan, sonogram, mammogram, X-ray, and the like. Positive biochemical or histopathologic markers can also be used to identify this population.
- a pharmaceutical composition comprising a cell provided herein is administered to a subject to elicit an anti-cancer response, with the objective of palliating the subject’s condition. Reduction in tumor mass of a subject having a tumor can occur, but any clinical improvement constitutes a benefit. Clinical improvement comprises decreased risk or rate of progression or reduction in pathological consequences of the tumor.
- Another group of suitable subjects can be a subject who has a history of cancer, but has been responsive to another mode of therapy.
- the prior therapy can have included, but is not restricted to, surgical resection, radiotherapy, and traditional chemotherapy.
- these individuals have no clinically measurable tumor.
- they are suspected of being at risk for progression of the disease, either near the original tumor site, or by metastases.
- This group can be further subdivided into high-risk and low-risk individuals. The subdivision is made on the basis of features observed before or after the initial treatment. These features are known in the clinical arts, and are suitably defined for different types of cancers.
- Features typical of high-risk subgroups are those in which the tumor has invaded neighboring tissues, or who show involvement of lymph nodes.
- a cell provided herein can be administered for treatment prophylactically to prevent the occurrence of cancer in a subject suspected of having a predisposition to a cancer, for example, based on family history and/or genetic testing.
- the subject can have an advanced form of disease, in which case the treatment objective can include mitigation or reversal of disease progression, and/or amelioration of side effects.
- the subjects can have a history of the condition, for which they have already been treated, in which case the therapeutic objective can be to decrease or delay the risk of recurrence. Additionally, refractory or recurrent malignancies can be treated using the cells provided herein.
- the cells provided herein are administered to a subject, such as a human subject, in need of cancer treatment.
- the cancer can involve a solid tumor or a blood cancer not involving a solid tumor.
- Cancers to be treated using the cells of the invention comprise cancers typically responsive to immunotherapy.
- Exemplary types of cancers include, but are not limited to, carcinomas, sarcoma, leukemia, lymphoma, multiple myeloma, melanoma, brain and spinal cord tumors, germ cell tumors, neuroendocrine tumors, carcinoid tumors, and the like.
- the cancer can be a solid tumor or a blood cancer that does not form a solid tumor. In the case of a solid tumor, the tumor can be a primary tumor or a metastatic tumor.
- neoplasias or cancers that can be treated using the methods provided herein include bone cancer, intestinal cancer, liver cancer, skin cancer, cancer of the head or neck, melanoma (cutaneous or intraocular malignant melanoma) , renal cancer (for example, clear cell carcinoma) , throat cancer, prostate cancer (for example, hormone refractory prostate adenocarcinoma) , blood cancers (for example, leukemias, lymphomas, and myelomas) , uterine cancer, rectal cancer, cancer of the anal region, bladder cancer, brain cancer, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, leukemias (for example, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomon
- the methods provided herein are used to treat a cancer selected from malignant pleural disease, mesothelioma, lung cancer (for example, non-small cell lung cancer) , pancreatic cancer, ovarian cancer, breast cancer (for example, metastatic breast cancer, metastatic triple-negative breast cancer) , colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, and synovial sarcoma.
- a cancer selected from malignant pleural disease, mesothelioma, lung cancer (for example, non-small cell lung cancer) , pancreatic cancer, ovarian cancer, breast cancer (for example, metastatic breast cancer, metastatic triple-negative breast cancer) , colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, and synovial sarcoma.
- Solid tumors can be primary tumors or tumors in a metastatic state.
- the amount administered is an amount effective for producing the desired effect.
- An effective amount or therapeutically effective amount is an amount sufficient to provide a beneficial or desired clinical result upon treatment.
- An effective amount can be provided in a single administration or a series of administrations (one or more doses) .
- An effective amount can be provided in a bolus or by continuous perfusion.
- an effective amount is an amount that is sufficient to palliate, ameliorate, stabilize, reverse or slow the progression of the disease, or otherwise reduce the pathological consequences of the disease.
- the effective amount can be determined by the physician for a particular subject. Several factors are typically taken into account when determining an appropriate dosage to achieve an effective amount. These factors include age, sex and weight of the subject, the condition being treated, the severity of the condition and the form and effective concentration of the cells of the invention being administered.
- the cells provided herein are generally administered as a dose based on cells per kilogram (cells/kg) of body weight of the subject to which the cells are administered.
- the cell doses are in the range of about 10 4 to about 10 10 cells/kg of body weight, for example, about 10 5 to about 10 9 , about 10 5 to about 10 8 , about 10 5 to about 10 7 , or about 10 5 to 10 6 , depending on the mode and location of administration.
- a higher dose is used than in regional administration, where the immune cells of the invention are administered in the region of a tumor.
- Exemplary dose ranges include, but are not limited to, 1x10 4 to 1x10 8 , 2x10 4 to 1x10 8 , 3x10 4 to 1x10 8 , 4x10 4 to 1x10 8 , 5x10 4 to 1x10 8 , 6x10 4 , to 1x10 8 , 7x10 4 to 1x10 8 , 8x10 4 to 1x10 8 , 9x10 4 to 1x10 8 , 1x10 5 to 1x10 8 , for example, 1x10 5 to 9x10 7 , 1x10 5 to 8x10 7 , 1x10 5 to 7x10 7 , 1x10 5 to 6x10 7 , 1x10 5 to 5x10 7 , 1x10 5 to 4x10 7 , 1x10 5 to 3x10 7 , 1x10 5 to 2x10 7 , 1x10 5 to 1x10 7 , 1x10 5 to 9x10 6 , 1x10 5 to 8x10 6 , 1x10 5 to
- cells are provided in a dose of 1x10 5 to 1x10 8 , for example 1x10 5 to 1x10 7 , 1x10 5 to 1x10 6 , 1x10 6 to 1x10 8 , 1x10 6 to 1x10 7 , 1x10 7 to 1x10 8 , 1x10 5 to 5x10 6 , in particular 1x10 5 to 3x10 6 or 3x10 5 to 3x10 6 cells/kg for regional administration, for example, intrapleural administration.
- 1x10 5 to 1x10 8 for example 1x10 5 to 1x10 7 , 1x10 5 to 1x10 6 , 1x10 6 to 1x10 7 , 1x10 7 to 1x10 8 , 1x10 5 to 5x10 6 , in particular 1x10 5 to 3x10 6 or 3x10 5 to 3x10 6 cells/kg for regional administration, for example, intrapleural administration.
- Exemplary dose ranges also can include, but are not limited to, 5x10 5 to 1x10 8 , for example, 6x10 5 to 1x10 8 , 7x10 5 to 1x10 8 , 8x10 5 to 1x10 8 , 9x10 5 to 1x10 8 , 1x10 6 to 1x10 8 , 1x10 6 to 9x10 7 , 1x10 6 to 8x10 7 , 1x10 6 to 7x10 7 , 1x10 6 to 6x10 7 , 1x10 6 to 5x10 7 , 1x10 6 to 4x10 7 , 1x10 6 to 3x10 7 cells/kg, and the like. Such does can be particularly useful for systemic administration.
- cells are provided in a dose of 1x10 6 to 3x10 7 cells/kg for systemic administration.
- Exemplary cell doses include, but are not limited to, a dose of 1x10 4 , 2x10 4 , 3x10 4 , 4x10 4 , 5x10 4 , 6x10 4 , 7x10 4 , 8x10 4 , 9x10 4 , 1x10 5 , 2x10 5 , 3x10 5 , 4x10 5 , 5x10 5 , 6x10 5 , 7x10 5 , 8x10 5 , 9x10 5 , 1x10 6 , 2x10 6 , 3x10 6 , 4x10 6 , 5x10 6 , 6x10 6 , 7x10 6 , 8x10 6 , 9x10 6 , 1x10 7 , 2x10 7 , 3x10 7 , 4x10 7 , 5x10 7 , 6x10 7 , 7x10 7 , 8x10 4 ,
- the dose can also be adjusted to account for whether a single dose is being administered or whether multiple doses are being administered.
- the precise determination of what would be considered an effective dose can be based on factors individual to each subject, including their size, age, sex, weight, and condition of the particular subject, as described above. Dosages can be readily determined by those skilled in the art based on the disclosure herein and knowledge in the art.
- the cells provided herein can be administered by any methods known in the art, including, but not limited to, pleural administration, intravenous administration, subcutaneous administration, intranodal administration, intratumoral administration, intrathecal administration, intrapleural administration, intraperitoneal administration, intracranial administration, and direct administration to the thymus.
- the cells provided herein can be delivered regionally to a tumor using well known methods, including but not limited to, hepatic or aortic pump; limb, lung or liver perfusion; in the portal vein; through a venous shunt; in a cavity or in a vein that is nearby a tumor, and the like.
- the cells provided herein can be administered systemically.
- the cells are administered regionally at the site of a tumor.
- the cells can also be administered intratumorally, for example, by direct injection of the cells at the site of a tumor and/or into the tumor vasculature.
- administration is preferably by intrapleural administration (see Adusumilli et al., Science Translational Medicine 6 (261) : 261ra151 (2014) ) .
- One skilled in the art can select a suitable mode of administration based on the type of cancer and/or location of a tumor to be treated.
- the cells can be introduced by injection or catheter.
- the cells are pleurally administered to the subject in need, for example, using an intrapleural catheter.
- expansion and/or differentiation agents can be administered to the subject prior to, during or after administration of cells to increase production of the cells provided herein in vivo.
- Proliferation of the cells provided herein is generally done ex vivo, prior to administration to a subject, and can be desirable in vivo after administration to a subject (see Kaiser et al., Cancer Gene Therapy 22: 72-78 (2015) ) .
- Cell proliferation should be accompanied by cell survival to permit cell expansion and persistence, such as with T cells.
- the methods provided herein can further comprise adjuvant therapy in combination with, either prior to, during, or after treatment with the cells provided herein.
- the cell therapy methods provided herein can be used with other standard cancer care and/or therapies that are compatible with administration of the cells provided herein.
- the invention is generally disclosed herein using affirmative language to describe the numerous embodiments.
- the invention also specifically includes embodiments in which particular subject matter is excluded, in full or in part, such as substances or materials, method steps and conditions, protocols, procedures, assays or analysis.
- the invention is generally not expressed herein in terms of what the invention does not include, aspects that are not expressly included in the invention are nevertheless disclosed herein.
- Allograft rejection is a main cause of the failure in allogeneic organ transplantation or allogeneic cell transplant.
- NK cell-mediated allogeneic responses including cytolysis of transplanted cells, are important factors of this rejection (Li, Transplantation. 2010; 90 (10) : 1043-1047) .
- Universal CAR-T therapies can potentially overcome drawbacks of autologous transplantation, but also face the challenge of allogeneic rejection.
- Studies described below illustrate the production of the genetically engineered cells disclosed herein that express fusion proteins comprising a presenting peptide covalently linked to human ⁇ 2M.
- Some cells illustrated herein are T cells co-expressing a CAR that specifically recognize a tumor antigen.
- cells provided herein were shown to have better survival and enhanced proliferation in allogeneic environment.
- cells provided herein were shown to be resistant to NK cell-mediated cell lysis.
- the CAR-T cells expressing the fusion proteins provided herein were also demonstrated to have greatly enhanced activities in inhibiting growth of tumor cells and promoting the death of tumor cells in an allogeneic environment.
- method for preparing an engineered cell comprises the steps: (i) expressing a fusion protein disclosed herein at the cell surface; the fusion protein comprising: (a) a presenting peptide; (b) a ⁇ 2M peptide; and (c) a linker sequence covalently linking the aforementioned (a) and (b) .
- the method can optionally further comprise: (ii) reducing the expression of an endogenous Class I MHC molecule at the cell surface.
- the gene encoding the Class I MHC molecule is mutated or knocked out. The order of steps (i) and (ii) above can be interchanged.
- Lentivirus preparation a three-plasmid system can be used, including: a lentivirus target expression plasmid (Addgene ID: #12252) wherein the GFP expression cassette is replaced with various expression cassettes to express CAR and fusion proteins) , and packaging helper plasmids psPAX2 (Addgene ID: #12260) and pMD2. G (Addgene ID: #12259) .
- Virus packaging can be performed in HEK293T cells (Shanghai Institute of Cell Research, Chinese Academy of Sciences) .
- the preparation process can be done as follows: the HEK293T cells in cryopreserved working cells are thawed, cultured in a DMEM medium (+10%FBS+1%P/S) (Cellgro 10-013-CMR) in a 10 cm culture dish, and the medium is changed 2 days of culturing. Once confluence is reached, the cells can be passaged (e.g. replate cells of 1 full plate to 5 plates) , and the cells of the 4 th passage can be transfected with plasmids. Transfection can be done using PEI as a transfection reagent (e.g. the mass ratio of PEI to plasmid is 2: 1) .
- PEI a transfection reagent
- a mixture of plasmids and PEI is added to an Opti-MEM medium (Gibco, cat #31985-070) , and then the mixed solution is added to the HEK293T cells of the 4 th passage. 6 hours after transfection, the medium is changed with a fresh medium containing 2%FBS, and then the cells are continuously cultured for 72 hours, when the supernatant of HEK293T cells is collected.
- the collected virus supernatant is concentrated by ultra-centrifugation (e.g. at a temperature of 2 to 8°C at 82200 g for 2 hours) , and the concentrated virus is sterilized by filtering through a 0.22 ⁇ m filter membrane and resuspended for use.
- a target gene (e.g. encoding a CAR alone or a CAR with a fusion protein disclosed herein) is cloned into a lentivirus vector.
- the lentivirus vector comprises a long terminal repeat 5’ LTR and truncated 3’ LTR, RRE, a rev response element (cPPT) , a central termination sequence (CTS) and a WHV post-transcriptional regulatory element (WPRE) .
- the fusion protein can be constitutively expressed by an EF-1a (elongation factor-1a) promoter and cloned to the lentivirus vector by BmHI and SalI digestion.
- Primary T cell activation Primary T cells can be derived from peripheral blood (PBMC) of healthy human volunteers.
- the medium used can be a complete medium, ImmunoCult TM -XF T Cell Expansion Medium (Stem Cell Technology, cat #10981) + 300 IU/ml IL2 (Cayan, cat#HEILP-0201c) .
- T cells can be activated using Dynabeads (Thermo, cat #11141D) , and the ratio of Dynabeads to cells is 3: 1.24 hours after being activated, the T cells are visibly agglomerated and enlarged.
- Lentivirus transduction of T cells after the primary T cells are activated, from 24 hours to 72 hours, the cells are agglomerated and enlarged, and are in a mitotic phase for lentivirus transduction.
- the protein expression detection can be performed 48 hours after transduction.
- Gene editing 4 days after the T cells are activated, or 2 days after the T cells are transduced with the virus, the cells are collected and washed 3 times with an electroporation buffer (Thermo, Resuspension Buffer T in the kit Cat#MPK1096) , Opti-MEM (Gibco, cat#31985-070) , or the like.
- the cells are resuspended in the electroporation buffer, and the cell density is adjusted to 1x10 8 /ml.
- the desired sgRNAs 300 to 400 ng in total
- 1 ⁇ g of Cas9 protein are uniformly mixed in vitro at the same time, and incubated for 10 min at room temperature, and then the mixture is added to the resuspended cells.
- the total volume of the cells for electroporation can be 10 ⁇ L, and a Neon electroporation system (Thermo, Cat# MPK1096) can be used for electroporation.
- the pulse voltage, pulse duration, and number of pulses of the electric shock can be as follows: 1200 to 1600 v, 10 ms, and 3 times.
- An sgRNA candidate sequence can be designed according to the predictive analysis of the related website; the Cas9 protein can be derived from an Alt-R s.p. Cas9 Nuclease 3NLS protein (IDT, Cat# 1074181) of IDT DNA Technology Company.
- UCAR-T cell expressing the fusion protein T cell activation, virus transduction, and gene editing methods are described as above.
- An exemplary process is as follows: on day 0, the primary PBMC activation is performed; on day 2, the virus transduction (for expressing the fusion protein) is performed, on day 4, the gene editing (TRAC and ⁇ 2M are knocked out) is performed, and on day 6 to 7, the expression of each protein is detected by flow cytometry.
- Anti-CD3-APC (BD, 555335) , anti-CD3-FITC (BD, 555916) , anti-B2M-PE (BD, 551337) , anti-B2M-FITC (BD, 551338) , anti-HLA-ABC-APC (R&D, FAB7098A) , anti-HLA-E-PE (Biolegend, 342604) , anti-HLA-E-APC (Biolegend, 342606) , anti-Mouse FMC63 (Shanghai Xingwan, R19PB-100) , and Dye eFluor TM 670 (eBioscience, 65-0840-90)
- CM lentivirus target expression plasmid with CAR19 (i.e. a CAR comprising an antigen binding domain that specifically binds tumor antigen CD19) alone or CAR 19 with a fusion protein (or a “chimeric molecule, ” a “CM” ) was constructed.
- the fusion protein (CM) used here has the following components from N terminus to C terminus: a 20-a. a. signal peptide (SEQ ID NO: 3) , a presenting peptide, a linker sequence GGGGSGGGGSGGGGS (SEQ ID NO: 1) , a ⁇ 2M mature form peptide (SEQ ID NO: 81) .
- the CAR19 and CM were linked by a sequence encoding a P2A peptide (ATNFSLLKQAGDVEENPGP; SEQ ID NO: 105 ) , which is a self-cleaving polypeptide commonly used to simultaneously express two or more independent polypeptides from the same vector. After being co-expressed from the same plasmid, self-cleavage of the P2A peptide allowed the two polypeptides linked thereto to be separated and function independently.
- the fusion protein (CM) as seen in SEQ ID NO: 5 comprised a HLA-E restricted presenting peptide (VMAPRTVLL; SEQ ID NO: 38) .
- the nucleic acid sequence encoding CAR19-P2A-CM is SEQ ID NO: 12.
- CAR19-P2A-CM-c was otherwise the same as CAR19-P2A-CM, except that the fusion protein (CM-c) comprised an HLA-C restricted presenting peptide IIDKSGSTV (SEQ ID NO: 117) .
- the nucleic acid sequence encoding CAR19-P2A-CM-c is SEQ ID NO: 19.
- a virus expression plasmid (Addgene ID: #12252) was digested with BamHI/SalI ahd served as a backbone.
- a CAR19 sequence (SEQ ID NO: 20) , a CAR19-P2A-CM sequence (SEQ ID NO: 12) , or a CAR19-P2A-CM-c sequence (SEQ ID NO: 19) was cloned into the backbone, forming the CAR19-P2A-CM, CAR19-P2A-CM-c, and CAR19 expression plasmids, respectively.
- the plasmid comprising the nucleotide sequence encoding CAR19-P2A-CM (SEQ ID NO: 12) was operably inserted into the digested virus expression backbone.
- Lentivirus preparation A three-plasmid system was used, which consisted of: a lentivirus target expression plasmid constructed by the methods described above, and packaging helper plasmids psPAX2 (Addgene ID: #12260) and pMD2. G (Addgene ID: #12259) .
- Virus packaging was performed in HEK293T cells (Shanghai Institute of Cell Research, Chinese Academy of Sciences) .
- the preparation process was as follows: the HEK293T cells in cryopreserved working cells were thawed, cultured in a DMEM medium (+10%FBS+1%P/S) (Cellgro 10-013-CMR) in a 10 cm culture dish, and the medium was changed after 2 days of culturing. The cells were passaged when confluence was reached (1 full plate of cells were passaged to 5 new plates) , and the cells of the 4 th passage could be transfected with plasmids. Polyethylenimine (PEI) was used as the transfection reagent with the mass ratio of PEI to plasmid being 2: 1.
- PEI Polyethylenimine
- a mixture of the three plasmids and PEI was then added to an Opti-MEM medium (Gibco, cat #31985-070) , and the mixed solution was added to the HEK293T cells of the 4 th passage. 6 hours after transfecting, the medium was changed with a fresh medium containing 2%FBS, and then the cells were continuously cultured for 72 hours before supernatant of the cell cultures was collected. The virus in the collected supernatant was concentrated by ultra-centrifugation (at 4 to 8°C at 82200 g for 2 hours) , and the concentrated virus was sterilized by filtering through a 0.22 ⁇ m filter membrane and resuspended for use.
- Primary T cell activation Primary T cells were derived from peripheral blood (PBMC) of healthy human volunteers. A complete medium was used, namely, ImmunoCult TM -XF T Cell Expansion Medium (Stem Cell Technology, cat #10981) + 300 IU/ml IL2 (Cayan, cat#HEILP-0201c) . T cells were activated using Dynabeads (Thermo, cat #11141D) , and the ratio of Dynabeads to cells was 3: 1.24 hours after being activated, the T cells were visibly agglomerated and enlarged.
- PBMC peripheral blood
- PBMC peripheral blood
- a complete medium was used, namely, ImmunoCult TM -XF T Cell Expansion Medium (Stem Cell Technology, cat #10981) + 300 IU/ml IL2 (Cayan, cat#HEILP-0201c) .
- T cells were activated using Dynabeads (Thermo, cat #11141
- Candidate sgRNA sgRNAs editing ⁇ 2M gene and sgRNA editing TRAC gene were designed and screened. sgRNAs (SEQ ID NO: 8; SEQ ID NO: 9) were used to edit ⁇ 2M gene and an sgRNA (SEQ ID NO: 10) was used to edit TRAC gene.
- Cas9 protein Alt-R s.p. Cas9 Nuclease 3NLS protein from the IDT DNA technology company was used.
- Electroporation 48 h after the primary T cells or Jurkat cells were transduced with the lentivirus, the cells were collected, washed 3 times with an electroporation buffer (Thermo, Resuspension Buffer T in the kit Cat#MPK1096) or Opti-MEM (Gibco, cat#31985-070) , and resuspended in the electroporation buffer. The cell density was adjusted to 1x10 8 /ml. The ⁇ 2M sgRNAs and TRAC sgRNA (150 ng respectively) and 1 ⁇ g of Cas9 protein were uniformly mixed in vitro, incubated for 10 min at room temperature, and then the mixture was added to the resuspended cells for electroporation. The total volume for electroporation was 10 ⁇ L, and a Neon electroporation system was used. The pulse voltage, pulse duration, and number of pulses of electric shock were as follows: 1200 V, and 10 ms, 3 times.
- the fusion protein having the HLA-E specific presenting polypeptide was efficiently expressed in cells expressing CAR on the surface (cells in the upper-right quadrant) , since the fusion protein and CAR were operatively linked together.
- the CAR-positive cells in Panel B were also stained positive for HLA-E heavy chain, showing that the CM was bound to the HLA-E heavy chain to form a complex on the cell membrane, since CM lacks the HLA-E heavy chain.
- CM-bound HLA-E at the cell membrane (FIG. 3, panel C) .
- CM fusion proteins
- NK92 cell a human NK cell line
- ImmunoCult TM (STEMCELL) was used as the culture medium as described above.
- NK92 cells (Shanghai Institute of Cell Research, Chinese Academy of Sciences) were used as effector cells.
- Three (3) types of target cells were used, all generated from primary T cells derived from peripheral blood of healthy human volunteers as described above, including: 1. CAR-T cells, which were the primary T cells transduced with the CAR19 virus; 2. UCAR-T cells, which were the primary T cells transduced with the CAR19 virus and having the TRAC and B2M genes knocked out; and 3. UCAR-T-CM cells, which were the primary T cells transduced with the CAR19-P2A-CM virus and having the TRAC and B2M genes knocked out. The final concentration of all target cells was 5x10 4 /mL.
- the NK92 cells as effector cells and the target cells were co-cultured at a ratio of 1: 1 (cell number ratio) .
- Each group of the target cells were also cultured alone as control. Cells were seeded in 96-well culture plates, supplemented with 100 ⁇ L of culture medium, and co-cultured in a 37°C incubator for 24 hours. Prior to co-culture, the NK92 cells were stained with Dye eFluor TM 670 to be distinguished from the target cells. 48 h after co-culture, the changes in target cell numbers in each of the groups of CAR-T cells, UCAR-T cells, or UCAR-T-CM cells were measured by detecting CAR-positive cells by flow cytometry.
- the anti-Mouse FMC63 kit was used for staining CAR-positive cells as described above.
- the killing rate of the target cells by the NK92 cells was calculated as: (number of CAR-positive cells in co-culture group) / (number of CAR-positive cells in target cell group only) .
- UCAR-T-CM cells from both volunteers showed significant resistance to NK cell-mediated cytolysis (**p ⁇ 0.05, ***p ⁇ 0.01) .
- CM fusion proteins
- This study further simulated the in vivo environment. Because human bodies have a complex system comprising many different types of immune cells in addition to NK cells, the primary allogeneic PBMCs were used to closely simulate the environment of an allogeneic immune system in human body. In order to measure the ability of the genetically engineered cells to survive and grow in the allogeneic PBMC environment, this study co-cultured three types of cells together, the UCAR-T cells or UCAR-T-CM cells as effector cells, the Raji tumor cells (Shanghai Institute of Cell Research, Chinese Academy of Sciences) as the target cells, and the allogeneic PBMCs from peripheral blood of healthy human volunteers as a mimic of an allogeneic immune environment.
- the UCAR-T cells or UCAR-T-CM cells co-cultured three types of cells together, the UCAR-T cells or UCAR-T-CM cells as effector cells, the Raji tumor cells (Shanghai Institute of Cell Research, Chinese Academy of Sciences) as the target cells,
- the primary PBMCs and T cells used for preparing UCAR-T or UCAR-T-CM were obtained from different donors to elicit allogeneic responses.
- Raji tumor cells were CD19 positive, so T cells containing CAR19 were activated by the CD19 antigen on Raji cells and started to proliferate.
- the cells were co-cultured according to the following ratio:
- CAR-positive cells in UCAR-T cells (or UCAR-T-CM cells) : Raji tumor cells: allogeneic PBMCs is 1: 5: 20 (cell number ratio) . 5x10 4 /ml CAR-positive cells in the UCAR-T cells (or UCAR-T-CM cells) were seeded in a 24-well culture plate, and appropriate amounts of the Raji tumor cells and allogeneic PBMCs were calculated according to the above ratio (i.e. 2.5x10 5 /ml Raji tumor cells and 1x10 6 /ml allogeneic PBMCs) and seeded. The cells were cultured at 37°C, and the numbers of CAR-positive cells in different groups were recorded at different time points.
- the number of CAR-positive cells at different time points was divided by the number of starting CAR-positive cells on day 0 to obtain the cell expansion fold changes (FIG. 5) .
- the same staining method of CAR-positive cells using anti-Mouse FMC63 kit was used.
- Allogeneic PBMCs and Raji cells were stained with Dye eFluor TM 670 prior to co-culture to be distinguished from the UCAR-T cells or UCAR-T-CM cells.
- Dye eFluor TM 670 was added to a final concentration of 10 ⁇ M, and the mixture was incubate at room temperature for 5 min in the dark, and wash with the medium three times before using.
- FIG. 5 shows that in the presence of the allogeneic PBMC cells, UCAR-T cells were not able to expand well with the stimulation of CD19-positive Raji cells, whereas UCAR-T-CM cells were able to expand rapidly.
- CM fusion proteins
- the experimental procedure was the same as described above in section 6.5, but different cells were measured. Instead of the numbers of CAR-positive cells, the numbers of Raji cells in different groups were measured at different time points in this experiment.
- the Raji cells were stained with the dye e670 prior to co-culture, which could be distinguished from UCAR-T or UCAR-T-CM via APC fluorescence channels in flow cytometry.
- the Raji cells and the PBMC cells could be clearly distinguished in flow cytometry analysis, because that the Raji cells are tumor cells and have significantly different morphology and size from PBMC cells, and also because that the continuous expansion of tumor cells during co-culture led to the continuous decrease of fluorescence of the dye e670.
- CM fusion protein
- HLA-E heavy chain on cell membrane of ⁇ 2M-null cells
- CM fusion protein
- HLA-E heavy chain molecule
- FIG. 7 The Jurkat cells in each group were stained with the anti-Mouse FMC63 kit for detecting CAR, and anti- ⁇ 2M-FITC and anti-HLA-E-APC, for detecting ⁇ 2M and HLA-E, respectively. A small amount of cells were taken, washed once with 1 ml of PBS (Gibco, cat#C10010500BT) , and resuspended in 100 ⁇ L of PBS.
- PBS Gibco, cat#C10010500BT
- a primary anti-FMC63 antibody for detecting CAR19 was added to the cell mixture, which was incubated for 30 min 4°C. Then 1 ml of PBS was added and the cell mixture was uniformly mixed and centrifuged at 350 g for 3 min. The cells were collected and the supernatant was discarded.
- FIGs. 7A-H were from Jurkat cells that were transduced with the CAR19-P2A-CM virus and had endogenous TRAC gene and ⁇ 2M gene knocked out.
- the flow cytometry data of FIGs. 7I-L were from the control group, in which the Jurkat cells had endogenous TRAC gene and ⁇ 2M gene knocked out but were not transduced with the CAR19-P2A-CM virus.
- FIG. 7, panel B shows the only the CAR-expressing cells were HLA-E positive. Since the nucleic acid encoding CAR and the nucleic acid encoding the fusion protein (CM) were cloned to be operably linked on the same viral vector (via a nucleotide sequence encoding a P2A peptide) , the cell expressing CAR also expressed CM. Therefore, only the CM-expressing cells were HLA-E positive.
- FIG. 7, panel C shows the co-expression of the CAR and the fusion protein (CM) , since CM comprised ⁇ 2M, CAR and ⁇ 2M double positive cells were observed.
- FIG. 7, panel D shows the co-localization of ⁇ 2M and HLA-E.
- FIG. 7, panel F shows that the CAR-positive cell population R2 almost exclusively included the ⁇ 2M and HLA-E double positive cells
- FIG. 7, panel H shows that ⁇ 2M and HLA-E double positive cells were not detected in CAR-negative cells.
- CM When CM was not expressed (in the CAR-negative cells) , HLA-E could not be detected on the cell surface of ⁇ 2M-knockout Jurkat cells. In those ⁇ 2M-knockout Jurkat cells, when CM was expressed (in the CAR-positing cells) , CM and the HLA-E heavy chain formed a complex that restored the presentation of the HLA-E heavy chain on the cell membrane, so that the HLA-E heavy chain molecule could be detected at the cell surface.
- FIG. 7 panels I-L shows that in the cells of the control group, no CAR or HLA-E was detected at the cell surface.
- the small amount of ⁇ 2M-positive cells represented the cells in which ⁇ 2M was not completely knocked out by gene editing.
- CM fusion protein
- HLA-E heavy chain a presenting peptide that affects the expression of the HLA-E complex on cell membrane.
- 18 different presenting peptides were (P1-P18; SEQ ID NOs: 21-38) selected and cloned into lentivirus expression vector as GFP-P2A-CMx (x for different peptide segments number P1-P18) .
- the fusion protein CMx used here has the following components from N terminus to C terminus: a 20-a.a.
- lentivirus target expression plasmids were the same as described above, using BamHI/SalI to clone GFP-P2A-CMx into the lentivirus vector.
- the viruses were transduced into Jurkat cells that had ⁇ 2M knocked out. Methods of lentivirus preparation and virus preparation were the same as described above.
- HLA-E complex on cell membrane was detected with anti-HLA-E-APC antibody (Biolegend, 342606) and by measuring GFP, which indicated the lentiviral transduction efficiency.
- FIG. 8A quantified in FIG. 8B
- NTC Negative Control; untransfected group
Abstract
Description
In some embodiments, a fusion protein provided herein can be co-expressed with a synthetic receptor in a cell. In some embodiments, a fusion protein provided herein can be conjugated to a synthetic receptor. As used herein, the term “synthetic receptor” refers to an engineered cell surface protein or protein complex comprising (1) a target-binding domain that can specifically bind a target molecule, and (2) a functional domain that can activate a signaling pathway in the engineered cell. The target-binding domain comprises an extracellular domain. The functional domain comprises an intracellular domain. The synthetic receptor further includes a transmembrane sequence. The synthetic receptor can be a protein complex that comprises proteins expressed from exogenous nucleic acids. The synthetic receptor can also be a protein complex that comprises at least one protein that is exogenously expressed, and at least one protein that is endogenously expressed. In some embodiments, the engineered cell can be an immune cell, such as a T cell, a natural killer (NK) cell, a B cell, a macrophage, etc., and the functional domain can activate the immune cell, either directly or indirectly. The synthetic receptor can be selected from the group consisting of: a chimeric antigen receptor ( “CAR” ) , a T cell receptor ( “TCR” ) , a TCR receptor fusion construct ( “TRuC” ) , a T cell antigen coupler ( “TAC” ) , an antibody TCR receptor ( “AbTCR” ) , and a chimeric CD3ε receptor. In some embodiments, the synthetic receptor is a CAR. In some embodiments, the synthetic receptor is a TCR. In some embodiments, the synthetic receptor is a TRuC. In some embodiments, the synthetic receptor is a TAC. In some embodiments, the synthetic receptor is an AbTCR. In some embodiments, the synthetic receptor is a chimeric CD3 receptor.
Claims (98)
- A fusion protein comprising a presenting peptide covalently linked to a beta-2-microglobulin (β2M) peptide via a linker, wherein the fusion protein binds a major histocompatibility (MHC) heavy chain to form an MHC complex that binds an inhibitory receptor of an immune cell to inhibit the immune cell, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- The fusion protein of claim 1, wherein the inhibitory receptor of the immune cell is NKG2A.
- The fusion protein of claim 1, wherein the inhibitory receptor of the immune cell is selected from the group consisting of KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, and LIR1.
- The fusion protein of any one of claim 1 to 3, wherein the MHC heavy chain is a classical Class I MHC heavy chain, a non-classical Class I MHC heavy chain, or an MHC-like heavy chain.
- The fusion protein of claim 4, wherein the MHC heavy chain is a classical Class I MHC heavy chain selected from the group consisting of an HLA-Aheavy chain, an HLA-B heavy chain, and an HLA-C heavy chain.
- The fusion protein of claim 4, wherein the MHC heavy chain is a nonclassical Class I MHC heavy chain selected from the group consisting of an HLA-E heavy chain, an HLA-F heavy chain, and an HLA-G heavy chain.
- The fusion protein of claim 4, wherein the MHC heavy chain is an MHC-like molecule heavy chain selected from the group consisting of a CD1 heavy chain, an MR1 heavy chain, an FcRn heavy chain, and UL18.
- The fusion protein of claim 4, wherein the MHC heavy chain is an HLA-E heavy chain.
- A fusion protein comprising a presenting peptide covalently linked to a β2M peptide via a linker, wherein the presenting peptide is an HLA-E-restricted presenting peptide, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- The fusion protein of any one of claims 1 to 9, wherein the presenting peptide is derived from a virus, a prokaryote, a eukaryote or a mammal.
- The fusion protein of any one of claims 1 to 9, wherein the presenting peptide is derived from a human.
- The fusion protein of any one of claims 1 to 11, wherein the presenting peptide is a signal peptide of a Class I MHC molecule or a fragment thereof.
- A fusion protein comprising a presenting peptide covalently linked to a β2M peptide via a linker, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- The fusion protein of any one of claims 1 to 13, wherein the presenting peptide has 5-30 amino acids.
- The fusion protein of claim 14, wherein the presenting peptide has 7-20 amino acids.
- The fusion protein of claim 14, wherein the presenting peptide has 8-10 amino acids.
- The fusion protein of any one of claims 12 to 16, wherein the presenting peptide is a signal peptide of a Class I MHC molecule, or a fragment thereof, wherein the Class I MHC molecule is selected from the group consisting of the heavy chains of HLA-A1, HLA-A2, HLA-A*3401, HLA-A*80, HLA-B7, HLA-B*13, HLA-B15, HLA-Cw3, HLA-Cw*2, HLA-Cw*0809, HLA-Cw7, HLA-Cw*1701, HLA-G, and HLA-F.
- The fusion protein of any one of claims 12 to 17, wherein the amino acid sequence of the presenting peptide comprises X 1X 2X 3X 4X 5X 6X 7X 8L; wherein X 1 is V or I; X 2 is T, A, M or L; X 3 is A, P, K or N; X 4 is P, L, or T; X 5 is R, Q or K; X 6 is T or A; X 7 is L, I, V or P; X 8 is V, L, I, F or T (SEQ ID NO: 115) .
- The fusion protein of any one of claims 12 to 17, wherein the amino acid sequence of the presenting peptide is selected from the group consisting of SEQ ID NOs: 21-73.
- The fusion protein of claim 19, wherein the amino acid sequence of presenting peptide is VMAPRTVLL (SEQ ID NO: 38) .
- The fusion protein of any one of claims 1 to 20, wherein the fusion protein comprises less than 500, less than 400, less than 300, or less than 200 amino acids.
- The fusion protein of claim 21, wherein the fusion protein comprises about 120-180 amino acids.
- The fusion protein of any one of claims 1 to 22, comprising the presenting peptide, the linker, and the β2M peptide from N-terminus to C-terminus.
- The fusion protein of any one of claims 1 to 23, wherein the amino acid sequence of the linker comprises (EAAAK) n, wherein n=3, 4 or 5 (SEQ ID NO: 110) , and wherein the linker has between 5 and 30 amino acids.
- The fusion protein of any one of claims 1 to 23, wherein the amino acid sequence of the linker comprises (GGGGS) n, wherein n=3, 4 or 5 (SEQ ID NO: 112) , and wherein the linker has between 5 and 30 amino acids.
- The fusion protein of claim 25, wherein the amino acid sequence of the linker is SEQ ID NO: 1 or 2.
- The fusion protein of any one of claims 1 to 26, wherein the amino acid sequence of the β2M peptide is at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 81.
- The fusion protein of claim 27, wherein the amino acid sequence of the β2M peptide is SEQ ID NO: 81.
- The fusion protein of any one of claims 1 to 28 consisting of the presenting peptide, the linker, and the β2M peptide.
- A fusion protein, wherein the amino acid sequence of the fusion protein is at least 85%, at least 90%, or at least 95%identical an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 13-18.
- A fusion protein wherein the amino acid sequence of the fusion protein is selected from the group consisting of SEQ ID NOs: 5 and 13-18.
- A nucleic acid that encodes the fusion protein of any one of claims 1 to 31.
- A nucleic acid comprising (i) a first fragment encoding a fusion protein comprising a presenting peptide and a β2M peptide covalently linked via a linker, wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain; and (ii) a second fragment encoding a synthetic receptor.
- The nucleic acid of claim [00223] , wherein the synthetic receptor is selected from the group consisting of a chimeric antigen receptor (CAR) , a T cell receptor (TCR) , a TCR receptor fusion construct (TRuC) , a T cell antigen coupler (TAC) , an antibody TCR receptor (AbTCR) and a chimeric CD3 receptor.
- The nucleic acid of claim [00223] , wherein the synthetic receptor is a CAR.
- The nucleic acid of any one of claims [00223] to 35, wherein the synthetic receptor comprises an antigen-binding domain that specifically binds a tumor antigen.
- The nucleic acid of claim 36, wherein the tumor antigen is selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- The nucleic acid of claim 36, wherein the tumor antigen is CD19 or BCMA.
- The nucleic acid of any one of claims [00223] to 35, wherein the synthetic receptor comprises an antigen-binding domain that specifically binds a viral antigen.
- The nucleic acid of claim 39, wherein the viral antigen is EBV or HPV.
- The nucleic acid of any one of claims [00223] to 40, wherein the first and second fragments are connected via a polynucleotide encoding a 2A peptide.
- The nucleic acid of claim 41, wherein the 2A peptide is a P2A peptide, a T2A peptide, a F2A peptide, or an E2A peptide.
- The nucleic acid of claim 41 or 42, encoding the synthetic receptor, the 2A peptide, the fusion protein, from N-terminus to C-terminus.
- The nucleic acid of any one of claims [00223] to 40, wherein the first and second fragments are connected via an IRES sequence.
- A vector that comprises the nucleic acid of claim 32.
- The vector of claim 45 that is a viral vector.
- The vector of claim 46 wherein the viral vector is a lentiviral vector, an adenoviral vector, or an adeno-associated viral vector.
- A vector that comprises the nucleic acid of any one of claims [00223] to 44.
- The vector of claim 48 that is a viral vector.
- The vector of claim 49 wherein the viral vector is a lentiviral vector, an adenoviral vector, or an adeno-associated viral vector.
- A genetically engineered cell expressing the fusion protein of claims 1 to 31.
- A genetically engineered cell comprising the nucleic acid of claim 32, or the vector of any one of claims 45 to 47.
- A genetically engineered cell comprising the nucleic acid of any one of claims [00223] to 44, or the vector of any one of claims 48 to 50.
- The cell of claim 51, further expressing a synthetic receptor.
- The cell of claim 52, further comprising a second nucleic acid that encodes a synthetic receptor.
- The cell of claim 54 or 55, wherein the synthetic receptor is selected from the group consisting of a CAR, a TCR, a TRuC, a TAC, an AbTCR, and a chimeric CD3 receptor.
- The cell of claim 56, wherein the synthetic receptor is a CAR.
- The cell of any one of claims 54 to 57, wherein the synthetic receptor comprises an antigen-binding domain that specifically binds a tumor antigen.
- The cell of claim 58, wherein the tumor antigen is selected from the group consisting of CD19, CD20, CD22, CD30, CD123, CD138, CD33, CD70, BCMA, CS1, C-Met, IL13Ra2, EGFRvIII, CEA, Her2, GD2, MAGE, GPC3, Mesothelin, PSMA, ROR1, EGFR, MUC1, and NY-ESO-1.
- The cell of claim 59, wherein the tumor antigen is CD19 or BCMA.
- The cell of any one of claims 54 to 57, wherein the synthetic receptor comprises an antigen-binding domain that specifically binds a viral antigen.
- The cell of claim 61, wherein the viral antigen is EBV or HPV.
- The cell of any one of claims 51 to 62, wherein the fusion protein forms a complex with an endogenous MHC heavy chain on the cell surface.
- The cell of any one of claims 51 to 63, wherein the cell lacks endogenous expression of at least one gene encoding a Class I MHC molecule or an MHC-like molecule on the cell surface.
- The cell of claim 64, wherein the cell lacks endogenous expression of a Class I MHC molecule selected from the group consisting of heavy chains of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G on the cell surface.
- The cell of claim 64, wherein the cell lacks endogenous expression of β2M on the cell surface.
- The cell of claim 64, wherein the cell lacks endogenous expression of an MHC-like molecule selected from the group consisting of a CD1 heavy chain, an MR1 heavy chain, an FcRn heavy chain, and UL18 on the cell surface.
- The cell of any one of claims 51 to 67, wherein the cell is an immune cell.
- The immune cell of claim 68, wherein the immune cell is a leukocyte.
- The immune cell of claim 69, wherein the leukocyte is selected from the group consisting of a T cell, a NK cell, a NKT cell, a B cell, a plasma cell, a dendritic cell, a neutrophil, a monocyte, a macrophage, and a granulocyte.
- The immune cell of claim 70, wherein the leukocyte is a NK cell.
- The immune cell of claim 70, wherein the leukocyte is a T cell.
- The immune cell of claim 72, wherein at least one gene encoding a component of TCR complex is inactivated in the T cell.
- A pharmaceutical composition having the cell of any one of claims 51 to 73 and a pharmaceutically acceptable excipient.
- Use of the cell of any one of claims 51 to 74 in an allogeneic transplant.
- Use of the cell of any one of claims 53 to 74 in cancer treatment.
- Use of the cell of any one of claims 53 to 74 for the preparation of a medicament for the treatment of cancer.
- Use of a cell in an allogeneic transplant, wherein the cell comprises a nucleic acid encoding a fusion protein comprising a presenting peptide and a β2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- Use of a cell in an allogeneic transplant, wherein the cell expresses a fusion protein comprising a presenting peptide and a β2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- A method of treating a subject in need of an allogeneic transplant, comprising administering an effective amount of the cell of any one of claims 51 to 74 to the subject.
- A method of treating cancer in a subject comprising administering a therapeutically effective amount of the cell of any one of claims 53 to 74 to the subject.
- A method of treating a subject in need of an allogeneic transplant, comprising administering an effective amount of an cell to the subject, wherein the cell comprises a nucleic acid encoding a fusion protein comprising a presenting peptide and a β2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- A method of treating a subject in need of an allogeneic transplant, comprising administering an effective amount of an cell to the subject, wherein the cell expresses a fusion protein comprising a presenting peptide and a β2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- A method of genetically engineering a cell for an allogeneic transplant, comprising transducing the cell with a nucleic acid encoding a fusion protein, wherein the fusion protein comprises a presenting peptide and a β2M peptide covalently linked via a linker, and wherein the fusion protein (1) comprises less than 500 amino acids, or (2) lacks an HLA-E heavy chain.
- A method of genetically engineering a cell for an allogeneic transplant, comprising transducing the cell with the nucleic acid of any one of claims 32 to 44.
- A method of genetically engineering a cell for an allogeneic transplant, comprising transducing the cell with the vector of any one of claims 45 to 50.
- The method of any one of claims 84 to 86, further comprising inactivating at least one gene encoding a Class I MHC molecule or an MHC-like molecule in the cell.
- The method of claim 87, wherein the inactivated gene encodes a Class I MHC molecule selected from the group consisting of heavy chains of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G.
- The method of claim 87, wherein the inactivated gene encodes β2M.
- The method of claim 87, wherein the inactivated gene encodes an MHC-like molecule selected from the group consisting of a CD1 heavy chain, an MR1 heavy chain, an FcRn heavy chain and UL18.
- The method of any one of claims 87 to 90, wherein the gene is inactivated by DNA cleavage, DNA cleavage and repair, base editing, prime editing, RNA interference, or RNA editing.
- The method of claim 91, wherein the gene is inactivated by DNA cleavage using a rare endonuclease selected from the group consisting of a RNA-directed endonuclease, a TAL nuclease, a homing endonuclease, a zinc-finger nuclease, and a Mega-TAL nuclease.
- The method of claim 91, wherein the gene is inactivated by DNA cleavage and repair.
- The method of claim 91, wherein the gene is inactivated by using a CRISPR-Cas system.
- The method of claim 94, wherein the CRISPR-Cas system is a CRISPR-Cas9 system.
- The method of any one of claims 84 to 95, wherein the cell is an immune cell.
- The method of claim 96, wherein the immune is selected from the group consisting of a T cell, a NK cell, a NKT cell, a B cell, a plasma cell, a monocyte, a macrophage, a dendritic cell and a granulocyte.
- A method of treating a subject in need of an allogeneic transplant, comprising preparing a genetically engineered cell according to any one of claims 84 to 97, and administering the engineered cell to the subject.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080057495.5A CN114450307A (en) | 2019-08-13 | 2020-08-10 | Genetically engineered cells and uses thereof |
PCT/CN2020/108116 WO2021027758A1 (en) | 2019-08-13 | 2020-08-10 | Genetically engineered cells and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910746355.8 | 2019-08-13 | ||
CN201910746355 | 2019-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021027200A1 true WO2021027200A1 (en) | 2021-02-18 |
Family
ID=74569818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/124321 WO2021027200A1 (en) | 2019-08-13 | 2019-12-10 | Genetically engineered cells and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021027200A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111320703A (en) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | Chimeric antigen receptor targeting CD22 and application thereof |
WO2023016514A1 (en) * | 2021-08-12 | 2023-02-16 | 苏州克睿基因生物科技有限公司 | Modified cell, and preparation method therefor and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103649125A (en) * | 2011-06-22 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | Removal of target cells by circulating virus-specific cytotoxic t-cells using MHC class I comprising complexes |
WO2018064594A2 (en) * | 2016-09-29 | 2018-04-05 | Nantkwest, Inc. | Hla class i-deficient nk-92 cells with decreased immunogenicity |
-
2019
- 2019-12-10 WO PCT/CN2019/124321 patent/WO2021027200A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103649125A (en) * | 2011-06-22 | 2014-03-19 | 霍夫曼-拉罗奇有限公司 | Removal of target cells by circulating virus-specific cytotoxic t-cells using MHC class I comprising complexes |
WO2018064594A2 (en) * | 2016-09-29 | 2018-04-05 | Nantkwest, Inc. | Hla class i-deficient nk-92 cells with decreased immunogenicity |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111320703A (en) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | Chimeric antigen receptor targeting CD22 and application thereof |
WO2023016514A1 (en) * | 2021-08-12 | 2023-02-16 | 苏州克睿基因生物科技有限公司 | Modified cell, and preparation method therefor and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11344577B2 (en) | Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA | |
KR102614675B1 (en) | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods | |
JP7008350B2 (en) | CAR expression vector and CAR expression T cells | |
AU2020250247A1 (en) | Gene modified immune effector cells and engineered cells for expansion of immune effector cells | |
US20190175651A1 (en) | Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression | |
JP6761113B2 (en) | Chimeric antigen receptor | |
CA3151781A1 (en) | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof | |
JP2024518011A (en) | Single- and multi-chain synthetic antigen receptors for a variety of immune cells | |
JP2023549098A (en) | Multiplexed engineered iPSCs and immune effector cells to target solid tumors | |
JP2023548467A (en) | Engineered iPSCs and persistent immune effector cells | |
JP2022512450A (en) | Immune effector cells targeting GPC3 and their applications | |
WO2021027200A1 (en) | Genetically engineered cells and uses thereof | |
US20240033355A1 (en) | ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS | |
WO2021027758A1 (en) | Genetically engineered cells and uses thereof | |
WO2023235440A2 (en) | Compositions and methods comprising chimeric adaptor polypeptides | |
US20230405121A1 (en) | Engineered ipsc and immune effector cells for heterogenous tumor control | |
JP2024509917A (en) | Method for selective stimulation of T cells in solid tumors using orthogonal IL-2 delivery by oncolytic viruses | |
WO2023230014A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
CN116457367A (en) | Engineered ipscs and armed immune effector cells | |
CN117202921A (en) | Single-and multi-chain synthetic antigen receptors for a variety of immune cells | |
CN117561330A (en) | Compositions and methods for generating gamma-delta T cells from induced pluripotent stem cells | |
CN116615531A (en) | Engineered ipscs and immune effector cells for heterogeneous tumor control | |
CN116615530A (en) | Multiple engineered ipscs and immune effector cells targeting solid tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19940964 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19940964 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19940964 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15.11.2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19940964 Country of ref document: EP Kind code of ref document: A1 |